MEDICAL USE OF SERRULATAN DITERPENES

DE602017086438T2Active Publication Date: 2024-11-27KYNAN DUKE IP LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE602017086438
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-09-07
Filing Date
2017-09-07
Publication Date
2024-11-27
Estimated Expiration
2037-09-07

AI Technical Summary

Technical Problem

The variability in chemical composition of propolis due to different plant sources limits its effectiveness in medicine, particularly in treating diseases like cancer, as the medicinal properties depend on the botanical origin and there is a lack of understanding about the metabolic modifications or additions by honey bees.

Method used

Isolation of serrulatane diterpenes from propolis sourced from Myoporum insulare, which are found to inhibit cancer cell proliferation and have moderate to strong inhibition of targets associated with cancer pathology, providing a potential lead for pharmaceutical research and development.

Benefits of technology

The serrulatane diterpenes from Myoporum insulare propolis demonstrate significant pharmacological activity, particularly in inhibiting cancer cell growth, offering a promising therapeutic agent for cancer treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to terpenes and uses thereof. In particular, the invention relates to serrulatane diterpenes and to the use of such compounds in the treatment of diseases and disorders such as cancer.

[0002] Throughout this application, various publications are referred to by first author and year of publication. Full citations for these publications, in the order they appear in the application, are presented in a References section immediately before the claims.Background of the Invention

[0003] Plant secondary metabolites have been a major source of medicinal substances providing lead compounds for drug discovery and development.

[0004] Plants produce resins and exudates containing secondary metabolites to protect young flower and leaf buds against bacteria and fungi, and damage from sunlight. Accordingly, compounds from plant resins and exudates frequently possess antimicrobial and antioxidant / free radical scavenging activities. Worker honey bees (Apis mellifera) collect plant resins / exudates of young shoots and buds from certain trees and shrubs. The resulting mixture is called propolis, or so called bee glue. Propolis is a complex resinous substance and a rich source of bioactive substances. It is used by the bees to mix with wax to seal cracks and holes in their hives and as a disinfectant to protect against microbial infections. The medicinal properties of propolis have been exploited by man since Ancient civilizations.

[0005] Currently, propolis is extensively available as a natural health product, and is widely used in cosmetics. However, its modem use in medicine is limited, largely due to the wide variations in chemical compositions arising from honey bees collecting from different or a mixture of plant sources. The composition of propolis is dependent upon the surrounding flora to which the bees have access, and as such, differences in flora may result in differences in propolis compositions. For example, it is known that flavonoids are the major pharmacologically active compounds in European propolis, polyprenylated benzophenones are the main substances in Cuban and Venuzuelan propolis, and prenylated cinnamic acid derivatives are predominant in Brazilian propolis.

[0006] Recognition of the botanical origin of the propolis produced by honey bees enables beehives to be placed in favourable locations such that propolis from a single botanical source may be produced to enable manufacture of medicines of high quality and efficacy.

[0007] The medicinal uniqueness of propolis is determined by the selective collecting ability of honey bees, as they can recognise natural materials that are relatively non-polar and have antibiotic properties. As reported, the common source of propolis is leaf and flower bud exudates, which are of high antibiotic character in order to protect the delicate growing of plant tissue from attack by microorganisms. It has also been reported that honey bees collect exudates from wounded or diseased plant tissues. Such sources are potentially rich in antibiotic substances produced by plants in response to wounding or attack from insects, microorganisms and viruses.

[0008] Medicinal properties of a propolis are associated with the biological activities of the individual plant resins / exudates. It is not clear from previous studies whether the bees simply collect a plant material that is known as propolis, or if there is metabolic modification or addition from the bees. However, there does not appear to be evidence of significant amounts of material added from honey bees, or strong evidence for metabolic transformation. Thus, a better understanding is required regarding the composition of propolis in specific geographical locations to be able to utilize it to its full benefit in the development of new agents in the treatment of diseases and disorders such as cancer.

[0009] US2002 / 091093 discloses compounds for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain.Summary of the Invention

[0010] The invention is defined by the appended claims. Any subject-matter falling outside the scope of the claims is provided for information purposes, only. The references to methods of treatment in this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy (or for diagnosis).

[0011] In work leading up to the present invention a survey of propolis samples isolated from Kangaroo Island (South Australia) was conducted. Surprisingly, the Inventors found that unlike other propolis which commonly contains flavonoids as active constituents, Kangaroo Island propolis from the Myoporum genus of plants, in particular Myoporum insulare, contains serrulatane diterpenes. Thus, the present invention relates to compounds isolated from the resins / exudates of leaves and leaf buds of Myoporum insulare, propolis sourced from the same plant and uses thereof.

[0012] Myoporum insulare species is a shrub occurring on ridges and coastal cliffs in Australia. Common names include boobialla, native juniper and, in Western Australia, blueberry tree. Myoporum is a genus of approximately 30 species, of which sixteen are found in Australia. Myoporum insulare species has a variable growth habitat and may be a dense or an open shrub or a small tree up to 6 metres. The leaves are lance-shaped to elliptical, 30-100 mm long by 10-20 mm wide with glossy green colour. The flowers occur in groups of up to 8 in the leaf axils in late spring and summer and are usually white or occasionally pale pink.

[0013] The Inventors have isolated five major compounds, namely compounds 1 to 5, from propolis obtained from Myoporum insulare. Compounds 1 to 5 are shown in Table 1. The conventional numbering for serrulatane compounds is shown with respect to compound 1. In general, serrulatane diterpenes have the (1R,4S)-configuration (Ghisalberti, 1994).

[0014] Compound 1 gives a derivative, compound 6, on oxidation. Further in regard to derivatization, the compounds can also be acylated, alkylated, alkenylated or benzoylated through the free hydroxyl groups. For example, compounds 1 and 2 can be acetylated to give derivatives 7 and 8 while benzoylation can give derivatives 9 and 10.

[0015] Representative compounds were evaluated for pharmacological activity and were found to be useful in modulating a number of diseases or disorders. For example, the compounds were found to inhibit cancer cell proliferation and showed moderate to strong inhibition of various targets associated with cancer pathology. This indicates that the serrulatane diterpene compounds of the present disclosure may be useful as therapeutic agents e.g. for the treatment of cancer. Therefore, the serrulatane diterpenes described herein provide a potentially attractive lead for pharmaceutical research and development and as biological tools for further understanding the pathophysiology of diseases and disorders such as cancer.

[0016] Accordingly, in a first aspect, there is provided a method of treating a cancer, the method comprising administering a therapeutically effective amount of a compound of Formula (I ), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, or pharmaceutical composition including said compounds, to a subject in need thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH.

[0017] According to a second aspect, there is provided use of a compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH, in the preparation of a medicament for treating a cancer.

[0018] According to a third aspect, there is provided use of a compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH, in treating a cancer.

[0019] According to a fourth aspect, there is provided a compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5\ alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH, for use in treating a cancer.

[0020] According to a fifth aspect, there is provided a compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH 2 for use as presently claimed.

[0021] According to a sixth aspect, there is provided a pharmaceutical composition comprising a compound, stereoisomer, pharmaceutically acceptable salt or solvate thereof, according to the fifth aspect and a pharmaceutically acceptable excipient for use as presently claimed.

[0022] According to a seventh aspect, there is provided a pharmaceutical composition comprising a compound, stereoisomer, pharmaceutically acceptable salt or solvate thereof, according to the fifth aspect, or a mixture thereof, and a pharmaceutically acceptable excipient for use as presently claimed.

[0023] According to an eighth aspect, there is provided a compound as defined in the fifth aspect isolated from propolis, wherein the propolis originates from plants of the Myoporum genus.

[0024] According to a ninth aspect, there is provided a compound as defined in the fifth aspect isolated from the resin, gum or exudate of Myoporum genus.

[0025] According to a tenth aspect, there is provided a method of treating a disease or disorder, as presently claimed, the method comprising administering a therapeutically effective amount of a compound according to the fifth aspect or a composition according to the sixth or seventh aspect. According to an eleventh aspect, there is provided use of a compound according to the fifth aspect in the preparation of a medicament for treating a disease or disorder, as presently claimed.

[0026] According to a twelfth aspect, there is provided use of a compound according to the fifth aspect or a composition according to the sixth aspect or seventh aspect in treating a disease or disorder, as presently claimed.

[0027] According to a thirteenth aspect of the present invention, there is provided a compound according to the fifth aspect or a composition according to the sixth aspect or seventh aspect for use in treating a disease or disorder as presently claimed.Brief Description of Drawings

[0028] Figure 1. Representative 1< H NMR (400 MHz, CDCl 3 ) spectrum of the 4:1 mixture of mono-methylated products (compounds 11 and 12 ). Figure 2. Representative 13< C NMR (100 MHz, CDCl 3 ) spectrum of the 4:1 mixture of mono-methylated products (compounds 11 and 12 ). Figures 3 to Figure 6 show example binding curves for compound 1 against epigenetic targets. Figure 3 ASH1L (h) bromodomain binding curve. Figure 4 CECR2(h) bromodomain binding curve. Figure 5 SP140 (h) bromodomain binding curve. Figure 6 UHRF1(108-286) (h) binding curve. Figure 7 shows binding against 5-lipoxygenase for compound 1 (blue circles, IC 50 = 2.31 µM) and a reference compound NGA (red squares, IC 50 = 0.64 µM). Figure 8 shows binding against lipid peroxidase for compound 1 (blue circles, IC 50 = 1.47 µM) and a reference compound N-propyl gallate (red squares, IC 50 = 165 µM). Figure 9 shows binding against monoamine oxidase (MAO-A) for compound 1 (blue circles, IC 50 = 6.74 µM) and a reference compound clorgyline (red squares, IC 50 = 1.43 nM). Figure 10 shows transcription response and binding against NF-κB for compound 1 (blue circles, IC 50 = 1.36 µM) and a reference compound cyclosporin A (red squares, IC 50 = 0.029 µM). Figure 11 shows proliferation response when cell line MDA-MB-415 is treated with compound 1. Figure 12 shows proliferation response when cell line RKO-AS45-1 is treated with compound 1. Figure 13 shows proliferation response when cell line SW480 is treated with compound 1. Figure 14 shows proliferation response when cell line 639-V is treated with compound 1. Figure 15 shows proliferation response when cell line Hs 729 is treated with compound 1. Figure 16 shows proliferation response when cell line Hs 852.T is treated with compound 1. Figure 17 shows proliferation response when cell line HCT-8 is treated with compound 1. Figure 18 shows proliferation response when cell line IM-9 is treated with compound 1. Figure 19 shows the response when the cell line HREC is treated with compound 1 in an OncoPanel Normal Cell Proliferation Assay.

[0029] Specific embodiments of the disclosure are described below.Detailed Description of the Invention

[0030] Disclosed herein is a method of treating a cancer, the method comprising administering a therapeutically effective amount of a compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, or pharmaceutical composition including said compounds, to a subject in need thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH.

[0031] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; and A---B is CH=C or CH 2 -CH.

[0032] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; and A---B is CH=C or CH 2 -CH.

[0033] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0034] Preferably: X is CH 2 ; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0035] Preferably: X is CHOH; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0036] Preferably: X is C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0037] Preferably, the compound is a compound of Formula (Ia):

[0038] Preferably, the compound is a compound of Formula (Ic):

[0039] Preferably, the compound is a compound of Formula (Ii):

[0040] Preferably, A---B is CH=C.

[0041] The compound is preferably selected from the group consisting of:

[0042] Preferably, the compound is selected from the group consisting of: and

[0043] The compound is preferably selected from the group consisting of:

[0044] Preferably, the compound is selected from the group consisting of: , and

[0045] The compound is preferably:

[0046] Preferably, the compound is:

[0047] The compound is preferably: I

[0048] Preferably, the compound is:

[0049] Preferably, the cancer is bladder cancer, bone cancer, brain cancer, breast cancer, a cancer of the central nervous system, cancer of the adrenal glands, cancer of the placenta, cancer of the testis, cervical cancer, colon cancer, kidney cancer, head and neck cancer, myeloma, leukemia, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, uterine cancer, a carcinoma, a lymphoma, a sarcoma, eye cancer, esophageal cancer, bile duct cancer or vulva cancer.

[0050] The cancer of the central nervous system is preferably a glioma. Preferably, the cancer of the central nervous system is a medulloblastoma. The cancer of the central nervous system is preferably a neuroblastoma.

[0051] Preferably, the lung cancer is a non-small cell lung cancer. The lung cancer is preferably a small cell lung cancer.

[0052] Preferably, the carcinoma is adenosquamous cell carcinoma or squamous cell carcinoma.

[0053] The sarcoma is preferably a liposarcoma, rhabdomyosarcoma, or fibrosarcoma. Preferably, the sarcoma is a soft tissue sarcoma. The soft tissue sarcoma is preferably a soft tissue osteosarcoma.

[0054] Preferably, the lymphoma is Burkitt's lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

[0055] While it is possible that, for use in therapy a therapeutically effective amount of the compounds as defined herein, or a pharmaceutically acceptable salt or solvate thereof, may be administered as the raw chemical; in the first aspect of the present invention the active ingredient is administered as a pharmaceutical composition. Thus, the present invention also contemplates a pharmaceutical composition comprising a compound of formula (I ) to (Ii ), or a pharmaceutically acceptable salt or a solvate thereof, and a pharmaceutically acceptable excipient. The excipient must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0056] When applicable, the compounds of the present invention, including the compounds of formula (I ) to (Ii ) may be in the form of and / or may be administered as a pharmaceutically acceptable salt.

[0057] As used herein the term "pharmaceutically acceptable salt" refers to salts which are toxicologically safe for systemic administration. The pharmaceutically acceptable salts may be selected from alkali or alkaline earth metal salts, including, sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, triethanolamine and the like.

[0058] As used herein the term "pharmaceutically acceptable excipient" refers to a solid or liquid filler, carrier, diluent or encapsulating substance that may be safely used in administration. Depending upon the particular route of administration, a variety of carriers, well known in the art may be used. These carriers or excipients may be selected from a group including sugars, starches, cellulose and its derivatives, malt, gelatine, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, and pyrogen-free water.

[0059] As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this disclosure, a compound of formula (I ) to (Ii ) or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. In particular the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol, acetic acid, glycerol, liquid polyethylene glycols and mixtures thereof. A particular solvent is water.

[0060] It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question.

[0061] The compounds of the present disclosure may be suitable for the treatment of diseases in a human or animal subject. In one example, the subject is a mammal including a human, horse, dog, cat, sheep, cow, or primate. In another example, the subject is a human. In a further example, the subject is not a human. The terms "subject" and "patient" are used interchangeably herein.

[0062] As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function. The term also includes within its scope amounts effective to prevent a disease, disorder, or side effect.

[0063] As used herein the term "treatment" refers to defending against or inhibiting a symptom, treating a symptom, delaying the appearance of a symptom, reducing the severity of the development of a symptom, and / or reducing the number or type of symptoms suffered by an individual, as compared to not administering a pharmaceutical composition comprising a compound of the invention. The term also includes within its scope prevention of a disease, disorder, or side effect. The term "treatment" encompasses use in a palliative setting

[0064] The antitumor effect of the compounds of the present disclosure may be applied as a sole therapy or as a combination therapy i.e. where two or more serrulatane diterpenoids may be administered in combination. Therapy may also involve administration of a mixture of two or more serrulatane diterpenoids. Therapy may involve, in addition, administration of one or more other substances and / or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer such as a combination of surgery, radiotherapy and / or chemotherapy. In particular, it is known that irradiation or treatment with antiangiogenic and / or vascular permeability reducing agents can enhance the amount of hypoxic tissue within a tumour. Therefore the effectiveness of the compounds of the present invention may be improved by conjoint treatment with radiotherapy and / or with an antiangiogenic agent.

[0065] The individual components of such combinations can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The present disclosure is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other anti-neoplastic agents includes in principle any combination with any pharmaceutical composition useful for treating cancer.

[0066] When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, conveniently in such a manner as are known for such compounds in the art.

[0067] Pharmaceutical compositions of the present disclosure may be formulated for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Therefore, the pharmaceutical compositions of the invention may be formulated, for example, as tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. Such pharmaceutical formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Such pharmaceutical formulations may be prepared as enterically coated granules, tablets or capsules suitable for oral administration and delayed release formulations.

[0068] When a compound is used in combination with a second therapeutic agent active against the same disease, the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

[0069] Also disclosed herein is use of a compound of Formula (I), wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH, in the preparation of a medicament for treating a cancer.

[0070] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; and A---B is CH=C or CH 2 -CH.

[0071] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; and A---B is CH=C or CH 2 -CH.

[0072] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0073] Preferably: X is CH 2 ; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0074] Preferably: X is CHOH; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0075] Preferably: X is C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0076] Preferably, the compound is a compound of Formula (Ia):

[0077] Preferably, the compound is a compound of Formula (Ic):

[0078] Preferably, the compound is a compound of Formula (Ii ):

[0079] Preferably, A---B is CH=C.

[0080] The compound is preferably selected from the group consisting of:

[0081] Preferably, the compound is selected from the group consisting of: and

[0082] The compound is preferably selected from the group consisting of:

[0083] Preferably, the compound is selected from the group consisting of: , and

[0084] The compound is preferably:

[0085] Preferably, the compound is:

[0086] The compound is preferably:

[0087] Preferably, the compound is:

[0088] Preferably, the cancer is bladder cancer, bone cancer, brain cancer, breast cancer, a cancer of the central nervous system, cancer of the adrenal glands, cancer of the placenta, cancer of the testis, cervical cancer, colon cancer, kidney cancer, head and neck cancer, myeloma, leukemia, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, uterine cancer, a carcinoma, a lymphoma, a sarcoma, eye cancer, esophageal cancer, bile duct cancer or vulva cancer.

[0089] The cancer of the central nervous system is preferably a glioma. Preferably, the cancer of the central nervous system is a medulloblastoma. The cancer of the central nervous system is preferably a neuroblastoma.

[0090] Preferably, the lung cancer is a non-small cell lung cancer. The lung cancer is preferably a small cell lung cancer.

[0091] Preferably, the carcinoma is adenosquamous cell carcinoma or squamous cell carcinoma.

[0092] The sarcoma is preferably a liposarcoma, rhabdomyosarcoma, or fibrosarcoma. Preferably, the sarcoma is a soft tissue sarcoma. The soft tissue sarcoma is preferably a soft tissue osteosarcoma.

[0093] Preferably, the lymphoma is Burkitt's lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

[0094] Also disclosed herein is use of a compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 affienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH, in treating a cancer.

[0095] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; and A---B is CH=C or CH 2 -CH.

[0096] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; and A---B is CH=C or CH 2 -CH.

[0097] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0098] Preferably: X is CH 2 ; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0099] Preferably: X is CHOH; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0100] Preferably: X is C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0101] Preferably, the compound is a compound of Formula (Ia):

[0102] Preferably, the compound is a compound of Formula (Ic):

[0103] Preferably, the compound is a compound of Formula (Ii):

[0104] Preferably, A---B is CH=C.

[0105] The compound is preferably selected from the group consisting of:

[0106] Preferably, the compound is selected from the group consisting of: and

[0107] The compound is preferably selected from the group consisting of:

[0108] Preferably, the compound is selected from the group consisting of: , and

[0109] The compound is preferably:

[0110] Preferably, the compound is:

[0111] The compound is preferably:

[0112] Preferably, the compound is:

[0113] Preferably, the cancer is bladder cancer, bone cancer, brain cancer, breast cancer, a cancer of the central nervous system, cancer of the adrenal glands, cancer of the placenta, cancer of the testis, cervical cancer, colon cancer, kidney cancer, head and neck cancer, myeloma, leukemia, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, uterine cancer, a carcinoma, a lymphoma, a sarcoma, eye cancer, esophageal cancer, bile duct cancer or vulva cancer.

[0114] The cancer of the central nervous system is preferably a glioma. Preferably, the cancer of the central nervous system is a medulloblastoma. The cancer of the central nervous system is preferably a neuroblastoma.

[0115] Preferably, the lung cancer is a non-small cell lung cancer. The lung cancer is preferably a small cell lung cancer.

[0116] Preferably, the carcinoma is adenosquamous cell carcinoma or squamous cell carcinoma.

[0117] The sarcoma is preferably a liposarcoma, rhabdomyosarcoma, or fibrosarcoma. Preferably, the sarcoma is a soft tissue sarcoma. The soft tissue sarcoma is preferably a soft tissue osteosarcoma.

[0118] Preferably, the lymphoma is Burkitt's lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

[0119] Also disclosed herein is a compound of Formula (I ), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl, OC(O)C 4-5 alkadienyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC 4-5 alkadienyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or OC(O)C 4-5 alkadienyl; and A---B is CH=C or CH 2 -CH, for use in treating a cancer.

[0120] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph, OC(O)C 2-5 alkenyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC 2-5 alkenyl, OC(O)C 1-5 alkyl, OC(O)Ph or OC(O)C 2-5 alkenyl; and A---B is CH=C or CH 2 -CH.

[0121] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 2 is independently H, OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl, OC(O)Ph or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; and A---B is CH=C or CH 2 -CH.

[0122] Preferably: X is CH 2 , CHOH or C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; where X is CH 2 , CHOH or C(O), R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0123] Preferably: X is CH 2 ; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0124] Preferably: X is CHOH; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0125] Preferably: X is C(O); R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH.

[0126] Preferably, the compound is a compound of Formula (Ia):

[0127] Preferably, the compound is a compound of Formula (Ic ):

[0128] Preferably, the compound is a compound of Formula (Ii ):

[0129] Preferably, A---B is CH=C.

[0130] The compound is preferably selected from the group consisting of:

[0131] Preferably, the compound is selected from the group consisting of: and

[0132] The compound is preferably selected from the group consisting of:

[0133] Preferably, the compound is selected from the group consisting of:

[0134] The compound is preferably:

[0135] Preferably, the compound is:

[0136] The compound is preferably:

[0137] Preferably, the compound is:

[0138] Preferably, the cancer is bladder cancer, bone cancer, brain cancer, breast cancer, a cancer of the central nervous system, cancer of the adrenal glands, cancer of the placenta, cancer of the testis, cervical cancer, colon cancer, kidney cancer, head and neck cancer, myeloma, leukemia, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, uterine cancer, a carcinoma, a lymphoma, a sarcoma, eye cancer, esophageal cancer, bile duct cancer or vulva cancer.

[0139] The cancer of the central nervous system is preferably a glioma. Preferably, the cancer of the central nervous system is a medulloblastoma. The cancer of the central nervous system is preferably a neuroblastoma.

[0140] Preferably, the lung cancer is a non-small cell lung cancer. The lung cancer is preferably a small cell lung cancer.

[0141] Preferably, the carcinoma is adenosquamous cell carcinoma or squamous cell carcinoma.

[0142] The sarcoma is preferably a liposarcoma, rhabdomyosarcoma, or fibrosarcoma. Preferably, the sarcoma is a soft tissue sarcoma. The soft tissue sarcoma is preferably a soft tissue osteosarcoma.

[0143] Preferably, the lymphoma is Burkitt's lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

[0144] Also part of the invention is a compound of Formula (I ), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH 2 ; R 1 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 2 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; R 3 is independently H, OH, OC 1-5 alkyl, OC(O)C 1-5 alkyl or =O; and no more than one of R 1 , R 2 and R 3 can be H; R 4 is OH, OC 1-5 alkyl, OCH 2 Ph, OC(O)C 1-5 alkyl or OC(O)Ph; or X and R 3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R 4 is respectively OH or OC 1-5 alkyl or OC(O)C 1-5 alkyl; and A---B is CH=C or CH 2 -CH 2 , provided that: (A) where R 2 is H, X is not CH 2 ; and (B) where R 2 is H, and X and R 3 form a six-membered ether ring or a six-membered ring containing a hemiacetal carbon atom or an acetal carbon atom, A---B is CH=C.

[0145] Preferably, the compound is a compound of Formula (Ia ):

[0146] Preferably, the compound is a compound of Formula (Ic ):

[0147] Preferably, the compound is a compound of Formula (Ii ):

[0148] Preferably, A---B is CH=CH.

[0149] The compound is preferably selected from the group consisting of:

[0150] Preferably, the compound is selected from the group consisting of: and

[0151] The compound is preferably selected from the group consisting of:

[0152] Preferably, the compound is selected from the group consisting of: , and

[0153] The compound is preferably:

[0154] Preferably, the compound is:

[0155] The compound is preferably:

[0156] Preferably, the compound is:

[0157] Also disclosed herein is a pharmaceutical composition comprising a compound, stereoisomer, pharmaceutically acceptable salt or solvate thereof, as described herein, and a pharmaceutically acceptable excipient.

[0158] Also disclosed herein is a pharmaceutical composition comprising a compound, stereoisomer, pharmaceutically acceptable salt or solvate thereof, as described herein, or a mixture thereof, and a pharmaceutically acceptable excipient.

[0159] The compounds or pharmaceutical compositions disclosed above are preferably for use as a medicament.

[0160] The compounds or pharmaceutical compositions disclosed above are preferably for use in therapy.

[0161] Also disclosed is a compound described above isolated from propolis, wherein the propolis originates from plants of the Myoporum genus. Preferably, the propolis originates from Myoporum insulare.

[0162] Also disclosed is a compound described above isolated from the resin, gum or exudate of Myoporum genus. Preferably, the compound is isolated from the resin, gum or exudate of Myoporum insulare.

[0163] Also disclosed is a method of treating a disease or disorder, the method comprising administering a therapeutically effective amount of a compound or a composition described herein.

[0164] Also disclosed is use of a compound described herein in the preparation of a medicament for treating a disease or disorder.

[0165] Also disclosed herein is use of a compound or a composition described herein in treating a disease or disorder.

[0166] Also disclosed herein is a compound or a composition described herein for use in treating a disease or disorder.

[0167] Preferably, the disease or disorder is selected from the group consisting of: acute coronary syndrome, an aging-related disease or disorder; an allergic disease or a related condition; Alzheimer's disease, atherosclerosis, an autoimmune disease; a bacterial infection, cancer; dementia, depression or a related condition; diabetes; dyslipidemia, hyperlipidemia, hypertension, itchytosis, an immune disease; a metabolic disease or disorder; a neurological disease or disorder; obesity; Parkinson's disease; pain; rheumatoid arthritis and a skin disease or disorder.

[0168] The disease or disorder is preferably cancer.

[0169] Preferably, the cancer is bladder cancer, bone cancer, brain cancer, breast cancer, a cancer of the central nervous system, cancer of the adrenal glands, cancer of the placenta, cancer of the testis, cervical cancer, colon cancer, kidney cancer, head and neck cancer, myeloma, leukemia, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, uterine cancer, a carcinoma, a lymphoma, a sarcoma, eye cancer, esophageal cancer, bile duct cancer or vulva cancer.

[0170] The cancer of the central nervous system is preferably a glioma. Preferably, the cancer of the central nervous system is a medulloblastoma. The cancer of the central nervous system is preferably a neuroblastoma.

[0171] Preferably, the lung cancer is a non-small cell lung cancer. The lung cancer is preferably a small cell lung cancer.

[0172] Preferably, the carcinoma is adenosquamous cell carcinoma or squamous cell carcinoma.

[0173] The sarcoma is preferably a liposarcoma, rhabdomyosarcoma, or fibrosarcoma. Preferably, the sarcoma is a soft tissue sarcoma. The soft tissue sarcoma is preferably a soft tissue osteosarcoma.

[0174] Preferably, the lymphoma is Burkitt's lymphoma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

[0175] The skin disease or disorder is preferably selected from the group consisting of: eczema, psoriasis, acne, a scar, inflammation, a burn, sunburn, skin damage and skin irritation.

[0176] Representative compounds were evaluated for pharmacological activity and were found to be useful in modulating a number of diseases or disorders. For example, the compounds were found to inhibit cancer cell proliferation and showed moderate to strong inhibition of various targets associated with cancer pathology. Further discussion of compound activity is presented below in the Examples.Examples

[0177] In order to better understand the nature of the invention a number of examples will now be described as follows:ExperimentalMaterials

[0178] Honey bees observed collecting from the boobialla trees and shrubs (Myoporum insulare) were captured in plastic tubes, capped and frozen. Sections of the bee hind legs holding propolis were cut and pooled. Plant samples were obtained and dried at 40°C in a ventilated oven (Thermoline, NSW Australia) a few days to provide voucher specimens for identification by botanist, A / Prof Murray Henwood, John Ray Herbarium, University of Sydney, Sydney, Australia, and registered as Myoporum insulare voucher number Duke-131202-01. Resin extracted from plant samples was stored at -20°C until analysis or further processing.

[0179] Propolis was obtained from apiary sites with from 1 to 10 colonies of European honey bee (Apis mellifera ligustica) in standard 10-frame box hives, each fixed with a propolis mat under the hive cover lid. The propolis samples were collected and provided by a few beekeepers in eight apiary sites located in different parts of Kangaroo Island, South Australia. These sites were located in the vicinity of Hanson Bay, Vivonne Bay, Flour Cask Bay, Island Beach, Kingscote, Brownlow, Rainy Creek and Eleanor River. These locations are known to be a habitat for the plant Myoporum insulare on Kangaroo Island. This provided 23 propolis samples which, based on TLC analysis and 1< H NMR techniques, were estimated to be at least 90% sourced from M. insulare. The samples were stored at -20°C until further analysis and processing.

[0180] Thin layer chromatography sheets precoated with silica gel 60 F 254 and silica gel 60H for normal-phase short-column vacuum chromatography (NPSCVC) were purchased from Merck. TLC plates were visualized with a UVGL-58 mineral-light lamp, Multiband UV-2544 / 366.

[0181] All the chemicals used in the isolation and synthesis, including deuterated NMR solvents such as d-chloroform, d 4 -methanol and d 6 -dimethyl sulfoxide were purchased from Novachem Pty Ltd (Collingwood, Vic, Australia). Solvents including hexane, dichloromethane, ethyl acetate, isopropanol, ethanol, methanol, and acetic acid were of analytical grade and purchased from Chem Supply, Gillman, SA, Australia.General Methods

[0182] Rotavapor model R-114 rotary evaporator with a water bath temperature ranging between 40-60°C was used to evaporate the solvent fraction. Vacuum pump V-700 or Vacuubrand MD 4C NT diaphragm pump (Vacuubrand GMBH, Wertheim, Germany) with vacuum controller V-800 or V-850 is used. Final drying is carried out by a Napco 5831 vacuum oven (NAPCO, Salt Lake City, USA) using a DirectTorr vacuum pump (Sargent-Welch, Buffalo, USA).

[0183] Isocratic analytical HPLC was performed on a Shimadzu UFLC, LC-20AD pump, SIL-20A HT autosampler, with a Hewlett-Packard Column, NUCLEOSIL 100 C 18 , 5 µm, 4 mm × 125 mm, injection volume 20 µl, eluted at 1 ml / min and detected at 230 nm with a UV-Vis detector (Shimadzu SPD-20A). The column was eluted with methanol-water-acetic acid (65:34.8:0.2).

[0184] Gradient analytical HPLC was performed on a Shimadzu Nexera X2 LC-30AD system, SIL-30 autosampler, with a Hewlett-Packard Column, NUCLEOSIL 100 C 18 , 5 µm, 4 mm × 125 mm, injection volume 10 µl, eluted at 1 ml / min and detected at 320 nm with a SPD-M30A UV-Vis diode array detector. The column was eluted with a gradient system made up of methanol (phase A), and methanol: water: acetic acid (40:59.8:0.2) (phase B). A solvent gradient was applied as follows: 0-2 min: 32-50% A, 2-9 min: 50-90% A, 9-12 min: 90-100% A, 12-14 min, 100% A, and finally 14-15 min: 100-32% A, maintained over 5 min.

[0185] 1< H and 13< C Nuclear magnetic resonance (NMR) analyses were carried out on Varian 400 MHz System with a SMS autosampler (Palo Alto, California, USA). Chemical shifts (δ) of peaks in NMR spectra are reported in parts per million (ppm) and are referenced to tetramethylsilane (Si(CH 3 ) 4 , TMS). 1< H NMR data is reported as chemical shift (δ), relative integral, multiplicity (abbreviations: s = singlet, d = doublet, t = triplet, td = triplet of doublets, q = quartet, dd = doublet of doublets, ddd = doublet of doublet of doublets, bs = broad singlet, bt = broad triplet), coupling constant (J in Hz) and assignment. 13< C NMR data is reported as chemical shift (δ) and assignment.

[0186] For low resolution ESI-MS, the samples were analyzed by Finnigan Polaris Ion Trap MS / MS system (Finnigan Corporation, San Jose, USA) using an Xcalibur 1.2 data system, in Electrospray Ionization (ESI) negative and positive modes using infusion technique.

[0187] High resolution ESI-MS were measured on a Bruker Daltonics Apex Ultra Fourier Transform Ion Cyclotron Resonance 7 Tesla Mass Spectrometer, mass spectrometry unit, School of Chemistry, The University of Sydney.Determination of the 1< H-NMR chemical profiles of the plant and propolis specimens

[0188] Young leaf shoots (25 g), bee hind leg (0.01 g) and beehive propolis (1.0 g) were extracted with dichloromethane at room temperature for 15 min. The extracts were filtered, dried under reduced pressure and analyzed by 1< H-NMR and HPLC. Samples were found to contain serrulatane diterpenes. Propolis and plant samples were subsequently selected for isolation of the components.Preparation of Myoporum insulare resin extract

[0189] Fresh young leaves and young shoot tips were harvested from several Myoporum insulare trees. The leaves were stored in plastic bags on ice until processing within 5 days. To extract the external resin / exudate the leaves and shoot tips (4 Kg) were mixed with dichloromethane (4 litres) and after 1 hour standing the dichloromethane extract was filtered and the dichloromethane was removed from the filtrate by evaporation under reduced pressure using a rotary evaporator to give a brown partially solid dried resin (12.5 g, yield 0.31%).Isolation and identification of serrulatane diterpenes from Myoporum insulare propolis from Kangaroo Island.General Method

[0190] Propolis (100 g) was extracted with dichloromethane at room temperature with stirring for 1 hr. The extract was subjected to purification using normal-phase short column vacuum chromatography (NPSCVC). A step-wise gradient of mobile phase (2 × 100 mL) consisting of dichloromethane (DCM) and ethyl acetate (EtOAc) at 0, 1, 2, 4, 8, 10, 15, 20, 50 and 100% was employed to elute the components which were analysed by TLC and NMR. Further purification of the compounds, if required, was subsequently carried out on the same NPSCVC with different mobile phases consisting of either hexane and EtOAc or hexane and isopropanol. Structures and identity of these purified compounds were characterized by 1< H- and 13< C-NMR and mass spectrometry including high resolution mass spectrometry. Detailed structural analyses of the isolated compound were also carried out when needed by 2D-NMR using Gradient Heteronuclear Multiple Bond Coherence (GHMBC). The major serrulatane diterpenoid was determined to be 7,8,18-trihydroxyserrulat-14-ene (1).

[0191] Isolated serrulatane diterpenes from the plant, Myoporum insulare.7,8,18-trihydroxyserrulat-14-ene (1)

[0192]

[0193] Yellowish liquid, yield 50 mg, [α] D 20< -27.3° (C = 1.0, CHCl 3 ). UV (CH 3 OH) λ max nm (log ε) 279 (3.37) and 320 (2.49). IR (v): 3381, 2924, 2864, 1625, 1581, 1448 cm -1< . HRESIMS: 341.2089 m / z [M+Na] +< (calcd 341.2087) C 20 H 30 O 3 . 1< H NMR (400 MHz, CDCl 3 ) δ: 6.56, (1H, s, H-5), 5.04 (1H, bt, J= 7.0 Hz, H-14), 3.63 (2H, d, J= 6.2 Hz, H-18), 3.07 (1H, pentet of d, J= 6.8, 1.6 Hz, H-1), δ 2.76 (1H, td, J= 5.6, 2.6 Hz, H-4), 2.20 (3H, s, H-19), 1.99 (1H, m , H-13A), 1.90 (1H, m, H-13B), 1.90 (1H, m, H-3A), 1.86 (1H, m, H-2A), 1.83 (1H, m, H-11), 1.68 (3H, s, H-16), 1.66 (1H, m, H-2B), 1.58 (3H, s, H-17), 1.51 (1H, m, H-3B), 1.25 (1H, m, H-12A), 1.36 (2H, m, H-12B), 1.21 (3H, d, J= 7.0 Hz, H-20). 13< C NMR (100 MHz, CDCl 3 ) δ: 15.54 (C-19), 17.68 (C-17), 20.51 (C-2), 21.11 (C-20), 25.70 (C-16), 26.16 (C-13), 26.47 (C-3), 26.98 (C-1), 29.85 (C-12), 37.91 (C-4), 45.45 (C-11), 64.38 (C-18), 121.31 (C-6), 122.00 (C-5), 124.43 (C-14), 127.18 (C-9), 130.70 (C-10), 131.75 (C-15), 139.74 (C-7), 141.61 (C-8).5,18-epoxyserrulat-14-en-8,18-diol (2)

[0194]

[0195] Red liquid, yield 84 mg, [α] D 20< -21.5° (C = 1.0, CHCl 3 ). UV (CH 3 OH) λ max nm (log ε) 293 (3.36) and 334 (2.91). IR (v): 3327, 2970, 2926, 2860, 1647, 1558, 1448, 1043 cm -1< . HRESIMS: 315.1970 m / z [M-H] -< (calcd 315.1966).C 20 H 28 O 3 . 1< H NMR (400 MHz, CDCl 3 ) δ 6.48 (1H, s, H-7), 5.59 (1H, bs, H-18), 5.14 (1H, bt, J= 7.0 Hz, H-14), 3.11 (1H, sextet, J= 7.6, H-1), 2.54 (1H, td, J= 11.4, 3.6 Hz, H-4), 2.25 (1H, m, H-2A), 2.20 (1H, m, H-13A), 2.13 (3H, s, H-19), 2.09 (1H, m , H-13B), 2.08 (1H, m, H-3A), 1.69 (1H, m, H-12A), 1.70 (3H, s, H-16), 1.63 (3H, s, H-17), 1.52 (1H, m, H-11), 1.41 (1H, m, H-2B), 1.28 (3H, d, J= 6.9 Hz, H-20), 1.27 (1H, m, H-12B), 1.05 (1H, m, H-3B). 13< C NMR (100 MHz, CDCl 3 ) δ 15.88 (C-19), 17.75 (C-17), 22.89 (C-20), 25.36 (C-13), 25.70 (C-16), 26.62 (C-3), 27.79 (C-1), 28.90 (C-12), 31.75 (C-2), 31.99 (C-4), 40.48 (C-11), 91.88 (C-18), 115.94 (C-7), 122.94 (C-6), 124.09 (C-14), 124.29 (C-10), 125.21 (C-9), 131.99 (C-15), 141.71 (C-5), 146.85 (C-8).5,18-epoxy-8-hydroxyserrulat-14-ene (3)

[0196]

[0197] Shiny yellow liquid, yield 87 mg, [α] D 20< -8.9° (C = 1.0, CHCl 3 ). UV (CH 3 OH) λ max nm (log ε) 296 (3.55) and 334 (2.66). IR (v): 3502, 2922, 2856, 1622, 1597, 1421, 1230 cm -1< . HRESIMS: 301.21635 m / z [M+H] +< (calcd 301.21621) C 20 H 28 O 2 . 1< H NMR (400 MHz, CDCl 3 ) δ: 6.46 (1H, s, H-7), 5.13 (1H, bt, J= 6.9 Hz, H-14), 4.35 (1H, dd, J= 10.5, 3.7 Hz, H-18A), 3.70 (1H, t, J= 10.8 Hz, H-18B), 3.13 (1H, sextet, J= 7.4 Hz, H-1), 2.31 (1H, m, H-4), 2.24 (1H, m, H-2A), 2.16(1H, m, H-13A), 2.15 (1H, m, H-3A), 2.12 (3H, s, H-19), 2.02 (1H, m, H-13B), 1.74 (1H, m, H-12A), 1.70 (3H, s, H-16), 1.63 (3H, s, H-17), 1.55, (1H, m, H-11), 1.40 (1H, m, H-2B), 1.28 (3H, d, J= 7.0 Hz, H-20), 1.18 (1H, m, H-12B), 1.06 (1H, td, J= 12.2, 4.4 Hz, H-3B). 13< C NMR (100 MHz, CDCl 3 ) δ: 15.82 (C-19), 17.73 (C-17), 23.12 (C-20), 25.44 (C-13), 25.70 (C-16), 26.97 (C-3), 27.61 (C-1), 29.97 (C-12), 31.47 (C-2), 37.17 (C-11), 39.00 (C-4), 69.52 (C-18), 115.79 (C-7), 122.64 (C-6), 124.12 (C-14), 124.26 (C-9), 125.70 (C-10), 131.99 (C-15), 145.27 (C-5), 146.16 (C-8).7,8-dihydroxyserrulat-14-ene (4) (Reference compound)

[0198]

[0199] Yellowish liquid, yield 56 mg, [α] D 20< -21.1° (C = 1.0, CHCl 3 ). UV (CH 3 OH) λ max nm (log ε) 278 (3.36) and 329 (2.95). IR (v): 3396, 2954, 2924, 2868, 1635, 1577, 1456 cm -1< . HRESIMS: 325.21413 m / z [M+Na] +< (calcd 325.21380) C 20 H 30 O 2 . 1< H NMR (400 MHz, CDCl 3 ) δ 6.53 (1H, s, H-5), 5.00 (1H, bt, J= 7.0 Hz, H-14), 3.06 (1H, pentet of d, J= 6.7, 2.8 Hz, H-1), 2.53 (1H, td, J= 5.5, 3.4 Hz, H-4), 2.22 (3H, s, H-19), 2.00 (1H, m , H-13A), 1.95 (1H, m, , H-2A), 1.84 (1H, m, H-11), 1.82 (1H, m, H-3A), 1.80 (1H, m , H-13B), 1.70 (1H, m, H-3B), 1.67 (3H, s, H-16), 1.59 (3H, s, H-17), 1.48 (1H, m, H-2B), 1.29 (1H, m, H-12A), 1.12 (3H, d, J= 6.8 Hz, H-20), 1.05 (1H, m, H-12B), 0.95 (3H, d, J=6.8 ,H-18). 13< C NMR (100 MHz, CDCl 3 ) δ: 15.53 (C-19), 17.62 (C-17), 18.66 (C-18), 19.63 (C-3), 21.10 (C-20), 25.71 (C-16), 26.25 (C-13), 27.1 (C-1), 27.43 (C-2), 33.35 (C-12), δ 37.8 (C-11), δ 41.88 (C-4), δ 120.50 (C-6), δ 122.46 (C-5), δ 124.96 (C-14), δ 127.09 (C-9), δ 131.10 (C-15), δ 131.90 (C-10), δ 139.19 (C-7), δ 140.93 (C-8).Serrulat-14-en-5,8-dione (5) (Reference compound)

[0200]

[0201] Light orange liquid, yield 30 mg. 1< H NMR (400 MHz, CDCl 3 ) δ 6.68 (1H, s, H-5), 5.02 (1H, bt, J= 7.1 Hz, H-14), 2.85 (1H, m, H-1), 2.20 (1H, m, H-4), 2.12 (1H, m, H-3A), 2.03 (1H, m , H-13A), 1.95 (3H, s, H-19), 1.88 (1H, m, H-11), 1.85 (1H, m , H-13B), 1.69 (1H, m, H-2A), 1.67 (3H, s, H-16), 1.58 (3H, s, H-17), 1.34 (1H, m, H-2B), 1.30 (1H, m, H-12A), 1.20 (1H, m, H-3B), 1.12 (1H, m, H-12B), 1.07 (6H, d, J= 6.9 Hz, H-18 and H-20). 13< C NMR (100 MHz, CDCl 3 ) δ 15.21 (C-19), 17.69 (C-17), 18.67 (C-20), 18.75 (C-18), 20.55 (C-3), 25.71 (C-16), 26.10 (C-13), 26.56 (C-1), 26.59 (C-2), 33.41 (C-12), 34.9 (C-11), 43.83 (C-4), 124.13 (C-14), 132.00 (C-15), 135.36 (C-6), 140.04 (C-7), 140.70 (C-9), 150.13 (C-10), 179.85 (C-5), 181.55 (C-8).5,18-epoxyserrulat-14-en-7,8-dione (6)

[0202]

[0203] Purple liquid, yield 50 mg, HRESIMS: 315.19573 m / z [M+H]+ (calcd 315.19547) C 20 H 26 O 3 . 1< H NMR (400 MHz, CDCl 3 ) δ 5.07 (1H, bt, J= 6.8 Hz, H-14), 4.49 (1H, dd, J= 11.0, 3.8 Hz, H-18A), 3.86 (1H, t, J= 11.1 Hz, H-18B), 2.82 (1H, m, H-1), 2.14 (1H, m, H-4), 2.15 (1H, m, H-2A), 2.13 (1H, m, H-3A), 2.09 (1H, m , H-13A), 1.97 (1H, m , H-13B), 1.81 (3H, s, H-19), 1.76 (1H, m, H-12A), 1.74 (1H, m, H-11), 1.71 (3H, s, H-16), 1.63 (3H, s, H-17), 1.23 (1H, m, H-2B), 1.19 (1H, m, H-12B), 1.13 (3H, d, H-20) 1.11 (1H, m , H-3B),. 13< C NMR (100 MHz, CDCl 3 ) δ 7.57 (C-19), 17.78 (C-17), 21.67 (C-20), 24.66 (C-13), 25.32 (C-3), 25.71 (C-16), 28.74 (C-1), 29.15 (C-12), 30.77 (C-2), 37.07 (C-11), 40.09 (C-4), 71.85 (C-18), 114.44 (C-6), 123.06 (C-14), 132.87 (C-15), 139.43 (C-9), 149.67(C-10), 162.76 (C-5), 179.38 (C-7), 181.91 (C-8).

[0204] Compound 6 was observed to be formed from oxidation of compound 1. Acetylation of serrulatane diterpenes7,8,18-triacetyloxyserrulat-14-ene (7)

[0205]

[0206] The serrulatane (1) (400 mg) was dissolved in acetic anhydride (1 mL) and in dry pyridine (1 mL) and stirred at room temperature overnight (Davis et al., 1999). The reaction mixture was quenched with distilled water (30 mL), and was extracted with dichloromethane (3 × 40 mL). The dichloromethane solution was extracted with aqueous 0.1 M hydrochloric acid (30 mL) to remove the residual trace of pyridine. The dichloromethane solutions were dried with Na 2 SO 4 , filtered and concentrated on a rotary evaporator to give a yellow oily residue. Finally, using normal-phase short-column vacuum chromatography (NPSCVC) with dichloromethane and ethyl acetate (100:0 to 90:10, v / v) the compound (7) (434 mg, 77%) was purified and isolated as a pale yellow oil, yield 27 mg. HRESIMS: 467.2404 m / z [M+Na] +< (calcd 467.2206). C 26 H 36 O 6 . 1< H NMR (400 MHz, CDCl 3 ) δ 6.92 (1H, s, H-5), 4.97 (1H, bt, J=7.1 Hz, H-14), 4.11 (2H, d, J= 6.3 Hz, H-18), 2.92 (1H, m, H-1), 2.88 (1H, m, H-4), 2.31 (3H, s, H-26), 2.29 (3H, s , H-24), 2.14 (3H, s, H-19), 2.12 (1H, m, H-11), 2.06 (3H, s, H-22), 1.99 (1H, m, H-13A), 1.87 (1H, m, H-13B), 1.87 (1H, m, H-3A), 1.87 (1H, m, H-2A), 1.68 (1H, m, H-3B), 1.66 (3H, s, H-16), 1.54 (3H, s, H-17), 1.50 (1H, m, H-2B), 1.33 (1H, m, H-12A), 1.23 (1H, m, H-12B), 1.15 (3H, d, J= 7.0 Hz, H-20). 13< C NMR (100 MHz, CDCl 3 ) δ 16.08 (C-19), 17.60 (C-17), 19.16 (C-3), 20.36 (C-24), 20.51 (C-26), 20.97 (C-22), 21.45 (C-20), 25.68 (C-16), 26.11 (C-13), 26.96 (C-2), 27.58 (C-1), 28.32 (C-12), 36.92 (C-4), 41.92 (C-11), 65.88 (C-18), 123.94 (C-14), 128.09 (C-5), 128.31 (C-6), 132.04 (C-15), 139.26 (C-7), 140.56 (C-8), 134.06 (C-9), 137.11 (C-10), 168.1 (C-23), 168.34 (C-25), 171.18 (C-21).5,18-epoxyserrulat-14-ene-8,18-diacetate (8)

[0207]

[0208] To acetylate compound (2), 80 mg of serrulatane (2) was dissolved in acetic anhydride (1 mL) and in dry pyridine (1 mL) and stirred at room temperature overnight, and with the same workup procedure and using short-column vacuum chromatography with hexane and ethyl acetate (100:0 to 80:20, v / v) the compound (8) (57.8 mg,58%) was purified and isolated. Red coloured liquid, yield 18 mg, HRESIMS: m / z 423.2143 [M+Na] +< calcd 423.2142. C 24 H 32 O 5 . 1< H NMR (400 MHz, CDCl 3 ) δ: 6.69 (1H, s, H-7), 6.53 (1H, d, J= 1.7 Hz, H-18), 5.08 (1H, bt, J= 6.5 Hz, H-14), 2.96 (1H, sextet, J= 7.4 Hz, H-1), 2.54 (1H, td, J= 11.6, 3.8 Hz, H-4), 2.3 (3H, s, H-24), 2.19 (1H, m, H-13A), 2.19 (1H, m, H-2A), 2.14 (3H, s, H-19), 2.12 (1H, m, H-3A), 2.09 (3H, s, H-22), 2.02, (1H, m, H-13B), 1.70 (1H, m, H-12A), 1.69 (3H, s, H-16), 1.62 (3H, s, H-17), 1.65 (1H, m, H-11), 1.42 (1H, m, H-2B), 1.30 (1H, m, H-12B), 1.23 (3H, d, J= 6.8 Hz, H-12), 1.10 (1H, m, H-3B). 13< C NMR (100 MHz, CDCl 3 ) δ: 15.88 (C-19), 17.68 (C-17), 21.09 (C-22), 21.23 (C-24), 22.78 (C-20), 25.15 (C-13), 25.70 (C-16), 26.22 (C-3), 28.26 (C-1), 28.29 (C-12), 31.41 (C-2), 32.3 (C-4), 38.93 (C-11), 90.18 (C-18), 41.92 (C-11), 122.53 (C-7), 123.48 (C-14), 123.77 (C-10), 123.96 (C-6), 130.9 (C-9), 132.57 (C-15), 142.44 (C-8), 145.63 (C-5), 170.05 (C-23), 170.19 (C-21).Methylation of serrulatane diterpenes8-methoxy-7,18-dihydroxyserrulat-14-ene (11) and 7-methoxy-8,18-dihydroxyserrulat-14-ene (12)

[0209]

[0210] Compound 1 (140 mg) was treated with diazomethane (excess equiv) in diethyl ether at 0°C to room temperature overnight to give an undetermined 4 to 1 ( 1< H-NMR) mixture of mono-methylated products 11 and 12 (35 mg, 88% purity by HPLC).Compounds 11 and 12

[0211] Yellow oil Mass Spectrum (positive mode) m / z = 333.2 (12%, (M+H) +< ), 315.2 (100%, (M+H-H 2 O) +< ), 205.2 (18%, (M+H-C 8 H 16 O) +< ). HPLC analysis: Wavelength, 210 nm, bandwidth 4; Column, SorbTech C18AQ, 2.1 × 50 mm, 3 µm; Retention time 7.474 min; Mobile phase acetonitrile / formic acid / water; Gradient method, 5-95% CAN + 0.1% Formic acid in Water + 0.1% Formic acid in 14 min, hold at 95% CAN + Formic acid for 4 min. UV max , 275 nm and 210 nm, shoulder at 225 nm. 1< H-NMR analysis indicated a 4:1 undetermined mixture of 11 and 12 (interchangeable major and minor isomers). 1< H NMR (400 MHz, CDCl 3 ) δ: 6.74 (1H, s, H-5)[minor], 6.56, (1H, s, H-5)[major], 5.78 (1H, OH)[major], 5.57 (1H, OH)[minor], 5.01 (1H, bt, J= 6.3 Hz, H-14), 3.78 (3H, s, CH 3 O)[minor], 3.77 (3H, s, CH 3 O)[major], 3.63 (2H, m, H-18), 3.14 (1H, m, H-1)[major], 3.07 (1H, m, H-1)[minor], δ 2.81 (1H, m, H-4), 2.25 (3H, s, H-19)[major], 2.21 (3H, s, H-19)[minor], 2.0 - 1.8 (5H, m, H-13, H-3A, H-2A, H-11), 1.7 - 1.6 (1H, m, H-2B), 1.66 (3H, bs, H-16), 1.55 (3H, bs, H-17), 1.52 - 1.46 (1H, m, H-3B), 1.35 - 1.23 (2H, m, H-12), 1.21 (3H, d, J= 6.8 Hz, H-20)[major] 1.20 (3H, d, J= 6.8 Hz, H-20)[minor]. 13< C NMR (100 MHz, CDCl 3 ) δ: 15.50 (C-19)[minor], 15.77 (C-19)[major], 17.62 (C-17), 20.22 (C-2)[major], 20.44 (C-2)[minor], 21.08 (C-20)[major], 22.22 (C-20)[minor], 25.66 (C-16), 26.27 (C-13), 26.81 (C-3), 27.14 (C-1)[major], 27.87 (C-1)[minor], 29.14 (C-12)[minor], 29.26 (C-12)[major], 37.53 (C-4)[minor], 37.55 (C-4)[major], 45.43 (C-11)[minor], 45.53 (C-11)[major], 60.64 (OCH 3 )[major], 60.89 (OCH 3 )[minor], 64.17 (C-18)[major], 64.30 (C-18)[minor], 121.89 (C-5), 124.55 (C-14), 126.39, 126.70, 127.69, 130.42, 131.63, 131.66, 133.17, 135.11, 143.15, 144.85, 145.26, 146.27.

[0212] Figure 1 and Figure 2 show the 1< H NMR (400 MHz, CDCl 3 ) and the 13< C NMR (100 MHz, CDCl 3 ) spectra of the 4:1 mixture of compounds 11 and 12. Biological evaluation of serrulatane terpene compounds

[0213] The serrutalene diterpenes 1 to 3 were evaluated for in vitro biological activities using assays for epigenetics (Tables 3 to 6). Table 3 shows the experimental conditions used in epigenetic binding assays. Table 4 shows the results of inhibition of compounds 1 to 3 on binding of epigenetic interacting protein modules. Tables 5 to 8 show representative inhibition data for compound 1 on binding example epigenetic targets (Table 5: ASH1L (h) bromodomain; Table 6: CECR2(h) bromodomain; Table 7: SP140 (h) bromodomain; Table 8: UHRF1(108-286) (h)). Corresponding binding curves for the data displayed in Tables 5 to 8 are shown in Figures 3 to 6. Table 9 shows the results of inhibition of compounds 1 to 3 on binding of epigenetic enzymes. Table 10 shows the results for enzyme and cell-based stimulation assays for compounds 1 to 3.

[0214] Diterpenes 1 to 3 were also evaluated for in vitro pharmacological activity (Tables 11 to 13). Table 11 shows the experimental conditions used in the pharmacological assays. Table 12 shows the pharmacological activity of compounds 1 to 3. Table 13 shows effects of compounds 1 to 4 on glucose uptake while Table 14 shows dose response and IC 50 values for the pharmacological activity of compounds 1 to 3.

[0215] Diterpenes 1 to 4 and Myoporum insulare resin were evaluated in a cell viability assay (Table 15).

[0216] Diterpenes 1, 2, 4 and Myoporum insulare resin were assayed for cell cancer cell proliferation in an OncoPanel assay (Table 16 and Table 17). Epigenetic Assays

[0217] Epigenetic binding assays were carried out by Eurofins CEREP (France). The conditions used in the assays including: enzymes, source of enzymes, substrate, substrate concentration, ligand, ligand concentration, tracer, incubation, detection method, and reference compound and concentration are detailed in Table 3. Appropriate literature references are also provided. The AlphaScreen detection method refers to an Amplified Luminescent Proximity Homogeneous Assay used to study biomolecular interactions (see Ullman et al. 1994). LANCE and LanthaScreen assays are based on the principle of time-resolved fluorescence energy transfer (TR-FRET) and are described, for example, in Ma et al. 2008.

[0218] The IC 50 values (concentration causing a half-maximal inhibition of control specific activity) were determined by non-linear regression analysis of the inhibition / concentration-response curves generated with mean replicate values using Hill equation curve fitting. Inhibition / concentration-response curve concentrations were 30, 3, 0.3, 0.03 and 0.003 µM. Table 3. Epigenetic binding assay detailsAssayMain FeatureBromodomain ATAD2B bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration75 nMIncubation30 min / RTDetection methodAlphaScreenReference:Ischemin sodium salt (IC50:76.6 µM)ASH1L bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 di acetyl Lys 5 / 8Ligand concentration75 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:13.8 µM)BAZ2A bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration25 nMIncubation30 min / RTDetection methodAlphaScreenReference:GSK2801 (IC50:1.8 µM)BRPF1-1 bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration10 nMIncubation30 min / RTDetection methodAlphaScreenReference:Bromosporine (IC50:0.026 µM)CECR2 bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration10 nMIncubation30 min / RTDetection methodAlphaScreenReference:Bromosporine (IC50:0.062 µM)EP300 bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys56Ligand concentration25 nMIncubation30 min / RTDetection methodAlphaScreenReference:SGC-CBP30 (IC50:0.050 µM)KAT2A (GCN5L2) bromodo main [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration30 nMIncubation15 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:45 µM)PCAF bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:12 µM)PB1(2) bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys 14Ligand concentration60 nMIncubation15 min / RTDetection methodAlphaScreenReference:PFI-3 (IC50:68 µM)PB1(3) bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys14Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:47 µM)PB1(4) bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys14Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:Ischemin sodium salt (IC50:6.8 µM)PHIP(2) bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 diacetyl Lys5 / 8Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:SGC-CBP30 (IC50:0.130 µM)SP140 bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys 9Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:Ischemin (IC50:86 µM)SMARCA2 bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)LigandBiotin H3 mono acetyl Lys 14Ligand concentration5 nMIncubation30 min / RTDetection methodAlphaScreenReference:PFI-3 (IC50:0.47 µM)TAF1(1) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:GSK2801 (IC50:4.4 µM)SMARCA4 bromodomain [Filippakopoulos et al. 2012]Sourcehuman recombinant (E. coli)LigandBiotin -H3 mono acetyl Lys14Ligand concentration15 nMIncubation30 min / RTDetection methodAlphaScreenReference:PFI-3 (IC50:3 µM)TAF1(2) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:GSK2801 (IC50:10 µM)BAZ2B bromodomain [Philpott et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys14Ligand concentration25 nMIncubation30 min / RTDetection methodAlphaScreenReference:GSK2801 (IC50:1.8 µM)ATAD2A bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:70 µM)BRD2(1) bromodomain [Philpott et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-11 (IC50:0.510 µM)BRD2(2) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:0.017 µM)BRD3(1) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration25 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:0.040 µM)BRD3(2) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 di acetyl Lys 5 / 8Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:PFI-1 (IC50:0.79 µM)BRD4(1) bromodomain [Philpott et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:0.018 µM)BRD4(2) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:PFI-1 (IC50:1.3 µM)BRDT(l) bromodomain [Filippakopoulos and Knapp 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration25 nMIncubation30 min / RTDetection methodAlphaScreenReference:JQ-1 (IC50:0.110 µM)CREBBP bromodomain [Philpott et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 acetyl Lys56Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:SGC-CBP30 (IC50:0.120 µM)FALZ bromodomain [Philpott et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 tetra acetyl Lys 5 / 8 / 12 / 16Ligand concentration50 nMIncubation30 min / RTDetection methodAlphaScreenReference:I-CBP112 (IC50:24.5 µM)Chromodomain CBX1 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys9Ligand concentration5 nMIncubation30 min / RTDetection methodAlphaScreenReference:NACBX2 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys27Ligand concentration20 nMIncubation30 min / RTDetection methodAlphaScreenReference:NACBX4 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys27Ligand concentration8 nMIncubation30 min / RTDetection methodAlphaScreenReference:NACBX6 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys27Ligand concentration5 nMIncubation30 min / RTDetection methodAlphaScreenReference:NACBX5 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys9Ligand concentration6 nMIncubation15 min / RTDetection methodAlphaScreenReference:NACBX7 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys27Ligand concentration10 nMIncubation30 min / RTDetection methodAlphaScreenReference:NACBX8 [Kaustov et al. 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys27Ligand concentration55 nMIncubation30 min / RTDetection methodAlphaScreenReference:NAMBT domain L3MBTL1 [Kim et al. 2006]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 methylated Lys4Ligand concentration50 nMIncubation15 min / RTDetection methodAlphaScreenReference:NAL3MBTL3 [Kim et al. 2006]Sourcehuman recombinant (E. coli)Ligandbiotin-H4 dimethylated lysine 20Ligand concentration60 nMIncubation15 min / RTDetection methodAlphaScreenReference:NAPHD Domain SP140 [Org et al. 2008]Sourcehuman recombinant (E. coli)LigandBiotin H3K4meLigand concentration15 nMIncubation30 min / RTDetection methodAlphaScreenReference:NATRIM 33 [Venturini et al. 1999]Sourcehuman recombinant (E. coli)Ligandbiotin- H3 trimethylated Lys9Ligand concentration8 nMIncubation30 min / RTDetection methodAlphaScreenReference:NAUHRF1(108-286) [Xie et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3 trimethylated Lys9Ligand concentration15 nMIncubation15 min / RTDetection methodAlphaScreenReference:NAPHF20(1) [Adams-Cioba et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin- H4 dimethylated Lys20Ligand concentration100 nMIncubation30 min / RTDetection methodAlphaScreenReference:NACell-based detection methyl modifications H3K27 ac [Hayashi-Takanaka et al. 2011]SourceHeLa CellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K27 me2-1 [Kubicek, S. et al. 2007]SourceMCF7 cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K27 me3 [Kubicek, S. et al. 2007]SourceSU-DHL-6 cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K36 me2 [Kubicek, S. et al. 2007]SourceHeLa cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K4 me2 [Ken-ichi Noma and Grewal 2002]SourceHeLa cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K79 me2 [Kubicek, S. et al. 2007]SourceMCF7 cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K9 ac [Hayashi-Takanaka et al. 2011]SourceHeLa cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NAH3K9 me2 [Kubicek, S. et al. 2007]SourceHeLa cellsIncubation24h / 37 °CDetection methodAlphaScreenReference:NADemethylases (KDMs) FBXL10 (h) [Rotili and Mai 2011]Sourcehuman recombinant (Sf9 cells)Substratebiotin-H3K36me2 (24 nM)Incubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.61 µM)FBXL11 (h) [Chowdhury 2011]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K36me2Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 1.5 µM)JARID1A (h) [Nottke et al. 2009]Sourcehuman recombinant (Sf9 cells)Ligandbiotin-H3K4me3Ligand concentration100 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.18 µM)JARID1B (h) [Kristensen 2012]Sourcehuman recombinant (Sf9 cells)Ligandbiotin-H3K4me3Ligand concentration60 nMIncubation30 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.15 µM)JARID1C (h) [Nottke et al. 2009]Sourcehuman recombinant (Sf9 cells)Substratebiotin-H3K4me3Substrate concentration15 nMIncubation30 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.23 µM)JMJD1A (h) [Heightman 2011]Sourcehuman recombinant (E. coli)Substratebiotin-H3K4melSubstrate concentration25 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.76 µM)JMJD2A (h) [King et al. 2010]Sourcehuman recombinant (E. coli)Ligandbiotin-H3K9me3Ligand concentration100 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.083 µM)JMJD2B (h) [King et al. 2010]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K9me3Ligand concentration100 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.14 µM)JMJD2C (h) [King et al. 2010]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K9me3Ligand concentration100 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.091 µM)JMJD2D (h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.091 µM)JMJD2E (h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin-H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:2,4 PDCA (IC50: 0.061 µM)JMJD3 (h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCE 1198Reference:2,4 PDCA (IC50: 52 µM)LSD1 (h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:Tranylcypromine (IC50: 22 µM)PHF8(h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCE 1198Reference:Daminozide (IC50: 0.28 µM)UTX (h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin-H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:IOX1 (0.15 µM)DNA methyltransferases (DNMTs) DNMT1 (h) [Pradhan et al. 1999]Sourcehuman recombinant (E. coli)SubstratePoly (dI-dC)-Poly(dIdC) [6 mU / mL]Tracer[3H] SAM (50 nM)Incubation30 min / 37 °CDetection methodScintillation countingReference:SAH (IC50:0.23 µM)DNMT3b [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:SAH (IC50:0.094 µM)DNMT3B / DNMT3L (h) [Suetake et al. 2004]Sourcehuman recombinant (Sf9 cells)SubstratePoly (dI-dC)-Poly(dIdC) [0.15 mU / mL]Tracer[3H] SAM (200 nM)Incubation20 min / 37 °CDetection methodScintillation countingReference:SAH (IC50:0.045 µM)hDNMT3a [Aoki et al. 2001]Sourcehuman recombinant (Sf9 cells)SubstratePoly (dI-dC)-Poly(dIdC) [0.15 mU / mL]Tracer[3H] SAM (200 nM)Incubation20 min / 37 °CDetection methodScintillation countingReference:SAH (IC50:0.052 µM)Histone acetyltransferases (HATs) CREBBP(h) [Hong et al. 2007]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:Garcinol (IC50:1.5 µM)GCNSL2(h) [Hong et al. 2007]Sourcehuman recombinant (Sf9 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodLANCEReference:Anacardic acid (IC50:4.7 µM)HAT1(h) [Zhang et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin-H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodScintillation countingReference:Garcinol (IC50:1.5 µM)MYST3(h) [Zhang et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodScintillation countingReference:Garcinol (IC50:1.8 µM)MYST4 (h) [Zhang et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodScintillation counting 1293Reference:Curcumin (IC50:11 µM)pCAF(h) [Zhang et al. 2012]Sourcehuman recombinant (E. coli)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodScintillation counting 1293Reference:Garcinol (IC50:2.9 µM)TIP60 (h) [Zhang et al. 2012]Sourcehuman recombinant (Sf 21 cells)Ligandbiotin- H3K27me3Ligand concentration50 nMIncubation10 min / RTDetection methodScintillation counting 1293Reference:Garcinol (IC50:1.5 µM)Histone deacetylase (HDACs) [Strahl and Allis 2000] HDAC1 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrateSubstrate concentration20 µMIncubation10 min / RTDetection methodfluoro-lysine fluorimetryReference:trichostatin A (IC50:0.0052 µM)HDAC2 (h)Sourcehuman recombinant fluorogenic HDAC substrateLigandNASubstrate concentration20 µMIncubation15 min / RTDetection methodfluoro-lysine fluorimetry 896Reference:trichostatin A (IC50:0.024 µM)HDAC3 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrateSubstrate concentration50 µMIncubation10 min / RTDetection methodfluoro-lysine fluorimetryReference:trichostatin A (IC50:0.0068 µM)HDAC4 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrateSubstrate concentration20 µMIncubation30 min / RTDetection methodfluoro-lysine fluorimetryReference:trichostatin A (IC50:4.0 µM)HDAC5 (h)Sourcehuman recombinantLigandfluorogenic HDAC substrateSubstrate concentration20 µMIncubation30 min / RTDetection methodfluoro-lysine fluorimetryReference:trichostatin A (IC50:1.0 µM)HDAC6 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrateSubstrate concentration25 µMIncubation30 min / RTDetection methodfluoro-lysine fluorimetryReference:trichostatin A (IC50:0.0074 µM)HDAC7 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation45 min / RTDetection methodfluoro-lysine fluorimetryReference:trichostatin A (IC50:1.8 µM)HDAC8 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation45 min / RTDetection methodfluoro-lysine fluorimetry 896Reference:trichostatin A (IC50:0.41 µM)HDAC9 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation30 min / RTDetection methodfluoro-lysine fluorimetry 896Reference:trichostatin A (IC50:9.1 µM)HDAC10 (h)Sourcehuman recombinantSubstratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation45 min / RTDetection methodfluoro-lysine fluorimetry 896Reference:trichostatin A (TC50:0.009 µM)HDAC11 (h)Sourcehuman recombinant (E. coli)Substratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation30 min / 37 °CDetection methodfluoro-lysine fluorimetry 896Reference:Scriptaid (IC50:8.9 µM)Sirtuins sirtuin 1 (h) (inhibitor effect) [Strahl and Allis 2000]Sourcehuman recombinant (E. coli)Substratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation30 min / 37 °CDetection methodfluoro-lysine fluorimetryReference:Suramin (IC50:7.9 µM)sirtuin 2 (h) (inhibitor effect) [Michan and Sinclair 2007]Sourcehuman recombinant (E. coli)Substratefluoro-lysine sirtuin 2 deacetylase substrateSubstrate concentration150 µMIncubation60 min / RTDetection methodfluoro-lysine fluorimetryReference:Suramin (IC50:21 µM)sirtuin 3 (h) (inhibitor effect) [Strahl and Allis 2000]Sourcehuman recombinant (E. coli)Substratefluorogenic HDAC substrate class 2aSubstrate concentration50 µMIncubation30 min / 37 °CDetection methodfluoro-lysine fluorimetryReference:Niacinamide (IC50:21 µM)Sirtuin 6 (h) [Michishita et al. 2008]Sourcehuman recombinant (E. coli)SubstrateFluorogenic HDACSubstrate concentration50 µMIncubation180 min / RTDetection methodfluoro-lysine fluorimetryReferenceEX-527 (IC50:550 µM)Sirtuin 7 (h) [Kim and Kim 2013]Sourcehuman recombinant (Sf9 cells)Substratefluorogenic HDACSubstrate concentration25 µMIncubation60 min / 37 °CDetection methodfluoro-lysine fluorimetryReference:JFD00244 (IC50:1300 µM)Methyltransferases (MTs) ASH1L [An et al. 2011]Sourcehuman recombinant (E. coli)Substratepolynucleosome (1.5 µg / mL)Tracer[3H] SAM (150 nM)Incubation15 min / RTDetection methodScintillation countingReference:SAH (IC50: 9.1 µM)DOT1L (h) [An et al. 2011]Sourcehuman recombinant (E. coli)Substratepolynucleosome (2.5 µg / mL)Tracer[3H] SAM (150 nM)Incubation15 min / RTDetection methodScintillation countingReference:SAH (IC50: 0.14 µM)EHMT1 (h) [Yost et al. 2011]Sourcehuman recombinant (E. coli)Substrate (concentration)histone H3 full length (10 nM)Co-substrate (concentration)[3H] SAM (25 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (IC50: 0.18 µM)EZH1 / EED / SUZ12 (h) [Shen et al. 2008]Sourcehuman recombinantSubstrate (concentration)histone H3 full length (70 nM)Co-substrate (concentration)[3H] SAM (120 nM)Incubation90 min / RTDetection methodScintillation countingReference:SAH (IC50: 8.4 µM)EZH2 / EED / SUZ12 (h) (PRC2 complex) [Philpott et al. 2011]Sourcehuman recombinant (Sf9 cells)Substrate (concentration)histone H3 full length (50 nM)Co-substrate (concentration)[3H] SAM (350 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (IC50: 22 µM)G9a (h) [Yost et al. 2011]Sourcehuman recombinant (E. coli)Substratehistone H3 full length (5 nM)Co-substrate[3H] SAM (25 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (2.1 µM)hSMYD2 [An et al. 2011]Sourcehuman recombinant (Sf9 cells)Substratehistone H4 full length (25 nM)Co-substrate[3H] SAM 150 nMIncubation10 min / RTDetection methodScintillation countingReference:SAH (0.16 µM)MLL complex (h) [Jiang et al. 2013]Sourcehuman recombinant (E. coli)SubstrateHistone H3 full length (35 nM)Tracer[3H] SAM (200 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (0.97 µM)MLL2(h) complex [Jiang et al. 2013]Sourcehuman recombinant (E. coli)SubstrateHistone H3 full length (35 nM)Tracer[3H] SAM (200 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (0.97 µM)MLL3(h) complex [Ali et al. 2014]Sourcehuman recombinant (E. coli)SubstrateCore histone (20 nM)Tracer[3H] SAM (200 nM)Incubation20 min / RTDetection methodScintillation countingReference:SAH (0.97 µM)MLL4(h) complex [Ali et al. 2014]Sourcehuman recombinant (E. coli)SubstrateCore histone (30 nM)Tracer[3H] SAM (200 nM)Incubation10 min / RTDetection methodScintillation countingReference:SAH (0.97 µM)NSD1 (h) [Allali-Hassani et al. 2014]Sourcehuman recombinant (E. coli)SubstrateHistone H3 full length (35 nM)Tracer[3H] SAM (200 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (0.97 µM)NSD3 / WHSC1L1 (h) [Selvi et al. 2010]Sourcehuman recombinant (E. coli)SubstrateHistone H3 full length (35 nM)Tracer[3H] SAM (200 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (0.97 µM)PRDM9 (h) [Munoz-Fuentes et al. 2011]Sourcehuman recombinant (E. coli)SubstrateHistone H3 full length (250 nM)Co-Substrate[3H] SAM (60 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (370 µM)PRMT1 (h) [Cheng et al. 2004]Sourcehuman recombinant (E. coli)Substratehistone H4 full length (25 nM)Co-substrate[3H] SAM (60 nM)Incubation90 min / RTDetection methodScintillation countingReference:SAH (0.094 µM)PRMT3 (h) [Li et al. 2012]Sourcehuman recombinant (E. coli)Substratehistone H4 full length (25 nM)Co-substrate[3H] SAM (60 nM)Incubation90 min / RTDetection methodScintillation countingReference:SAH (0.86 µM)PRMT4 (h) [Selvi et al. 2010]Sourcehuman recombinant (Sf9 cells)Substratehistone H4 full length (25 nM)Co-substrate[3H] SAM (60 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (0.094 µM)PRMT5 complex (h) [Yost et al. 2011]Sourcehuman recombinant (Sf9 cells)Substratehistone H4 full length (250 nM)Co-substrate[3H] SAM (600 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (0.65 µM)PRMT6 (h) [Iberg et al. 2007]Sourcehuman recombinant (Sf9 cells)Substratehistone H4 full length (250 nM)Co-substrate[3H] SAM (600 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (0.65 µM)PRMT7 (h) [Zurita-Lopez et al. 2012]Sourcehuman recombinant (Sf9 cells)Substratehistone H2B (21-41) biotin labeled (4 nM)Co-substrate[3H] SAM (250 nM)Incubation90 min / RTDetection methodScintillation countingReference:SAH (0.65 µM)PRMT8 (h) [Lee et al. 2005]Sourcehuman recombinant (Sf9 cells)Substratehistone H4 full length (250 nM)Co-substrate[3H] SAM (600 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (0.65 µM)SETD2(h) [Du et al. 2008]Sourcehuman recombinant (E. coli)SubstrateNucleosome (0.5 µg / mL)Co-substrate[3H] SAM (250 nM)Incubation10 min / RTDetection methodScintillation countingReference:SAH (1.2 µM)SETD7 (h) [Li et al. 2012]Sourcehuman recombinant (E. coli)Substratehistone H3 full length (120 nM)Co-substrate[3H] SAM (850 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (24 µM)SETD8 (h) [Yost et al. 2011]Sourcehuman recombinant (E. coli)Substratehistone H3 full length (120 nM)Co-substrate[3H] SAM (850 nM)Incubation30 min / RTDetection methodScintillation countingReference:SAH (24 µM)SETDB1 (h) [Schultz et al. 2002]Sourcehuman recombinant (Sf9 cells)Substratehistone H3 full length (15 nM)Co-substrate[3H] SAM (25 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (1.8 µM)SUV39H2 (h) [Yost et al. 2011]Sourcehuman recombinant (Sf9 cells)Substratehistone H3 full length (500 nM)Co-substrate[3H] SAM (350 nM)Incubation120 min / RTDetection methodScintillation countingReference:SAH (24 µM)SUV4-20H2 (h) [Li et al. 2012]Sourcehuman recombinant (E. coli)SubstrateNucleosome (1.5 µg / ml)Co-substrate[3H] SAM (75 nM)Incubation15 min / RTDetection methodScintillation countingReference:SAH (24 µM)WHSC1(h) (NSD2(h)) [Kang et al. 2009]Sourcehuman recombinant (E. coli)SubstrateCore Histone (1500 nM)Tracer[3H] SAM (250 nM)Incubation15 min / RTDetection methodScintillation countingReference:Chaetocin (IC50: 0.48 µM)Kinases Aurora B (h) (substrate histone H3 full length) [Sabbattini et al. 2007]SourceBaculovirusSubstrateHistone H3 full length (150nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (0.038 µM)DAPK3 / ZIP (substrate histone H3 full length) [Preuss et al. 2003]SourceBaculovirusSubstrateHistone H3 full length (50nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.0073 µM)Haspin (h) (substrate histone H3 full length) [Han et al. 2011]Sourcehuman recombinant (E. coli)Substratebaculovirus Histone H3 full length (250nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.0073 µM)IKK alpha(h) (substrate histone H3 full length) [Baek 2011]Sourcehuman recombinant (Sf21 cells)SubstrateHistone H3 full length (50nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.03 µM)MSK1(h) (substrate histone H3 full length) [Baek 2011]Sourcehuman recombinant insect cellsSubstrateHistone H3 full length (100nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.015 µM)MSK2(h) (substrate histone H3 full length) [Baek 2011]Sourcehuman recombinant (insect cells)SubstrateHistone H3 full length (20nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.0058 µM)PIM1(h) (histone H3 full length substrate) [Baek 2011]Sourcehuman recombinant (Sf21 cells)SubstrateHistone H3 full length (50nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.03 µM)PKB alpha / AKTl(h) (substrate histone H3 full length) [Barnett et al. 2005]Sourcehuman recombinant (Sf21 cells)SubstrateHistone H3 full length (50nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.03 µM)PKBbeta / AKT2(h) (substrate histone H3 full length) [Barnett et al. 2005]Sourcehuman recombinant (baculovirus)SubstrateHistone H3 full length (100nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.03 µM)PKBgamma / AKT3(h) (substrate histone H3 full length) [Baek 2011]Sourcehuman recombinant (baculovirus)SubstrateHistone H3 full length (150nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.03 µM)Rsk2(h) (substrate histone H3 full length) [Baek 2011]Sourcehuman recombinant (baculovirus)SubstrateHistone H3 full length (250nM)Tracer[33P] ATPIncubation10 min / RTDetection methodScintillation countingReference:Staurosporine (IC50: 0.007 µM)Small molecule methyltransferases Catechol O-methyltransferase (h)Sourcehuman recombinant (E. coli)SubstratePyrocatechol (250nM)TracerSAM (10 µM)Incubation15 min / 37 °CDetection methodMSReference:SAH-d4 (IC50: 14 µM)Glycine N-methyltransferase (h)Sourcehuman recombinant (E. coli)SubstrateGlycine (100 µM)TracerSAM (20 µM)Incubation30 min / 22 °CDetection methodMSReference:SAH-d4 (IC50: 17 µM)Guanidinoacetate N-methyltransferase (h)Sourcehuman recombinant (E. coli)SubstrateGuanidineacetic acid (4 µM)TracerSAM (7 µM)Incubation30 min / 22 °CDetection methodMSReference:SAH-d4 (IC50: 2.3 µM)Histamine N-methyltransferase (h)Sourcehuman recombinant (E. coli)SubstrateHistamine (4 µM)TracerSAM (4 µM)Incubation30 min / 22 °CDetection methodMSReference:SAH-d4 (IC50: 13 µM)Nicotinamide N-methyltransferase (h)Sourcehuman recombinant (E. coli)SubstrateNicotinamide (8 µM)TracerSAM (6 µM)Incubation15 min / 22 °CDetection methodMSReference:SAH-d4 (IC50: 13 µM)Phenylethanolamine N-methyltransferase (h)Sourcehuman recombinant (E. coli)SubstrateDL-Normetanephrine SAM (35 µM)TracerSAM (6 µM)Incubation45 min / 22 °CDetection methodMSReference:SAH-d4 (IC50: 13 µM)Thiopurine S-methyltransferase (h)Sourcehuman recombinant (E. coli)Substrate6-mercaptopurine (1.5 µM)TracerSAM (1.5 µM)Incubation30 min / 22 °CDetection methodMSReference:SAH-d4 (IC50: 2.3 µM)Ubiquitin modifying enzymes BAP1 (h) [Misaghi et al. 2009]Sourcehuman recombinant (E. coli)SubstrateLanthaScreen DUB substrateSubstrate concentration20 nMIncubation180 min / RTDetection methodLanthaScreenReference:Ubiquitin aldehyde (IC50: 0.23 µM)USP 10 (h) [Horton et al. 2007]Sourcehuman recombinant (Sf9 cells)SubstrateLanthaScreen DUB substrateSubstrate concentration10 nMIncubation60 min / 22 °CDetection methodLanthaScreenReference:Ubiquitin aldehyde (IC50: 0.23 µM)USP 14 (h) [Hu et al. 2005]Sourcehuman recombinant (Sf9 cells)SubstrateLanthaScreen DUB substrateSubstrate concentration10 nMIncubation240 min / RTDetection methodLanthaScreenReference:Ubiquitin Aldehyde (0.004 µM)USP 16 (h) [Horton et al. 2007]SourceHuman recombinant HEK 293 cellsSubstrateLanthaScreen DUB substrateSubstrate concentration20 nMIncubation180 min / 22 °CDetection methodLanthaScreenReference:Iodoacetamide (3.5 µM)USP 21 (h) [Ye et al. 2011]Sourcehuman recombinant (E. coli)SubstrateLanthaScreen DUB substrateSubstrate concentration10 nMIncubation15 min / RTDetection methodLanthaScreenReference:Ubiquitin aldehyde (IC50: 0.17 µM)USP 7 (h) [Tian et al. 2011]Sourcehuman recombinant (Sf21 cells)SubstrateLanthaScreen DUB substrateSubstrate concentration10 nMIncubation60 min / RTDetection methodLanthaScreenReference:Ubiquitin Aldehyde (0.11 µM)

[0219] Results for the binding assays are shown below in Table 4. Table 4. Inhibition of Compounds 1 to 3 at 10 µM on binding of epigenetic interacting protein modules against reference compounds.Binding Assay % Inhibition A< Reference Comp 1 Comp 2 Comp 3 Compound IC 50 µM Bromodomain ATAD2B (h)522528Ischemin sodium salt76.6ASH1L (h)955942JQ-113.8BAZ2A (h)561716GSK28011.8BRPF1-1 (h)-25-25-4Bromosporine0.026CECR2 (h)1002515Bromosporine0.062EP300 (h)893740SGC-CBP300.050KAT2A (GCN5L2) (h)761918JQ-145PCAF (h)37163JQ-112PB1(2) (h)312213PFI-368PB1(3) (h)38136JQ-147PB1(4) (h)41-316Ischemin sodium salt6.8PHIP(2) (h)613023SGC-CBP300.130SP140 (h)84431Ischemin86SMARCA2 (h)832118PFI-30.47TAF1(1) (h)481717GSK28014.4SMARCA4 (h)531613PFI-33TAF1(2)(h)622822GSK280110BAZ2B (h)582321GSK28011.8ATAD2A (h)100169JQ-170BRD2(1) (h)608919JQ-10.510BRD2(2) (h)582218JQ-10.017BRD3(1) (h)471713JQ-10.040BRD3(2) (h)35251PFI-10.79BRD4(1) (h)49118JQ-10.018BRD4(2) (h)761613PFI-11.3BRDT(1) (h)432329JQ-10.110CREBBP (h)652117SGC-CBP300.120FALZ (h)42185I-CBP11224.5Chromodomain CBX1 (h)150-1NACBX2 (h)1763NACBX4 (h)252940NACBX6 (h)-12758NACBX5 (h)252425NACBX7 (h)253343NACBX8 (h)273123NAMBT domain L3MBTL1416159NAL3MBTL3 (h)222933NAPHD domain SP140 (h)7402NATRIM 33 (h)593-2NAUHRF1(108-286) (h)733429NATudor domain PHF20(1)722NA A< % Inhibition of Control Specific Binding NA Not-applicable

[0220] Representative inhibition data for compound 1 on binding example epigenetic targets is shown in Tables 5 to 8. Table 5. ASH1L (h) bromodomainConc. 1 st< 2 nd< Mean 3.0E-09 M-2.6-8.2-5.43.0E-08 M-12.31.8-5.23.0E-07 M-0.2-2.9-1.63.0E-06 M17.028.022.53.0E-05 M100.699.6100.1 Table 6. CECR2(h) bromodomain binding curve Conc. 1 st< 2 nd< Mean 3.0E-09 M5.92.44.23.0E-08 M-0.9-1.7-1.33.0E-07 M-1.50.9-0.33.0E-06 M7.38.67.93.0E-05 M99.499.699.5 Table 7. SP140 (h) bromodomain binding curve. Conc. 1 st< 2 nd< Mean 3.0E-09 M-6.0-8.6-7.33.0E-08 M-9.7-14.6-12.13.0E-07 M-14.1-11.0-12.63.0E-06 M8.411.39.93.0E-05 M102.3102.3102.3 Table 8. UHRF1(108-286) (h) binding curve. Conc. 1 st< 2 nd< Mean 3.0E-09 M-11.9-13.1-12.53.0E-08 M-13.3-12.6-12.93.0E-07 M-12.1-13.2-12.73.0E-06 M-1.8-0.1-0.93.0E-05 M81.583.382.4 Table 9. IC 50 values from inhibition / concentration-response curves of compounds 1 and 2 for binding of epigenetic interacting protein modules against reference compounds. Compound 12ReferenceReferenceIC 50 (µM)IC 50 (µM)Comp.IC 50 (µM)Bromodomain ASH1L (h)4.2JQ-18.7ATAD2A (h)3.1Ischemin5.2BRD2(1) (h)221-BET 1510.028BRD4(2) (h)5.6PFI-11.1CECR2(h)5Bromosporine0.14CREBBP (h)3.4SGC-CBP300.046EP300 (h)4.5SGC-CBP300.068KAT2A (GCN5L2) (h)3.9GSK280110SP140 (h)3.8Ischemin11 PHD domain SP140 (h)4.6NANAUHRF1(108-286) (h)11NANA Table 10. Inhibition of compounds 1 to 3 at 10 µM on activity of epigenetic enzymes against references. % Inhibition A< Reference Assay Comp 1 Comp 2 Comp 3 Compound IC 50 µM Cell-based detection methyl modifications H3K27 ac-16-12-11(Not-applicable) NAH3K27 me2-1-232NAH3K27 me3-8-70NAH3K36 me2107-8NAH3K4 me2-5-1-9NAH3K79 me2-2-16-5NAH3K9 ac173-1NAH3K9 me211120NA Demethylases (KDMs) FBXL10 (h)377222,4 PDCA0.61FBXL11 (h)342112,4 PDCA1.5JARID1A (h)64-932,4 PDCA0.18JARID1B (h)706-22,4 PDCA0.15JARID1C (h)49-13252,4 PDCA0.23JMJD1A (h)8037-12,4 PDCA0.76JMJD2A (h)29-10122,4 PDCA0.083JMJD2B (h)651682,4 PDCA0.14JMJD2C (h)35282,4 PDCA0.091JMJD2D (h)36-17182,4 PDCA0.091JMJD2E (h)651062,4 PDCA0.061JMJD3 (h)919112,4 PDCA52LSD1 (h)1010-3Tranylcypromine22PHF8(h)36-1113Daminozide0.28UTX (h)68527IOX10.15 DNA methyltransferases (DNMTs) DNMT1 (h)104-5SAH0.23DNMT3b-3-17-4SAH0.094DNMT3B / DNMT3L (h)2327-20SAH0.045hDNMT3a33-31SAH0.052 Histone acetyltransferases (HATs) CREBBP(h)747843Garcinol1.5GCN5L2(h)1151Anacardic Acid4.7HAT1(h)-33-3Garcinol1.5MYST3(h)18113Garcinol1.8MYST4(h)253971Curcumin11pCAF(h)-25-26-20Garcinol2.9TIP60(h)2010-3Garcinol1.5 Histone deacetylase (HDACs) HDAC1 (h)-2-1-1trichostatin A0.0052HDAC2 (h)10-2trichostatin A0.024HDAC3 (h)113trichostatin A0.0068HDAC4 (h)-73-20-11trichostatin A4.0HDAC5 (h)-3-2-1trichostatin A1.0HDAC6 (h)122-18trichostatin A0.0074HDAC7 (h)-111-616trichostatin A1.8HDAC8 (h)-8-190trichostatin A0.41HDAC9 (h)-50-1-9trichostatin A9.1HDAC10 (h)136trichostatin A0.0090HDAC11 (h)27-47-130scriptaid8.9 Sirtuins sirtuin 1 (h) (inhibitor effect)2-3-5suramin7.9sirtuin 2 (h) (inhibitor effect)-46-19suramin21sirtuin 3 (h) (inhibitor effect)-14-8-3niacinamide21Sirtuin 6 (h)26-4EX-527550Sirtuin 7 (h)7-2-8JFD002441300 Methyltransferases (MTs) ASH1L320-54SAH9.1DOT1L (h)-51813SAH0.14EHMT1 (h)13963SAH0.18EZH1 / EED / SUZ12 (h)-13-12SAH8.4EZH2 / EED / SUZ12 (h) (PRC2 complex)19264SAH22G9a (h)866449SAH2.1hSMYD2125-12SAH0.16MLL complex (h)22211SAH0.97MLL2(h) complex63-15SAH24MLL3(h) complex-22-21-33SAH9.0MLL4(h) complex-16-18-4SAH0.55NSD1 (h)6929-10chaetocin0.13NSD3 / WHSC1L1 (h)-1711-35Suramin1.5PRDM9 (h)954SAH370PRMT1 (h)1626-1SAH0.094PRMT3 (h)225014SAH0.86PRMT4 (h)908477SAH0.094PRMT5 complex (h)8-89SAH0.65PRMT6 (h)495734SAH0.053PRMT7 (h)-20-36SAH0.86PRMT8 (h)524-26SAH0.14SETD2(h)-9-4-11SAH1.2SETD7 (h)1216-2SAH24SETD8 (h)425-10mercurochrome2.4SETDB1 (h)534352SAH1.8SUV39H2 (h)-8-1614SAH24SUV4-20H2 (h)1120-45SAH4.7WHSC1(h) (NSD2(h))3147Chaetocin0.48 Kinases Aurora B (h) (substrate histone H3 full length)64-1Staurosporine0.038DAPK3 / ZIP (substrate histone H3 full length)498Staurosporine0.0073Haspin (h) (substrate histone H3 full length)2117Staurosporine0.032IKK alpha(h) (substrate histone H3 full length)262814staurosporine0.03MSK1(h) (substrate histone H3 full length)6210Staurosporine0.015MSK2(h) (substrate histone H3 full length)912-1Staurosporine0.0058PIM1(h) (histone H3 full length substrate)22115Staurosporine0.025PKB alpha / AKTl(h) (substrate histone H3 full length)-1-19-15Staurosporine0.0073PKBbeta / AKT2(h) (substrate histone H3 full length)131112Staurosporine0.021PKBgamma / AKT3(h) (substrate histone H3 full length)5-73Staurosporine0.03Rsk2(h) (substrate histone H3 full length)57-4Staurosporine0.007 Small molecule methyltransferases Catechol O-methyltransferase (h)610SAH-d414Glycine N-methyltransferase (h)555-11SAH-d417Guanidinoacetate N-methyltransferase (h)8-1-1SAH-d42.3Histamine N-methyltransferase (h)18-218SAH-d413Nicotinamide N-methyltransferase (h)13-2-2SAH-d413Phenylethanolamine N-methyltransferase (h)2395SAH-d43.9Thiopurine S-methyltransferase (h)402819SAH-d42.3 Ubiquitin modifying enzymes BAP1 (h)1-924Ubiquitin Aldehyde0.23USP 10 (h)72-7N-Methylmaleimide1000USP 14 (h)10-24Ubiquitin Aldehyde0.004USP 16 (h)111412Iodoacetamide3.5USP 21 (h)-1833Ubiquitin aldehyde0.17USP 7 (h)-18-149Ubiquitin Aldehyde0.11 A< % Inhibition of Control Values Table 11. IC 50 values from inhibition / concentration-response curves of compounds 1, 2 and 4 for inhibition of epigenetic enzymes against reference compounds. Compound 1 2 4 ReferenceReferenceEnzyme and Cell-based assays IC 50 (µM)IC 50 (µM)IC 50 (µM)CompoundIC 50 (µM)Demethylases JARID1A (h)9.62,4 PDCA0.099JARID1B (h)3.62,4 PDCA0.12JMJD1A (h)4.52,4 PDCA3.9JMJD2B (h)122,4 PDCA0.095JMJD2E (h)4.72,4 PDCA0.11JMJD3 (h)142,4 PDCA73UTX (h)6.7IOX10.056 Histone acetyltransferases CREBBP(h)3.96.1Garcinol5.4MYST4 (h)4.2Curcumin8.9 Histone methyltransferases G9a (h)115.4SAH4.6NSD1 (h)4.9chaetocin0.24PRMT4 (h)4.75.44.7SAH0.056 Results: epigenetic targets, diseases and cancer

[0221] Epigenetic modifications can have a role in the development of a variety of diseases. Epigenetic regulation involves hierarchical covalent modification of DNA and proteins that package such as histones. DNA is regulated by methylation and demethylation on the cytosine residues. DNA methylation is mediated by members of the DNA-methyl transferase family (DNMT1, DNMT3A and DNMT3B) whereas demethylation is mediated by the family ten-eleven translocation (TET1-3). Besides methylation and demethylation, histone is also regulated by acetylation and deacetylation. The key proteins that mediate epigenetic signaling though acetylation and methylation of histones comprise histone acetyltransferases (HATs), histone deacetylases (HDMs), protein methyltransferases (PMTs) including lysine methyltransferases (KMTs) protein arginine methyltransferases (PRMTs), and bromodomain-containing proteins and proteins that bind to methylated histones (Arrowsmith et al., 2012; Plass et al., 2013; Tough et al., 2014; Biggar and Li, 2015).Bromodomain containing proteins

[0222] Compound 1 showed significant inhibitory activity towards many of the bromodomain containing proteins (Table 10), in particular ASH1L, CECR2, EP300, KAT2A, PHIP(2), SP140, SMARCA2, TAF1(2), ATAD2A, BRD2(1), BRD4(2) and CREBBP. Compound 2 only showed significant activity towards BRD2(1). Recent studies have implicated bromodomain (BRD) containing proteins in a wide range of human diseases, including cancer (Taverna et al., 2007; Prinjha et al., 2012; Biggar and Li, 2015). The most investigated member of BRD containing proteins (BCPs) as drug targets is the BET family proteins. Currently, there are several BET inhibitors in various stages of clinical trials including RVX-208, I-BET 762, OTX 015, CPI-0610 and TEN-010 (see Table 14 in Tough et al., 2014).

[0223] In addition, JQ1 and I-BET have been shown to interact with NF-κB and induce apoptosis in drug resistant leukemia (Ciceri et al., 2014). NF-κB plays a central role inflammation and unresolved inflammation is involved in many disease states including cancer.

[0224] Several bromodomain containing proteins, including ASH1L,ATAD2A / B, BAZ2A / B, CECR2, EP300, KAT2A, PHIP(2), PB1, SMARCA2 / 4, BRD2 / 4 and CREBBP, have been shown to be up-regulated in many types of cancers (Tough et al., 2014; Fu et al., 2015). Hence, BRDs are therefore therapeutic targets for cancer. BRD-containing domains have been linked to the development of a number of extremely aggressive tumours containing BRD4-NUT and BRD3-NUT. CREBBP mutations have been identified in relapsed acute lymphoblastic leukaemia and are very common in diffuse large B-cell lymphoma and follicular lymphoma, Hodgkin's lymphoma. CREBBP and the related HAT are highly expressed in advanced prostate cancer and expression levels have been linked with patient survival. ATAD2 is over expressed in more than 70% of breast tumours and higher protein levels correlate with poor overall survival and disease recurrence (Ciro et al., 2009). ATAD2B is highly expressed in glioblastoma and oligodendroglioma as well as breast carcinoma (Krakstad et al., 2015). BRD4 is linked to development of cervical cancer (Weidner-Glunde et al.; 2010).

[0225] Compound 1 showed good inhibitory activity against domain PHD (plant homology domain) containing domain proteins SP140, TRIM 33, UHRF1 (108-286)).Methyltransferases

[0226] Compound 1 was a strong inhibitor of the lysine methyltransferase enzyme G9a whereas compounds 2 and 3 were weaker (Table 10). G9a is a multipotent regulator of gene expression which has been shown to be over expressed in many different types of cancers (See reviews for details: Shankar et al., 2013; Casciello et al., 2015). Compounds 1 to 3 strongly inhibited the activity of PRMT4 and moderately inhibited the activity of PRMT6. Dysregulated PRMT expression and activity have been observed in a variety of cancers and PRMT1-5 and 7 have been shown to be overexpressed or otherwise contribute to tumorigenesis whereas PRMT8, and 9 have not been implicated in oncogenesis (Fuhrmann et al., 2015). PRMT4 (CARM1) is necessary for NFκB target gene expression. Further study showed a link between PRMT4 and p300 acetyltransferase activity in NFκB recruitment and gene activation.Demethylases

[0227] Compound 1 showed significant inhibitory activity towards many of the lysine demethylase enzymes (Table 10), in particular JARIDLA, JARIDLB, JMJD1A, JMJD2B, JMJ02E, JMJD3 and UTX. Aberrant expression and mutations of lysine demethylases have been linked to various cancers (Hojfeldt et al., 2013; Tough et al., 2014). Mutation of lysine demethylases including FBXL10, JMJD2A, JMJDB, JMJD2C, JARID1B and PHF2 have been shown to be overexpressed in breast, colorectal, lung, prostrate, bladder and other tumours; the functional significance of JMJD2C overexpression is further suggested by the presence of the JMJD2C gene within an amplified region of a chromosome in multiple cancers (Xiang et al., 2007; Couvelard et al., 2008; Roesch et al., 2010; He et al., 2011a; Berry and Janknecht, 2013; Kogure et al., 2013; Tzatsos et al., 2013).Histone acetyltransferases

[0228] The serrulatanes diterpenes showed significant inhibitory activity on histone acetyltransferases CREBBP and MYST4 (Table 10). Misregulation of histone acetyltransferase activity has been linked to many different pathogenic states including cancers, neurodegenerative disorders, and metabolic, respiratory, inflammatory and cardiovascular diseases (Adcock and Lee, 2006; Avvakumov and Cote, 2007; Grabiec et al., 2008; Ghizzo et al., 2011, Iyer et al., 2011; Pirooznia and Elefant, 2013). Table 12. Enzyme and Cell-based stimulation assays for compounds 1 to 3 at 10 µM concentration% Stimulation Relative to Control Reference Assay Comp 1 Comp 2 Comp 3 Compound EC 50 (µM) H3K9 ac (increase)-21-26-8(Not-applicable) NAnoneH3K27 ac (increase)-28-17-25NAsirtuin 1 (h) (activator effect)-5-3-4Resveratrol27 Pharmacology Assays

[0229] The in vitro pharmacological studies were conducted by Eurofins PanLab (Taiwan) using the parameters shown in Table 13 with respect to appropriate literature references. Table 13. Pharmacology assay methods.Angiotensin system Angiotensin AT2 [Lee et al. 2001] SourceHuman recombinant CHO-K1 cellsVehicle1.00% DMSOLigand0.050 nM [ 125< I] CGP-42112ANon-Specific Ligand10.0 µM (Sar 1< , Ile 8< )-Angiotensin IIIncubation (Time / Temperature)3 hours @ 37°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 5 mMMgCl 2 , 1 mM EDTA, 0.1% BSAQuantitation MethodRadio ligand BindingAngiotensin, AT 1 / ACE [Rubin et al. 1978] SourceDunkin Hartley Guinea pig 600 ± 80.0 g ileumVehicle0.10% DMSOIncubation (Time / Temperature)5 minutes @ 32°CIncubation BufferKrebs, pH 7.4Quantitation MethodIsotonic (cm changes)Peptidase, Angiotensin Converting Enzyme [Bunning et al. 1983] SourceRabbit lungSubstrate500 µM (N-3-[2-furyl] acryloyl)-Phe-Gly- Gly (FAPGG)Vehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)30 minutes @ 25°CIncubation Buffer50 mM HEPES, pH 7.5, 300 mM NaClQuantitation MethodSpectrophotometric quantitation of FAPGGChemokines Chemokine CCR1 [Hesselgesser et al. 1998] SourceHuman recombinant Chem-2 cellsVehicle1.00% DMSOLigand0.10 nM [ 125< I] MIP-1αNon-Specific Ligand0.10 µM MCP-3Incubation (Time / Temperature)3 hours @ 25°CIncubation Buffer50 mM HEPES, pH 7.4, 5 mM MgCl2, 1 mM CaCl 2 , 0.2% BSAQuantitation MethodRadio ligand BindingChemokine CCR2B [Gong et al. 1997] SourceHuman recombinant CHO-K1 cellsVehicle1.00% DMSOLigand0.10 nM [ 125< I] MCP-1Non-Specific Ligand0.030 µM MCP-1Incubation (Time / Temperature)60 minutes @ 25°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 5 mMMgCl 2 , 1 mM EDTA, 0.1% BSAQuantitation MethodRadio ligand BindingChemokine CX3CR1 [Combadiere et al. 1998] SourceHuman recombinant Chem-1 cellsVehicle1.00% DMSOLigand20.0 pM [ 125< I] FractalkineNon-Specific Ligand10 nM FractalkineIncubation (Time / Temperature)90 minutes @ 25°CIncubation Buffer50 mM HEPES, pH 7.5, 1 mM CaCl 2 , 5 mM MgCl 2 , 0.5% BSA, 0.1% NaN 3 Quantitation MethodRadio ligand BindingChemokine CXCR1 / 2 (IL-8, Non-Selective) [Grob et al. 1990] SourceHuman neutrophilsVehicle1.00% DMSOLigand15.0 pM [ 125< I] IL-8Non-Specific Ligand10 nM IL-8Incubation (Time / Temperature)2 hours @ 4°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM MgCl 2 , 5 mg / ml BSAQuantitation MethodRadio ligand BindingChemokine CXCR2 (IL-8RB) [Ahuja and Murphy 1996] SourceHuman recombinant CHO-K1 cellsVehicle1.00% DMSOLigand15.0 pM [ 125< I] IL-8Non-Specific Ligand10 nM IL-8Incubation (Time / Temperature)60 minutes @ 25°CIncubation Buffer25 mM HEPES, pH 7.4, 2 mM CaCl 2 , 1 mM MgCl 2 , 0.2% BSAQuantitation MethodRadio ligand BindingChemokine CXCR4 [Valenzuela-Fernandez 2002] SourceHuman recombinant Chem-1 cellsVehicle1.00% DMSOLigand0.030 nM [ 125< I] SDF-1αNon-Specific Ligand0.030 µM SDF-1αIncubation (Time / Temperature)90 minutes @ 25°CIncubation Buffer50 mM HEPES, pH 7.4, 5 mM MgCl 2 , 1 mM CaCl 2 , 0.2% BSAQuantitation MethodRadio ligand BindingHistone Deacetylases (HDACs) Deacetylase, Histone 1 [Strahl and Allis 2000] SourceHuman recombinant Insect Sf9 cellsSubstrate25.0 µM Fluor-de-Lys deacetylaseVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)60 minutes @ 25°CIncubation Buffer25 mM Tris-HCl, pH 8.0, 2.7 mM KCl, 1mM MgCl 2 , 137 mM NaClQuantitation MethodSpectrofluorimetric quantitation of Fluor- de-Lys deacetylsubstrateDeacetylase, Histone 2 [Strahl and Allis 2000] SourceHuman recombinant Insect Sf9 cellsSubstrate25.0 µM Fluor-de-Lys deacetylaseVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)60 minutes @ 25°CIncubation Buffer25 mM Tris-HCl, pH 8.0, 2.7 mM KCl, 1 mM MgCl 2 , 137 mM NaClQuantitation MethodSpectrofluorimetric quantitation of Fluor- de-Lys deacetylsubstrateGrowth FactorEpidermal Growth Factor (EGF) [Dittadi et al. 1990] SourceHuman A431 cellsVehicle1.00% DMSOLigand0.080 nM [ 125< I] EGF (human)Non-Specific Ligand0.10 µM EGF (human)Incubation (Time / Temperature)60 minutes @ 25°CIncubation Buffer50 mM HEPES, pH 7.7, 0.1% BSA, 1.2 mM CaCl 2 , 5 mM KCl, 1.2 mM MgSO4, 138 mM NaClQuantitation MethodRadio ligand BindingOther classes Catechol-O-Methyl Transferase (COMT) [Muller-Enoch et al. 1976] SourcePorcine liverSubstrate1.0 µM EsculetinVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)30 minutes @ 37°CIncubation Buffer36 mM Tris-HCl, pH 8.0, 1.35 mM DTT, 0.54 mM MgCl 2 , 30.6 µM SAMQuantitation MethodSpectrofluorimetric quantitation of scopoletinPhospholipase sPLA2-V [Tietge et al. 2005] SourceHuman E. coliSubstrate250 µM diheptanoyl thio-PCVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)30 minutes @ 25°CIncubation Buffer16.25 mM Tris-HCl, 6.5 mM CaCl 2 , 65 mM KCl, 0.2 mM Triton X-100Quantitation MethodSpectrophotometric quantitation of heptanoyl thio-PCProtein Tyrosine Phosphatase, PTPN1 (PTP1B) [Montalibet et al. 2005] SourceHuman recombinant E. coliSubstrate10.0 µM DiFMUPVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)60 minutes @ 37°CIncubation Buffer50 mM HEPES, pH 7.2, 0.1% BSA, 1 mM DTTQuantitation MethodSpectrofluorimetric quantitation of DiFMUSteroid 5α-Reductase [Sun and Tu 1998] SourceWistar Rat liverSubstrate0.90 µM TestosteroneVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)30 minutes @ 37°CIncubation Buffer40 mM Potassium Phosphate, pH 6.5, containing 1 mM DTT, 50 µM NADPHQuantitation MethodEIA quantitation of TestosteroneThioredoxin Reductase [Becker et al. 2000] SourceE. coliSubstrate1.0 mM 5,5'-Dithiobis (2-nitrobenzoic acid) (DTNB)Vehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)60 minutes @ 25°CIncubation Buffer100 mM Potassium Phosphate, pH 7.4, 2 mM EDTA, 0.2 mg / ml BSAQuantitation MethodSpectrophotometric quantitation of 5- Mercapto-2-nitrobenzoic acidXanthine Oxidase [Hatano et al. 1990] SourceBovine buttermilkSubstrate165 µM XanthineVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)30 minutes @ 25°CIncubation Buffer33.3 mM Potassium Phosphate, pH 7.5Quantitation MethodSpectrophotometric quantitation of Uric acidHistamine H 1 [ De Backer et al., 1993] SourceHuman recombinant Chem-1 cellsSubstrate1.00% DMSOVehicle1.20 nM [ 3< H] PyrilaminePre incubation (Time / Temperature)1.0 µM PyrilamineIncubation (Time / Temperature)3 hours @ 25°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 Quantitation MethodRadio ligand BindingHistamine H2 [Ruat et al., 1990] SourceHuman recombinant CHO-K1 cellsVehicle1.00% DMSOLigand0.10 nM [ 125< I] AminopotentidineNon-Specific Ligand3.0 µM TiotidineIncubation (Time / Temperature)2 hours @ 25°CIncubation Buffer50 mM Phosphate, pH 7.4Quantitation MethodRadio ligand BindingHistamine H3 [Krueger et al., 2005] SourceHuman recombinant Chem-1 cellsSubstrate1.00% DMSOVehicle0.40 nM [ 3< H] N-α-Methylhistamine (NAMH)Pre incubation (Time / Temperature)1.0 µM R(-)-α-Methylhistamine (RAMH)Incubation (Time / Temperature)2 hours @ 25°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 5 mMMgCl 2 , 0.1% BSAQuantitation MethodRadio ligand BindingHistamine H4 [Liu et al., 2001] SourceHuman recombinant Chem-1 cellsSubstrate1.00% DMSOVehicle8.20 nM [ 3< H] HistaminePre incubation (Time / Temperature)1.0 µM HistamineIncubation (Time / Temperature)90 minutes @ 25°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 1.25 mM EDTAQuantitation MethodRadio ligand BindingHMG-CoA Reductase [Kubo and Strott, 1987] SourceHuman recombinant E. coliSubstrate2.50 µM [ 14< C]HMG-CoAVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)20 minutes @ 37°CIncubation Buffer100 mM KH2PO4, pH 7.5, 8 mM G-6-P, 1 mM NADP, 4 mM EDTA, 2 mM DTT, 0.6 U / ml G-6-P-DHQuantitation MethodQuantitation of [ 14< C] Mevalonate5-Lipoxygenase [Pufahl et al., 2007] SourceHuman recombinant Insect Sf9 cellsSubstrate25.0 µM Arachidonic acidVehicle1.00% DMSOPre incubation (Time / Temperature)5 minutes @ 25°CIncubation (Time / Temperature)20 minutes @ 25°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 5 mM CaCl 2 , 2 mM EDTA, 1 µM ATPQuantitation MethodSpectrofluorimetric quantitation of rhodamine 123Lipid Peroxidase [Mansuy et al., 1986] SourceDunkin Hartley Guinea pig liver microsomesSubstratePolyunsaturated fatty acidVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)20 minutes @ 37°CIncubation Buffer0.25 M Potassium Phosphate, pH 7.4, 0.1 mM EDTAQuantitation MethodSpectrophotometric quantitation of MalondialdehydeLipoxygenase 12-LO [Romano et al., 1993] SourceHuman plateletsSubstrate30.0 µM Arachidonic acidVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)15 minutes @ 25°CIncubation Buffer50 mM Tris-HCl, pH 7.4, 0.1% Triton X-100Quantitation MethodSpectrophotometric quantitation of 12- HETEMonoamine Oxidase MAO-A [Urban et al., 1991] SourceHuman recombinant Insect Hi5 cellsSubstrate50.0 µM KynuramineVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)60 minutes @ 37°CIncubation Buffer100 mM Potassium Phosphate, pH 7.4Quantitation MethodSpectrofluorimetric quantitation of 4- hydroxyquinolineMonoamine Oxidase MAO-B [Urban et al., 1991] SourceHuman recombinant Insect Hi5 cellsSubstrate50.0 µM KynuramineVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)60 minutes @ 37°CIncubation Buffer100 mM Potassium Phosphate, pH 7.4Quantitation MethodSpectrofluorimetric quantitation of 4- hydroxyquinolineMyeloperoxidase [ Svensson et al., 1987] SourceHuman PMN leukocytesSubstrate20.0 mM GuaiacolVehicle1.00% DMSOPre incubation (Time / Temperature)15 minutes @ 25°CIncubation (Time / Temperature)5 minutes @ 25°CIncubation Buffer0.1 M Sodium Phosphate, pH 7.4Quantitation MethodSpectrophotometric quantitation of Tetraguaiacol[3H]-2-Deoxy-D-glucose uptake[ Yamamoto et al., 2006] SourceRat L6 skeletal muscle cellsSubstrate0.10% DMSOVehicle24 hours @ 37°CPre incubation (Time / Temperature)15 minutes @ 37°CIncubation (Time / Temperature)KRPH, pH 7.4Incubation BufferRadiometric quantitation of insulin-induced 2-DG uptakeQuantitation MethodRat L6 skeletal muscle cellsAdhesion and Transcription responseAdhesion, ICAM-1-Mediated [Cobb et al. 1992] SourceHumanVehicle0.40% DMSOLigand0.030 nM [ 125< I] SDF-laNon-Specific Ligand0.030 µM SDF-laIncubation (Time / Temperature)30 minutes @ 37°CIncubation Buffer25 mM HEPES, pH 7.4, RPMI-1640,1% FBSQuantitation MethodSpectrofluorimetric quantitation of adhesionAdhesion, VCAM-1-Mediated [Stoltenborg et al. 1994] SourceHumanVehicle0.40% DMSOIncubation (Time / Temperature)60 minutes @ 37°CIncubation Buffer25 mM HEPES, pH 7.4, RPMI-1640, 1% FBSQuantitation MethodSpectrofluorimetric quantitation of adhesionTranscription Response, NF-κB [Lenardo and Baltimore 1989] SourceHumanVehicle0.50% DMSOIncubation (Time / Temperature)4 hours @ 37°CIncubation BufferRPMI-1640, pH 7.4Quantitation MethodSpectrofluorimetric quantitation of β- galactosidase

[0230] The results of pharmacological assays are shown in Table 14. Table 14. Pharmacological activity of compounds 1 to 3 at 10 µM.% Control Response Assay Ascii Assay Name 1 2 3 Year Angiotensin system Angiotensin AT2291892015Angiotensin, AT 1 / ACE - Agonist0002015Angiotensin, AT 1 / ACE - Antagonist3410172015Peptidase, Angiotensin Converting Enzyme0-3-32015Chemokines Chemokine CCR133-3-52015Chemokine CCR2B1-23-102015Chemokine CX3CR1-1572015Chemokine CXCR1 / 2 (IL-8, Non-Selective)30-28-12015Chemokine CXCR2 (IL-8RB)12-712015Chemokine CXCR414-27-132015Histone Deacetylases (HDACs) Deacetylase, Histone 11723NA2014Deacetylase, Histone 1-27-18-262015Deacetylase, Histone 25644NA2014Deacetylase, Histone 23421122015Deacetylase, Histone 3-525NA2014Deacetylase, Histone 44-5NA2014Deacetylase, Histone 5-9-11NA2014Deacetylase, Histone 60-17NA2014Deacetylase, Histone 71-16NA2014Deacetylase, Histone 82913NA2014Deacetylase, Histone 9-14-13NA2014Deacetylase, Histone 10119NA2014Deacetylase, Histone 1195NA2014Sirtuins Deacetylase, Sirtuin SIRT16-3NA2014Deacetylase, Sirtuin SIRT2026NA2014Deacetylase, Sirtuin SIRT3-6-9NA2014Deacetylase, Sirtuin SIRT5-1624NA2014Deacetylase, Sirtuin SIRT63518NA2014Growth Factor Epidermal Growth Factor (EGF)-8-942015Nitric Oxide Synthases Nitric Oxide Synthase, Endothelial (eNOS)65NA2014Nitric Oxide Synthase, Inducible (iNOS)167NA2014Nitric Oxide Synthase, Neuronal (nNOS)145NA2014Other classes Catechol-O-Methyl Transferase (COMT)0-132015Histamine H18566NA2014Histamine H19760502015Histamine H26724NA2014Histamine H273-5662015Histamine H3-10-5NA2014Histamine H3122412015Histamine H45016NA2014Histamine H412-1102015HMG-CoA Reductase29272420155-Lipoxygenase7953672015Lipid Peroxidase9853742015Lipoxygenase 12-LO6040292015Monoamine Oxidase MAO-A9134272015Monoamine Oxidase MAO-B7539182015Myeloperoxidase525NA2014Myeloperoxidase271-72015Phospholipase sPLA2-V4302015Protein Tyrosine Phosphatase, PTPN1 (PTP1B)203-32015Steroid 5alpha-Reductase2-632015Thioredoxin Reductase716NA2014Thioredoxin Reductase351292015Xanthine Oxidase1420272015 Pharmacological Assays: further lipoxygenase, lipid peroxidase and monoamine oxidase assays

[0231] Further in vitro pharmacological studies were conducted by Eurofins Panlabs (Taiwan) Ltd. using the parameters shown in Table 3 with respect to appropriate literature references.

[0232] For the compound 1 5-lipoxygenase, lipid peroxidase and monoamine oxidase MAO-A assays, the inhibition / concentration-response curve concentrations were 10, 3, 1, 0.3, 0.01, 0.03 and 0.01 µM (Table 15). Table 15. Activity of compound 1 against 5-lipoxygenase, lipid peroxidase and monoamine oxidase (MAO-A) IC 50 (µM) and reference compoundsCompound1 ReferenceAssayIC 50 µMCompoundIC 50 µM5-Lipoxygenase2.31NDGA0.64Lipid Peroxidase1.47N-Propyl Gallate206Monoamine oxidase A (MAO-A)6.74Clorgyline0.00143

[0233] Compounds 1 to 3 are potent to moderately potent inhibitors of lipid oxidation (Table 10). Therefore, they can be used in blocking inflammation induced by oxidative damage in cancer.

[0234] 5-Lipoxygenase promotes lipid oxidation and produces leukotrienes. Compounds 1 to 3 are potent to moderately potent inhibitor of 5-lipoxygenase (Table 10). Therefore, they can be used in blocking inflammation induced by oxidative damage and inflammatory pathophysiology in cancer.

[0235] 12-Lipoxygenase promotes lipid oxidation and produces leukotrienes. Compounds 1 to 3 are moderately potent inhibitor of 12-lipoxygenase (Table 10). Therefore, they can be used in blocking inflammation induced by oxidative damage and inflammatory pathophysiology in cancer.

[0236] Compound 1 is a potent inhibitor of monoamine oxidase A and B (Table 10). Therefore, it can be used in blocking oxidative damage induced by oxidation of monoamines and as an antidepressant in cancer.

[0237] Compounds 1 to 3 inhibit binding of the radioligand to histamine H1 and H2 receptors (Table 10). Therefore, they can be used in blocking inflammation induced by histamine resulting in anti-inflammatory action useful in cancer treatment.

[0238] Compound 1 inhibited the activity of thioredoxin reductase (Table 10). Inhibition of thioredoxin reductase activity can be used to selectively increasing oxidative stress in cancer cell while reducing oxidative stress in normal cells and

[0239] Compound 1 inhibited the activity of myeloperoxidase (Table 10). Inhibition of myeloperoxidase activity can be used to selectively reduce oxidative stress in immune cells during cancer therapy.

[0240] Curves showing binding against 5-lipoxygenase; lipid peroxidase; and monoamine oxidase (MAO-A) for compound 1 are presented in Figures 7 to 9. Pharmacology Assays: 2-deoxy-D-glucose uptake into muscle cells

[0241] Table 16. Effect of compounds 1 to 4 at 10 µM on 2-deoxy-D-glucose uptake into muscle cells.% Control Response Assay Ascii Assay Name 1 2 3 4 Year [3H]-2-Deoxy-D-glucose uptake - agonist*-6115-52-452016[3H]-2-Deoxy-D-glucose uptake - antagonist*152671951512016* agonist - Increase in 2-DG uptake relative to insulin response* antagonist - Inhibition of insulin-induced 2-DG uptake Table 17. Oncopanel cell proliferation results for Compounds 11 and 12. Compound 11 and 12 Cell LineTypeCell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)647-VBladder> 30> 30> 30AU565Breast16.417.116.9CAMA-1Breast> 30> 30> 30MCF7Breast27.527.527MDA MB 231Breast> 30> 30> 30MDA MB 453Breast10.610.610.4MDA-MB-415Breast17.817.815.7Hs 683CNS - Glioma272725.6M059JCNS - Glioma> 30> 30> 30HuTu 80Colon8.618.78.65LS-174TColon> 30> 30> 30HeLaFemale GU - Cervix> 30> 30> 30OVCAR3Female GU - Ovary> 30> 30> 30AN3 CAFemale GU - Uterus10.813.313.1MEG01Leukemia17.517.517.3MOLT-16Leukemia21.821.821.7MOLT-3Leukemia11.814.114MV-4-11Leukemia> 30> 30> 30MX1Leukemia14.914.914.9A427Lung - NSCLC161615.8Calu1Lung - NSCLC> 30> 30> 30Calu6Lung - NSCLC> 30> 30> 30Hs 229.TLung - NSCLC> 30> 30> 30NCI-H292Lung - NSCLC12.1> 30> 30NCI-H520Lung - NSCLC> 30> 30> 30NCI-H596Lung - NSCLC> 30> 30> 30DOHH-2Lymphoma12.213.413.4EB2Lymphoma> 30> 30> 30JiyoyeLymphoma> 30> 30> 30L-428Lymphoma21.321.321.1NAMALWALymphoma> 30> 30> 30RajiLymphoma> 30> 30> 30SUP-T1Lymphoma> 30> 30> 30PSN-1Pancreas> 30> 30> 30Hs 934.TSkin (Melanoma)21.9> 3016.3HOSSoft Tissue - Osteosarcoma> 30> 30> 30KHOS-240SSoft Tissue - Osteosarcoma> 30> 30> 30SW1353Soft Tissue - Osteosarcoma> 30> 30> 30Hs 729Soft Tissue - Sarcoma26.4> 30> 30HT-1080Soft Tissue - Sarcoma12.712.712.7 Pharmacology Assays: adhesion and transcription response

[0242] Table 18. Dose response and IC 50 values for the pharmacological activity of representative serrulatane diterpenes.Compound 1 Compound 2 Compound 3 Ascii Assay Name Conc µM Resp Av % IC 50 µM Resp Av % IC 50 µM Resp Av % IC 50 µM Adhesion, ICAM-1-Mediated106>105>107>10Adhesion, ICAM-1-Mediated13>104>106>10Adhesion, ICAM-1-Mediated0.1-2>103>10-4>10Adhesion, ICAM-1-Mediated0.011>100>10-5>10Adhesion, ICAM-1-Mediated0.001-4>107>10-7>10Adhesion, VCAM-1-Mediated - Antagonist10-7>10-18>10-4>10Adhesion, VCAM-1-Mediated - Antagonist1-9>10-18>107>10Adhesion, VCAM-1-Mediated - Antagonist0.13>10-8>1013>10Adhesion, VCAM-1-Mediated - Antagonist0.010>10-17>1018>10Adhesion, VCAM-1-Mediated - Antagonist0.00113>10-7>1013>10Transcription Response, NF-kappaB - Antagonist101031.434>10-19>10Transcription Response, NF-kappaB - Antagonist1171.410>101>10Transcription Response, NF-kappaB - Antagonist0.101.4-3>10-7>10Transcription Response, NF-kappaB - Antagonist0.01-51.4-7>10-11>10Transcription Response, NF-kappaB - Antagonist0.001-251.4-7>10-16>10

[0243] Nuclear factor kappa B (NF-κB) was first discovered as a factor in the nucleus of B lymphocytes that binds to the enhancer of kappa light chain of immunoglobulin and is also a lymphoid specific (Sen and Baltimore, 1986). The NF-κB family includes RelA / p65, NF-κB1 p50 / p105, NF-κB2 p52 / p100, C-Rel and RelB. These proteins contain an N-terminal Rel homology domain (RHD) that is responsible for binding to DNA and other proteins and harbour a nuclear leading sequence (NLS). NF-κB proteins function as a dimeric transcription factor that regulates the expression of genes influencing a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development and lymphoid organogenesis (Pantano et al., 2006; Brigelius-Fohê and Fohê 2011; Ghosh et al., 2012; Akdis et al., 2017).

[0244] NF-κB has been shown to have diverse and complex roles in cancer and immune modulation (Perkins, 2012; Sethi et al., 2012; Parri and Chiarugi, 2013; D'Ignazio et al., 2015). Based on significant inhibitory activity against NF-κB (IC 50 0. 69 µM) and cytokines (IC 50 6.6, 8.8, 4.3, 8.9 µM, for IL1β, IL-6, IL10, TNFα respectively, compound 1 can potentially influence the expression of the aforementioned biological processes as well as modulation of immune responses. In support for these results, Eurofins Oncopanel Genomic analysis showed compound 1 clustered near to ABT-199, a BH3 domain inhibitor of BCL-2. ABT-199 blocked anti-apoptotic of BCL-2 leading to programmed cell death. In addition to antitumor effect of BCL-2 therapeutics, the BH3 mimetics have been proposed in the context of immune modulation (Ludwig et al., 2016). Taken together, compound 1 could target cancer cell death as well as immune modulation. Figure 10 shows transcription response and binding against NF-κB for compound 1. In vitro cell viability assay of serrulatane terpenes

[0245] Four serrulatane diterpenes, namely compounds 1 to 4, and Myoporum insulare resin were evaluated for in vitro inhibition of cell growth in 43 cancer cell lines and one normal cell line as shown in Table 19. The assay is a 72 hour (three day) assay.Methodology of the in vitro cell viability assay

[0246] Cell viability assays were carried out by Eurofins PanLab (Taiwan). The assays are based on the established principle that cell viability (survival) can be evaluated by measuring the intracellular levels of adenosine triphosphate (ATP) by bioluminescence in metabolically active cells (Xia, M et al. 2008). Assays are carried out by seeding cells in two plates (T 0 and T 72 ). At time "zero" cell plate (T 0 ) is harvested, treated, and incubated for 72h (three days) when the T 72 plate will be harvested. The intracellular levels of ATP are measured and represent the amount of viable cells.

[0247] Cell viability assay results for compounds 1 to 4 and Myoporum insulare resin / exudate extract towards 43 cancer cell lines and 1 normal cell line are shown in Table 19. Table 19. Inhibition of cell growth at 10.5 µg / mL of Myoporum insulare resin and 10 µM of compounds 1 to 4. Cell lines % Cell growth Myoporum insulare resin 1 2 3 4 Normal HUVEC, Endothelium32-90979137Brain U-87 MG36710111181SK-N-MC4-877382-92Leukemia HL-60 (TB)13-62-35138-83K-562-20-55699360MV-411-96-963776-94MOLT-4-97-943877-93Non-Small Cell Lung Cancer A549 / ATCC60-9210210693LL / 241-6210511198NCI-H46063-378810093PC-630-6292964Colon Cancer CT26.WT36212010333SW-620-94-899710774DLD-129-659510168HCT-1515-629411669HCT-11645-74819964HT-2969-6610710191Melanoma B16-F084712311656SK-MEL-5-69-969511888Ovarian Cancer OVCAR-3-33-93678660SK-OV-36-35829874Prostrate Cancer LNCaP-5-86738456PC-3-87709964Breast Cancer BT47456-6711810864MCF7-51-7111411277MCF-7 AdrR-43-909210177MDA-MB-231-38-929710084MDA-MB-468-69-92378552T-47D10220104119474T17552609926Kidney Cancer A-49843-43919289ACHN34-41101105105Liver Cancer HC-480-9110410591Hep3B20-84878493HepG227-239510390Lymphoma Ramos-94-9233129-82H33HJ-JA1-73-905790-87U93728-8610210520Pancreas MIA PaCa-22039210692PANC-164368711682Skin A-43164-89100102107A3759-57410065Stomach KATO III12-918410583Uterus MES-SA-57-88759468 Cell Viability Assay Results

[0248] At 10 µM compound 1 showed potent reduction in cell viability (-80 to -100%) towards 20 cancer cell lines. Moderate reduction in cell viability (-40 to -80%) was observed towards 12 cancer cell lines and weak effect towards cell viability for 4 cell lines. Growth inhibition was observed for the remaining cell lines.

[0249] At 10 µM compound 2 showed weak reduction in cell viability (-35%) towards the HL-60 leukemia cells and no significant effect on the remaining cell lines. At 10 µM compound 3 showed no significant effect on all 44 cell lines. At 10 µM compound 4 showed potent reduction in cell viability (-82 to -94%) towards six lymphoma, leukemia and brain cancer cell lines: Ramos and H33HJ-JA1 (lymphoma); HL-60 (TB), MOLT-4 and MV-411 (leukemia), and SK-N-MC (brain). Compound 4 was selective with no significant reduction in the growth of HUVEC endothelium cells (normal cell line).

[0250] At 10.5 µg / mL Myoporum insulare resin showed potent reduction in cell viability (-80 to -100%) towards four cancer cell lines: SW-620 (colon); Ramos (lymphoma); and MV-411 and MOLT4 (leukemia). Moderate reduction in cell viability (-40 to -80%) was observed towards six cancer cell lines: MCF-7, MCF7 AdrR, MDA-MB-468 (breast); H33HJ-JA1 (lymphoma); SK-MEL-5 (melanoma); and MES-SA (uterus). Weak cell viability reduction (-5 to -38%) towards five cell lines: K-562 (leukemia); OVCAR-3 (ovarian); LNCaP (prostrate); MDA-MB-231 (breast); and A375 (skin). No significant effect was observed towards HUVEC endothelium cells (normal cell line).OncoPanel Cell Proliferation Assay

[0251] The OncoPanel cell proliferation assay measures the proliferation response of cancer cell lines to drug treatments through high-content fluorescence imaging or bioluminescence. Whereas the cell viability assay described above is a three-day assay, the OncoPanel assay is a 10-day assay.Experimental procedure

[0252] Cells were grown in RPMI 1640, 10% FBS, 2 mM L-alanyl-L-glutamine, 1 mM Na pyruvate or a special medium. Cells were seeded into 384-well plates and incubated in a humidified atmosphere of 5% CO 2 at 37°C. Compounds were added the day following cell seeding. At the same time, a time zero untreated cell plate was generated. After a 10-day incubation period, cells were fixed and stained to allow fluorescence imaging of nuclei. At 7 days post-seeding, the growth media were replaced and the plates were re-dosed with the test compound.

[0253] Compounds were serially diluted in half-log steps from the highest test concentration specified in the above table, and assayed over 10 concentrations with a maximum assay concentration of 0.1% DMSO. Automated fluorescence microscopy was carried out using a Molecular Devices ImageXpress Micro XL high-content imager, and images were collected with a 4X objective. 16-bit TIFF images were acquired and analyzed with MetaXpress 5.1.0.41 software.Data Analysis

[0254] Cell proliferation was measured by the fluorescence intensity of an incorporated nuclear dye. The output is referred to as the relative cell count, where the measured nuclear intensity is transformed to percent of control (POC) using the following formula: POC = I x I 0 × 100

[0255] Where I x is the nuclear intensity at concentration x, and I 0 is the average nuclear intensity of the untreated vehicle wells.

[0256] Cellular response parameters were calculated using nonlinear regression to a sigmoidal single-site dose response model: y = A + B − A 1 + C x D

[0257] Where y is a response measured at concentration x, A and B are the lower and upper limits of the response, C is the concentration at the response midpoint (EC 50 ), and D is the Hill Slope (Fallahi-Sichani, M., S. et al. 2013).

[0258] Time zero non-treated plates were used to determine the number of doublings during the assay period, using the formula: Doublings = log 2 N N T0

[0259] Where N is the cell number in untreated wells at the assay end point and N T0 is the cell number at the time of compound addition.

[0260] Cell count IC 50 is the test compound concentration at 50% of maximal possible response. EC 50 is the test compound concentration at the curve inflection point or half the effective response (parameter C of the fitted curve solution). GI 50 is the concentration needed to reduce the observed growth by half (midway between the curve maximum and the time zero value). Activity area is an estimate of the integrated area above the curve (Barretina, J. G. et al. 2012). Activity area values range from 0-10, where a value of zero indicates no inhibition of proliferation at all concentrations, and a value of 10 indicates complete inhibition of proliferation at all concentrations. In rare instances, values <0 or >10 may be observed. In these instances, values <0 should be considered as equivalent to 0, whereas values >10 should be considered equivalent to 10.

[0261] Curve-fitting, calculations, and report generation were performed using a custom data reduction engine and MathIQ based software (AIM).

[0262] The OncoPanel cell proliferation results (OncoPanel, Eurofins PanLab, USA, across 280 human cancer cell lines) for compounds 1, 2 and 4 are shown below in Table 20. Tables 21 to 28 show representative proliferation response data (Table 21: MDA-MB-415; Table 22: RKO-AS45-1; Table 23: SW480; Table 24: 639-V; Table 25: Hs 729; Table 26: Hs 852.T; Table 27: HCT-8; Table 28: IM-9) and the cell proliferation results for Myoporum insulare resin are shown below in Table 29. Table 20. OncoPanel cell proliferation results for compounds 1, 2 and 4. Compound 1 Compound 2 Compound 4 Cell LineTypeCell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)Cell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)Cell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)5637Bladder3.383.383.32> 30> 30> 3015.2015.2015.10639-VBladder2.012.012.016.548.007.9812.0012.0012.00647-VBladder3.123.123.1111.3011.3011.205.996.005.99BFTC-905Bladder1.791.791.788.038.038.019.709.709.68HT-1197Bladder2.312.342.2810.7010.7010.3015.6015.6015.20HT1376Bladder1.451.461.434.714.714.4714.1014.1013.80J82Bladder1.061.061.0512.9012.9012.706.226.226.09SCaBERBladder3.123.123.1011.5011.5011.4016.9016.9016.80T24Bladder1.441.441.4420.4020.4020.3012.2012.2012.20TCCSUPBladder1.751.751.728.208.207.788.918.918.67UM-UC-3Bladder1.851.851.845.305.755.743.833.833.82AU565Breast1.621.621.616.406.406.2910.1010.1010.00BT20Breast1.591.611.5312.2012.7012.3014.1014.3013.90BT474Breast5.415.464.95> 30> 30> 3025.5025.7025.00BT-549Breast3.143.143.1225.8025.9025.8015.3015.3015.10CAMA-1Breast3.513.513.40> 30> 30> 30> 30> 30> 30EFM-19Breast1.611.611.5411.2011.2010.6011.9011.9011.30Hs 578TBreast4.744.764.6828.7028.7028.2015.0015.0014.90KPL-1Breast0.810.810.814.704.734.704.184.184.13MCF7Breast1.371.371.3510.4010.409.9612.1012.1011.90MDA MB 231Breast1.471.481.474.394.394.3611.4011.4011.30MDA MB 453Breast0.780.780.773.683.693.653.763.763.68MDA MB 468Breast2.752.762.748.078.088.007.417.437.34MDA-MB-415Breast1.021.021.0011.5011.5010.8028.5028.5027.40MDA-MB-436Breast2.682.692.679.729.779.7310.3010.3010.20SK-BR-3Breast1.791.801.7612.2012.2011.9010.3010.309.97T47DBreast4.634.634.2810.2010.209.403.283.282.92A172CNS - Glioma1.121.151.149.029.028.938.088.088.03CCF-STTG1CNS - Glioma5.796.605.24> 30> 30> 3019.7019.7016.00DBTRG-05MGCNS - Glioma2.652.662.6412.2013.0012.8017.6017.6017.40DK-MGCNS - Glioma6.166.416.121.64> 30> 3017.2017.2016.40H4CNS - Glioma2.772.772.773.06> 30> 3013.0013.0013.00Hs 683CNS - Glioma4.904.914.7629.8029.8028.3024.5024.6024.30M059JCNS - Glioma3.093.093.029.9815.8014.2013.0013.0012.90PFSK-1CNS - Glioma4.324.334.3114.7014.7014.603.823.823.80SNB-19CNS - Glioma1.661.661.6517.3017.3016.8013.0013.0012.90SW1088CNS - Glioma2.442.442.4310.7010.7010.508.778.778.69SW1783CNS - Glioma3.193.193.0910.2011.0010.5012.3012.3012.10T98GCNS - Glioma2.052.052.0519.1019.1019.0024.5024.5024.50U-118 MGCNS - Glioma4.564.584.4929.6029.6029.4013.9013.9013.60U-138MGCNS - Glioma6.296.336.15> 30> 30> 3025.0025.0024.90U-87 MGCNS - Glioma2.122.122.04> 30> 30> 3013.8013.8013.60D341 MedCNS-Medulloblastoma9.099.469.3719.2019.2018.708.578.578.40DaoyCNS-Medulloblastoma1.061.061.068.648.658.643.193.193.19BE(2)CCNS-Neuroblastoma4.234.234.186.917.527.4813.1013.1013.00CHP-212CNS-Neuroblastoma1.431.431.4111.4011.4011.109.779.789.74MC-IXCCNS-Neuroblastoma4.014.014.0016.9016.9016.906.886.886.88SK-N-ASCNS-Neuroblastoma3.583.583.546.237.927.705.865.865.75SK-N-DZCNS-Neuroblastoma3.163.162.94> 30> 30> 3011.9011.9011.50SK-N-FICNS-Neuroblastoma7.317.316.32>30> 30> 3021.5021.5020.60Colo 201Colon0.920.920.928.518.518.454.074.074.04Colo 205Colon1.311.311.3110.7010.7010.7011.9011.9011.90Colo 320 HSRColon3.093.133.1311.6011.6011.605.155.165.15Colo 320DMColon3.203.203.187.727.727.677.917.917.87DLD-1Colon2.962.962.9610.7011.2011.2015.7015.7015.70HCT-116Colon1.751.751.756.686.686.6710.3010.3010.30HCT-15Colon1.841.841.838.649.499.4813.4013.4013.40HCT-8Colon1.231.231.236.276.276.2412.9012.9012.90HT-29Colon4.014.014.0019.5019.5019.4017.0017.0017.00LS1034Colon1.971.971.8312.7012.7012.0023.6023.6023.50LS123Colon1.131.161.036.5718.4013.4012.0012.0010.70LS411NColon8.728.728.5123.9023.9023.4023.1023.1022.60MT-3Colon3.673.673.6616.9016.9016.8023.9023.9023.80NCI-H508Colon14.4014.4014.30> 30> 30> 30> 30> 30> 30NCI-H747Colon3.093.113.1012.30> 30> 3028.1028.2028.10RKOColon1.691.691.697.227.927.9212.0012.0012.00RKO-AS45-1Colon1.501.501.509.649.649.6212.8012.8012.80RKOE6Colon1.721.721.726.956.956.936.796.796.76SW1417Colon3.153.153.0722.8022.8021.80> 30> 3029.30SW1463Colon3.733.753.71> 30> 30> 3029.4029.6029.50SW403Colon8.098.117.89> 30> 30> 30> 30> 30> 30SW48Colon1.331.331.328.738.738.6513.0013.0013.00SW480Colon1.211.211.2010.1010.109.9312.3012.3012.30SW620Colon1.481.481.4813.2013.2013.2011.3011.3011.30SW837Colon2.352.372.33> 30> 30> 3018.9018.9018.70SW948Colon2.212.212.2014.7014.7014.5029.70> 30> 30WiDrColon2.322.322.3114.5014.5014.4012.8012.8012.80NCI-H295REndocrine - Adrenal gland14.7014.7013.50> 30> 30> 3025.6025.6021.60BHT-101Endocrine - Thyroid2.162.172.1714.0014.0013.906.806.806.77CAL-62Endocrine - Thyroid1.691.691.695.605.795.785.365.365.36CGTH-W-1Endocrine - Thyroid1.201.201.205.835.835.813.453.483.47SW579Endocrine - Thyroid1.711.711.6912.3012.3012.2011.0011.0011.00Y79Eye5.605.605.336.577.657.415.655.655.34C-33AFemale GU - Cervix7.187.187.0812.0012.0011.909.579.579.42C-4 IIFemale GU - Cervix1.091.101.098.949.039.0012.6012.6012.50HeLaFemale GU - Cervix2.992.992.9816.6016.6016.5021.1021.1021.10HT-3Female GU - Cervix3.883.893.8417.6019.3018.6014.5014.5014.30SiHaFemale GU - Cervix5.225.235.1728.3028.3025.8011.3013.5013.20Ca SkiFemale GU - Ovary5.285.295.24> 30> 30> 3017.6017.6017.60CaOV3Female GU - Ovary1.911.921.8510.2010.209.6110.2010.3010.20ME-180Female GU - Ovary2.252.262.21> 30> 30> 3025.3025.3025.20MS751Female GU - Ovary2.232.232.217.558.788.7212.1012.1012.00OVCAR3Female GU - Ovary1.531.571.5214.4014.4013.7015.6015.6014.90PA-1Female GU - Ovary4.214.214.2111.6016.3016.207.897.907.89SKOV3Female GU - Ovary1.581.581.5615.4015.4015.208.438.438.33AN3 CAFemale GU - Uterus1.521.521.4911.3011.3011.109.629.629.43HEC-1-AFemale GU - Uterus2.572.572.5612.1012.1012.0012.3012.3012.20KLEFemale GU - Uterus3.703.823.5626.3026.3020.5018.2018.2016.60SW954Female GU - Vulva7.637.637.60> 30> 30> 3021.7021.7021.60BV-173Leukemia3.803.803.799.339.339.333.563.563.55CCRFCEMLeukemia4.734.734.7111.5011.5011.404.924.934.91CEM-C1Leukemia1.961.961.953.263.263.261.471.471.47CML-T1Leukemia1.931.931.933.693.693.683.933.933.93EM-2Leukemia2.392.392.3710.8010.8010.803.994.004.00HEL-92-1-7Leukemia13.9013.9013.9013.4013.4013.404.054.054.05J-RT3-T3-5Leukemia0.010.010.0102.082.082.062.712.712.71JurkatLeukemia2.252.252.242.662.662.653.593.593.58K562Leukemia4.604.604.5810.2010.2010.1012.2012.2012.20KG-1Leukemia0.120.120.1111.3012.0011.9013.3013.3013.10KU812Leukemia2.812.812.576.526.525.669.509.509.13MEG01Leukemia7.357.357.2213.8013.8013.708.398.398.37MHH-PREB-1Leukemia6.176.176.177.857.857.855.715.715.71MOLT-16Leukemia1.841.841.8413.3013.3013.304.024.024.01MOLT-3Leukemia2.132.132.111.271.271.263.153.153.13MV-4-11Leukemia3.583.583.578.568.568.523.813.813.80MX1Leukemia1.291.291.2910.8010.8010.802.462.462.46NALM-6Leukemia1.811.811.811.671.681.682.612.612.61RS4;11Leukemia1.771.771.716.436.436.304.154.234.16TF-1Leukemia2.112.111.982.752.752.446.576.576.26Thp1Leukemia1.381.381.345.325.695.6112.0012.0011.90BC-1Lymphoma1.521.521.517.957.957.934.164.164.16BCP-1Lymphoma3.183.183.148.488.488.408.828.828.75CA46Lymphoma2.272.272.263.833.833.824.064.064.06CRO-AP2Lymphoma5.725.725.666.386.386.369.949.949.88DaudiLymphoma1.841.841.843.933.933.922.282.282.28DBLymphoma2.102.102.093.233.253.243.853.853.84DOHH-2Lymphoma1.411.411.413.243.243.242.242.242.24DoTc2 4510Lymphoma1.031.031.016.076.075.849.239.239.09EB2Lymphoma6.476.496.4523.3023.3023.008.358.388.32EB-3Lymphoma3.563.563.569.729.729.713.933.933.93GA-10Lymphoma1.931.941.943.723.733.731.231.231.23Hs 445Lymphoma1.301.321.314.344.344.235.805.805.74Hs 611.TLymphoma2.922.942.9110.7010.7010.605.115.115.05HTLymphoma1.521.531.516.516.516.434.494.494.46JeKo-1Lymphoma5.235.235.214.484.484.473.913.913.91JiyoyeLymphoma5.885.885.8717.8017.8017.703.553.553.55L-428Lymphoma1.081.091.088.878.878.832.072.072.06MC116Lymphoma3.793.793.7813.8013.8013.8012.5012.5012.40NAMALWALymphoma3.393.393.395.715.715.703.913.913.90RajiLymphoma4.604.604.598.048.048.043.923.923.92Ramos (RA 1)Lymphoma2.962.962.964.394.394.394.174.174.17RPMI 6666Lymphoma3.533.533.4410.4010.7010.7023.1023.1023.00SRLymphoma3.803.803.8010.7010.7010.704.394.394.39ST486Lymphoma1.091.091.083.873.873.862.662.662.65SU-DHL-10Lymphoma3.943.943.939.929.929.907.687.687.67SU-DHL-4Lymphoma2.012.012.014.204.204.205.745.745.74SU-DHL-5Lymphoma1.201.201.194.284.284.273.803.803.80SU-DHL-8Lymphoma1.771.771.777.407.407.403.903.903.90SUP-T1Lymphoma3.963.963.9512.1012.1012.006.516.516.49TURLymphoma5.095.095.082.63> 30> 308.988.988.98ARH-77Myeloma1.951.971.959.509.609.5713.5013.5013.40IM-9Myeloma0.420.420.423.923.923.926.716.716.71RPMI 8226Myeloma0.680.680.672.022.021.953.033.043.03SKO-007Myeloma0.990.990.931.591.591.424.664.714.55U266B1Myeloma3.223.223.089.159.289.0110.1010.109.81A-253Head and Neck4.134.144.1328.5028.7028.7018.2018.2018.10A388Head and Neck1.661.671.6613.5013.5013.407.667.667.59A431Head and Neck2.802.812.80> 30> 30> 3024.8024.8024.80Cal 27Head and Neck2.162.162.157.647.647.6212.3012.3012.20Detroit 562Head and Neck1.961.971.9614.5014.5014.4025.0025.0025.00FaDuHead and Neck0.870.870.878.668.668.668.288.288.28OE19Head and Neck3.233.233.21> 30> 30> 3020.7020.7020.50OE21Head and Neck3.683.683.67> 30> 30> 3012.7012.7012.70SCC-25Head and Neck3.943.963.95> 30> 30> 3025.0025.0025.00SCC-4Head and Neck4.664.724.63> 30> 30> 3015.8015.8015.50SCC-9Head and Neck3.443.453.4426.7027.3027.3016.5016.5016.40769-PKidney0.850.850.856.956.956.943.723.723.71786-OKidney2.052.052.0527.9027.9027.9014.0014.0013.90A498Kidney1.291.291.2913.3013.3013.2012.3012.3012.20A-704Kidney1.571.601.54> 30> 30> 305.705.705.41ACHNKidney1.741.741.748.798.798.769.509.509.47Caki-1Kidney2.862.862.750.17> 30> 3014.4014.4014.10Caki-2Kidney4.384.384.3528.8029.1028.9013.1013.6013.50G-401Kidney4.004.003.9926.0026.2026.208.088.088.05SK-NEP-1Kidney0.010.010.0060.060.060.069.629.639.62HepG2Liver0.820.820.816.746.956.8625.6025.7025.60HLELiver4.624.634.5910.0016.4016.007.247.247.15HLFLiver4.474.484.4513.7015.7015.608.728.748.70HuCCT1Liver2.482.482.4822.6022.6022.6024.8024.8024.80HUH-6 Clone 5Liver1.521.521.5115.5015.5015.309.639.639.46OCUG-1Liver4.304.304.29> 30> 3029.9015.6015.6015.50SNU-423Liver1.481.491.465.295.315.269.309.319.28A427Lung - NSCLC4.524.524.5011.2011.2011.2010.0010.009.98A549Lung - NSCLC1.661.671.6622.0022.0021.9010.9010.9010.80Calu1Lung - NSCLC3.103.103.0713.9013.9013.808.888.888.77Calu6Lung - NSCLC9.249.248.5914.5016.6015.7025.0025.0024.50ChaGoK1Lung - NSCLC1.531.541.538.328.328.268.928.928.82COR-L105Lung - NSCLC1.441.451.424.764.764.618.668.668.47COR-L23Lung - NSCLC7.187.187.1423.8023.8023.6013.3013.3013.20Hs 229.TLung - NSCLC2.882.942.8929.3029.8028.6025.9026.3025.20NCI-H292Lung - NSCLC3.203.203.1816.7016.7016.609.219.219.19NCIH441Lung - NSCLC12.1012.1011.70> 30> 30> 304.76> 30> 30NCI-H460Lung - NSCLC2.342.342.335.575.925.9112.2013.0013.00NCI-H520Lung - NSCLC2.432.432.419.039.209.1720.8020.8020.60NCI-H596Lung - NSCLC8.788.788.4112.0015.1014.4028.20> 30> 30NCI-H661Lung - NSCLC2.282.292.289.519.519.515.945.945.86SKMES1Lung - NSCLC1.061.061.067.807.807.6711.6011.6011.50DMS114Lung - SCLC2.772.772.5711.5013.8013.1011.5011.6011.40DMS53Lung - SCLC0.810.810.775.915.955.758.958.958.60NCIH446Lung - SCLC10.3010.3010.009.759.859.777.817.817.62NCI-H69Lung - SCLC6.306.445.8416.2016.2014.9015.9015.9015.10SHP-77Lung - SCLC0.890.900.898.018.017.906.836.836.75SW900Lung - SCLC3.293.333.2426.6026.8026.7023.3023.3023.10AsPC-1Pancreas2.872.872.8414.1014.1013.8014.7014.7014.50BxPC-3Pancreas3.293.303.2913.00> 30> 3013.4013.4013.40Capan-1Pancreas> 30> 30> 30> 30> 30> 30> 30> 30> 30Capan-2Pancreas1.331.331.328.648.648.4824.8024.8024.70CFPAC-1Pancreas3.653.663.6512.3013.5013.4025.2025.2025.10HPAF-IIPancreas1.381.381.379.469.629.6012.4012.5012.40Hs 766TPancreas1.611.611.5428.4028.4026.209.349.349.08HuP-T4Pancreas4.524.544.53> 30> 30> 3013.7013.7013.60Mia PaCa-2Pancreas2.972.972.9716.3016.3016.2011.0011.0011.00PANC-1Pancreas2.872.872.837.067.067.0111.7011.7011.60PSN-1Pancreas2.322.322.3212.0012.0012.005.045.045.04SU.86.86Pancreas7.617.637.5813.10> 30> 30> 30> 30> 30YAPCPancreas1.911.911.9013.0013.0012.9018.0018.2018.20BeWoPlacenta9.069.068.927.68> 30> 3015.6015.6015.50JARPlacenta12.2012.2012.20> 30> 30> 306.536.536.49JEG-3Placenta4.334.334.32> 30> 30> 306.506.516.4822Rv1Prostate4.084.084.0611.4011.4011.309.089.089.00BM-1604Prostate2.582.582.5619.1019.1018.90> 30> 30> 30BPH1Prostate5.245.245.20> 30> 30> 3017.3017.3017.30DU145Prostate2.802.802.7821.0021.0020.7018.1018.1018.10LNCaPProstate3.903.903.470.860.860.2811.5012.9012.40PC-3Prostate3.883.883.8612.0012.0011.807.717.717.64A101DSkin (Melanoma)8.428.428.25> 30> 30> 30> 30> 30> 30A375Skin (Melanoma)1.051.051.056.456.456.445.745.745.74A7Skin (Melanoma)0.940.940.945.545.635.6010.5010.5010.50C32Skin (Melanoma)2.112.111.8119.2019.2015.507.847.846.37CHL-1Skin (Melanoma)1.371.371.3614.3014.3014.2011.9011.9011.80COLO 829Skin (Melanoma)0.680.680.625.355.354.933.713.713.29G-361Skin (Melanoma)1.791.791.7711.7011.8011.8013.8013.9013.80HMCBSkin (Melanoma)1.371.371.366.686.686.579.499.499.38Hs 294TSkin (Melanoma)2.642.642.597.017.016.728.338.338.23Hs 688(A).TSkin (Melanoma)1.331.441.2711.6013.2012.207.437.686.88Hs 695TSkin (Melanoma)1.181.271.169.079.488.995.005.184.02Hs 852.TSkin (Melanoma)2.492.562.4215.4015.4014.7012.0012.0011.60Hs 934.TSkin (Melanoma)2.533.272.34> 30> 3024.1011.1011.6010.20Hs 936.T(C1)Skin (Melanoma)2.002.001.973.623.763.749.1010.4010.20MALME3MSkin (Melanoma)1.791.791.6619.8019.8017.3020.6020.6017.80MeWoSkin (Melanoma)1.321.321.319.459.979.919.669.669.51RPMI-7951Skin (Melanoma)0.700.700.705.776.156.139.989.989.96SH-4Skin (Melanoma)1.951.951.949.6011.9011.8011.6011.6011.50SK-MEL-1Skin (Melanoma)4.294.414.1115.7015.7014.70> 30> 30> 30SK-MEL-28Skin (Melanoma)1.541.541.539.469.899.8511.2011.2011.10SK-MEL-3Skin (Melanoma)4.374.384.2822.0022.0020.80> 30> 30> 30WM-266-4Skin (Melanoma)1.151.151.146.396.396.2510.9010.9010.80G-292, clone A141B1Soft Tissue - Osteosarcoma4.554.574.418.808.808.576.236.256.07HOSSoft Tissue - Osteosarcoma0.960.960.964.824.824.813.083.083.08Hs 888.SkSoft Tissue - Osteosarcoma2.202.382.0528.3028.5027.9012.3012.7012.10KHOS-240SSoft Tissue - Osteosarcoma0.950.950.954.594.594.584.964.964.96MG-63Soft Tissue - Osteosarcoma9.249.249.16> 30> 30> 3011.2011.2011.10SaOS2Soft Tissue - Osteosarcoma1.982.102.0415.7015.7015.1010.6010.7010.70SJSA1Soft Tissue - Osteosarcoma1.411.411.417.117.117.027.457.457.45SW1353Soft Tissue - Osteosarcoma1.001.000.999.499.499.464.154.154.14U2OSSoft Tissue - Osteosarcoma1.661.661.6512.7012.7012.704.214.214.20A204Soft Tissue - Sarcoma0.520.540.528.468.548.500.720.720.68A-673Soft Tissue - Sarcoma1.541.551.5410.8011.1011.102.882.882.87Hs 729Soft Tissue - Sarcoma2.772.782.6723.3023.3021.8011.9011.9011.60Hs 821.TSoft Tissue - Sarcoma4.224.221.80> 30> 3013.9012.6012.909.99HT-1080Soft Tissue - Sarcoma0.960.960.963.313.313.304.424.424.42MES-SASoft Tissue - Sarcoma1.231.231.229.269.269.226.496.496.44RDSoft Tissue - Sarcoma0.810.810.812.982.982.965.195.195.17SJRH30Soft Tissue - Sarcoma1.421.421.415.095.105.073.683.683.68SK-LMS-1Soft Tissue - Sarcoma1.571.571.566.7911.3011.209.049.048.98SK-UT-1Soft Tissue - Sarcoma2.232.232.2211.7011.7011.605.495.495.46SW684Soft Tissue - Sarcoma9.379.378.28> 30> 30> 30> 30> 30> 30SW872Soft Tissue - Sarcoma0.960.960.964.464.464.454.394.394.38SW982Soft Tissue - Sarcoma1.071.071.077.637.637.537.297.307.26TE 125.TSoft Tissue - Sarcoma6.479.211.48> 30> 3028.7023.6023.6017.00TE 381.TSoft Tissue - Sarcoma1.621.621.598.148.147.996.286.286.08VA-ES-BJSoft Tissue - Sarcoma3.673.673.55> 30> 30> 3015.2015.2015.00AGSStomach0.700.700.704.694.694.695.255.255.24HS 746TStomach5.585.744.64> 30> 30> 3020.0020.0017.10KATO IIIStomach3.283.283.278.9816.8016.6010.9011.1011.10SK-PN-DWStomach4.664.664.6310.8010.9010.904.914.914.88SNU-1Stomach1.251.251.258.519.429.416.996.996.98SNU-16Stomach1.311.311.319.969.969.9111.0011.0011.00SNU-5Stomach3.923.923.87> 30> 30> 3014.4014.4014.20NTERA-2 cl.D1Testis2.252.252.2012.5012.5012.307.417.417.39 Table 21. Representative data for proliferation response when cell line MDA-MB-415 is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-0490.21.33.02E-03100.06.49.53E-0398.08.73.01E-0293.42.79.52E-0298.110.33.01E-01100.28.69.51E-0162.35.33.00E+001.30.29.49E+000.30.03.00E+010.20.0

[0263] The data displayed in Table 21 is graphed in Figure 11. Table 22. Representative data for proliferation response when cell line RKO-AS45-1 is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-0495.42.03.02E-0383.77.79.53E-0388.33.73.01E-0286.25.69.52E-0280.54.73.01E-0190.06.99.51E-0172.19.73.00E+007.63.59.49E+000.10.03.00E+010.10.0

[0264] The data displayed in Table 22 is graphed in Figure 12. Table 23. Representative data for proliferation response when cell line SW480 is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-04111.87.03.02E-03116.519.39.53E-03103.79.43.01E-0299.50.59.52E-0294.110.23.01E-0193.56.49.51E-0169.917.03.00E+004.14.69.49E+000.20.03.00E+010.40.4

[0265] The data displayed in Table 23 is graphed in Figure 13. Table 24. Representative data for proliferation response when cell line 639-V is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-0492.014.33.02E-0396.11.99.53E-03101.25.03.01E-02103.68.69.52E-0291.69.63.01E-0192.614.19.51E-0191.912.23.00E+0015.84.29.49E+000.30.13.00E+010.00.0

[0266] The data displayed in Table 24 is graphed in Figure 14. Table 25. Representative data for proliferation response when cell line Hs 729 is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-04100.67.63.02E-03103.010.59.53E-03108.74.13.01E-02107.02.19.52E-0299.90.73.01E-0199.47.79.51E-0198.91.23.00E+0046.08.89.49E+003.20.23.00E+011.00.3

[0267] The data displayed in Table 25 is graphed in Figure 15. Table 26. Representative data for proliferation response when cell line Hs 852.T is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-04104.39.13.02E-03104.55.19.53E-03100.26.23.01E-0294.55.69.52E-0292.22.43.01E-0195.32.99.51E-0185.54.33.00E+0041.65.19.49E+0013.11.73.00E+012.70.5

[0268] The data displayed in Table 26 is graphed in Figure 16. Table 27. Representative data for proliferation response when cell line HCT-8 is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-04102.63.73.02E-03104.19.79.53E-0391.010.13.01E-0291.83.59.52E-02100.82.63.01E-0194.94.89.51E-0172.62.33.00E+001.90.59.49E+000.00.03.00E+010.00.0

[0269] The data displayed in Table 27 is graphed in Figure 17. Table 28. Representative data for proliferation response when cell line IM-9 is treated with compound 1 Concentration (microM)Relative cell count (%)MeanStdDev9.55E-0494.934.73.02E-03102.89.59.53E-03103.12.43.01E-02107.39.39.52E-0297.73.43.01E-0197.58.69.51E-010.00.03.00E+000.10.09.49E+000.10.13.00E+010.00.0

[0270] The data displayed in Table 28 is graphed in Figure 18.

[0271] For compound 1, a broad spectrum of activity was observed over the 280 cell types with very potent to strong (GI 50 = 0.006 to 2.98 µM) activity towards 174 cell lines. Very potent activity was observed towards SK-NEP-1 kidney (GI 50 = 0.00618 µM) and J-RT3-T3-5 leukemia (GI 50 = 0.0101 µM) cell lines. Moderately potent activity was observed (GI 50 = 0.11 µM) towards KG-1 leukemia cell line. Moderately potent activity (GI 50 = 0.4 to 1.0 µM) was observed towards the following cell lines: 2 breast cell lines KPL-1, MDA-MB-453; 3 myeloma cell lines IM-9, RPMI8226, SKO-007; 3 melanoma cell lines A7, COLO829, RPMI-7951; 7 soft tissue cell lines HOS (osteosarcoma), KHOS-240S (osteosarcoma), SW1353 (osteosarcoma), A204 (sarcoma), HT-1080 (sarcoma), RD (sarcoma), SW 872 (sarcoma); 2 small cell lung carcinoma cell lines DMS53, SHP-77; and also Colo 201 (colon); FaDu (head and neck), 769-P (kidney), HepG2 (liver), and AGS (stomach). Strong activity (GI 50 = 1 to 2.98 µM) was shown towards 149 cell lines: 16 melanoma; 15 lymphoma; 9 female genitourinary; 14 soft tissue (sarcoma); 16 colon; 12 leukemia; 8 non-small cell lung carcinoma; 8 pancreas; 9 breast; 10 CNS; 8 bladder; 5 kidney; 4 head and neck, 4 endocrine, 1 myeloma, 3 liver, 2 small cell lung carcinoma, 2 prostrate, 2 stomach and 1 testis.

[0272] For compound 2, a narrow spectrum of activity was observed over the 280 cell types with potent to strong (GI 50 = 0.06 to 2.96 µM) activity towards 10 cell lines. Potent activity was observed towards SK-NEP-1 kidney (GI 50 = 0.0606 µM) Strong activity (GI 50 = 1 to 2.96 µM) was observed towards the following cell lines: 5 leukemia cell lines J-RT3-T3-5, Jurkat, MOLT-3, NALM-6, TF-1; 2 myeloma cell lines RPM18226, SKO-007; 1 soft tissue cell line RD (sarcoma). For compound 2 activities towards Jurkat, MOLT-3, NALM-6, TF-1 (leukemia) and SKO-007 (myeloma) were similar in magnitude to compound 1.

[0273] For compound 4, a narrow spectrum of activity was observed over the 280 cell types with moderately potent to strong (GI 50 = 0.68 to 2.92 µM) activity towards 12 cell lines. One strong activity (GI 50 = 0.684 µM) was observed towards A204 (soft tissue sarcoma) similar in magnitude to that observed for compound 1. Strong activity (GI 50 = 1.23 to 2.92 µM) for compound 4 was observed towards the following cell lines: 5 lymphoma (Daudi, DOHH-2, GA-10, L-428, ST486); 2 leukemia (MX1, NALM-6); also for T47D (breast), CEM-C1 (leukemia), A-673 (soft tissue sarcoma). The activity towards these cell lines is comparable in magnitude to compound 1, however, compound 4 show strong activity towards the J-RT3-T3-5 leukemia cell line (GI 50 = 2.71 µM) approximately 270 times less activity than the very potent activity observed for compound 1 (GI 50 = 0.0101 µM) towards this cell line.

[0274] The plant resin extract showed strong activity (GI 50 = 0.11 to 1.03 µg / mL) towards 24 cell lines: 4 soft tissue sarcoma (A204, HT-1080, RD, SW 872); 4 melanoma (A7, COL0829, Hs695T, RPMI-7951); 3 myeloma (IM-9, RPMI8226, SKO-007); 2 breast (KPL-1, MDA-MB-453); 2 lymphoma (DOHH-2, SU-DHL-5); 2 small cell carcinoma (DMS53, SHP-77); 2 leukemia (Jurkat, NALM-6) and also bladder (UM-UC-3); colon (SW480); thyroid (CGTH-W-1); head and neck (FaDu); and stomach (AGS). For the Hs695T melanoma cell line, calculated on a weight-weight basis, the plant resin extract (GI 50 = 0.11 µg / mL) was approximately 3 times more active than compound 1 (GI 50 = 0.37 µg / mL) towards this particular cell line. From weight comparison for all other cell lines the plant extract was less active than compound 1.

[0275] Overall, compound 1 provides a broad spectrum of anticancer activity towards a wide range of cell lines. Compound 2 shows specificity for the LNCaP prostrate cell line, also specific activity towards SK-NEP-1 (kidney), Jurkat, MOLT-3, NALM-6, TF-1 (leukemia) and SKO-007, RPMI8226 (myeloma) similar in magnitude to compound 1. Compound 4 showed moderately potent to strong activity (GI 50 = 0.68 to 2.92 µM) towards a narrow range of cell lines (12 out of 280) compared with compound 1 (174 out of 280). Table 30. Number of cancer cell types for levels of growth inhibitory activity for Compounds 1, 2 and 4 Number of cell types GI Activity GI 50 range (µM) Comp Comp Comp 1 2 4 very potent0.001 - 0.029200potent0.03 - 0.099010moderately potent0.1 - 0.992311strong1 - 2.99149811moderately strong3 - 9.9999110125weak10 - 30.006118130very weak> 3014213TOTAL280280280 Table 31. Number of cancer cell types for levels of growth inhibitory activity for M. insulare extract Number of cell types GI Activity GI 50 range (µg / mL) M. insulare extract very potent0.00035 - 0.01040potent0.0105 - 0.0340moderately potent0.035 - 0.341strong0.35 - 1.0423moderately strong1.05 - 3.49165weak3.5 - 10.4983very weak> 10.58TOTAL280 Inhibition of Toll-like receptor 4 (TLR4) activation on human peripheral blood mononuclear cells (PBMC's).Study Objective

[0276] To evaluate compound capability to inhibit Toll-like receptor 4 (TLR4) activation on human peripheral blood mononuclear cells (PBMC's).Experimental Protocol

[0277] Compound 1 was evaluated for ability to inhibit TLR4 in human PBMC's, as measured by release of specific cytokines. Evaluation was conducted by Eurofins Panlabs Inc., St Charles, Missouri, USA.TLR4 Inhibition Assay Protocol

[0278] a) Cryopreserved human PBMC's were drip-thawed. b) Cells were diluted to the appropriate density (1x105 per well) and seeded into 96-well polypropylene plates with 150 µL per well of culture medium (RPMI 1640, 10% heat-inactivated FBS, 1% penicillin / streptomycin, 2 mM L-glutamine). c) Cells were incubated at 37°C, 5% CO 2 for 1 hour prior to the addition of test compounds or controls. d) Test compounds were solubilized in DMSO to make stock solutions, and then diluted further with cell culture medium. The positive control, LPS (from S. Minnesota R595), was resuspended in endotoxin-free water at 0.5 mg / mL to make working stock solutions. Dexamethasone was used as a reference control compound. e) Compounds and controls, including appropriate vehicle controls, were added to the PBMC's in volumes of 10 µL and incubated for 1 hour at 37°C, 5% CO 2 . Compounds were tested in duplicate at final assay concentrations of 10, 3, 1, 0.3, 0.1, and 0.03 µM. Vehicle control wells simply received 10 µL of the appropriate vehicle. f) After a 1-hour incubation, 40 µL of diluted working stock LPS were added to the test compound and control wells to give final assay volumes of 200 µL. Plates were incubated for 24 hours at 37°C, 5% CO 2 . g) Plates were centrifuged at 200 x g for 10 minutes. Cell culture supernatants were collected and stored at -80°C until needed for analysis. h) Cytokine levels in each sample were determined using Luminex methodology, per the manufacturer's protocol. PBMC Donor: Human donor 1 (lot # 100)Results and Discussion

[0279] Stimulation of human PBMC's with LPS for 24 hours elicited the measurable release of appropriate cytokines within expected ranges. Conversely, dexamethasone inhibited the LPS-stimulated release of cytokines from human PBMC's, also within expected ranges. Compound 1 elicited measurable inhibition of the LPS-induced release of specific cytokines from human PBMC's, following a 24-hour stimulation.

[0280] As seen from the results shown in Table 32, compound 1 elicited a moderate to strong inhibition of the secretion of all cytokines at the top test concentration, giving measured IC 50 values of 4.3 µM, 6.6 µM, 8.8 µM, and 8.9 µM for IL-10, IL-1β, IL-6, and TNFα, respectively. (IC 50 values could not be measured for IL-8 and MIP-1α.) Table 32. Compound 1 activity against certain LPS-induced cytokinesCompound 1 LPS-induced cytokineAssay IC 50 (µM) I-1β6.6IL-68.8IL-8NAIL-104.3MIP-1αNATNF-α8.9 Bioprint Assays

[0281] The Bioprint assay (conducted by Eurofins Cerep, France) provides a profile that is designed with the dual purpose of assessing safety at targets with known safety liabilities as well as providing a rich enough profile to search for compounds with similar profiles.Methodology

[0282] Compound 1 was tested at 10 µM. For compound 1 at 10 µM, the agonist radioligand assays for control specific inhibition of interest for biological activity or safety are as follows:-

[0283] GPCR Family:- adenosine A3 (h), 92%; adrenergic alpha 2C (h), 92%; cannabinoid CB2 (h), 71 %; cholecystokinin CCK1 (CCKA) (h), 81%; dopamine D1 (h), 67%; dopamine D3 (h), 85%; histamine H1 (h), 64%; melatonin MT1 (ML1A) (h), 91%.

[0284] Transporters:- norepinephrine transporter (h), 76%.

[0285] Non-steroid Nuclear Receptors:- PPARgamma (h), 91%.

[0286] For compound 1 at 10 µM, the enzyme assays for control specific inhibition of interest for biological activity or safety are as follows:-

[0287] AA Metabolism:- COX1 (h), 81%; COX2 (h), 74%.

[0288] Compound binding was calculated as a % inhibition of the binding of a radioactively labeled ligand specific for each target. Compound enzyme inhibition effect was calculated as a % inhibition of control enzyme activity. Results showing an inhibition or stimulation higher than 50% are considered to represent significant effects of the test compounds.Results

[0289] Compound 1 results for inhibition of control specific binding to receptors are shown in Table 33 whilst results for inhibition of control specific binding inhibition of enzymes in enzyme and cell-based assays are shown in Table 34. Table 33. Bioprint results for Compound 1 tested at 10 µM for inhibition of control specific binding to receptors.Compound1 ReferenceFamilyBinding Assay% Inhibition of Control Specific BindingCompoundIC 50 (µM)GPCR ADENOSINEA1 (h) (agonist radioligand)10CPA0.0021ADENOSINEA2A (h) (agonist radioligand)18NECA0.036ADENOSINEA2B (h) (antagonist radioligand)8NECA0.59ADENOSINEA3 (h) (agonist radioligand)92IB-MECA4.5E-04ADRENERGICalpha 1A (h) (antagonist radioligand)17WB 41012.7E-04ADRENERGICalpha 1B (h) (antagonist radioligand)41prazosin1.7E-04ADRENERGICalpha 2A (h) (antagonist radioligand)35yohimbine0.0065ADRENERGICalpha 2B (h) (antagonist radioligand)7yohimbine0.0065ADRENERGICalpha 2C (h) (antagonist radioligand)92yohimbine0.004ADRENERGICbeta 1 (h) (agonist radioligand)19atenolol0.34ADRENERGICbeta 2 (h) (agonist radioligand)2ICI 1185517.8E-04ADRENERGICAdrenergic beta333Alprenolol0.25ANGIOTENSIN IIAT1 (h) (antagonist radioligand)60saralasin0.0019ANGIOTENSIN IIAT2 (h) (agonist radioligand)54angiotensin-II1.4E-04APELINAPJ (apelin) (h) (agonist radioligand)24apelin-13,TFA3.4E-04BOMBESINBB3 (h) (agonist radioligand)26Bn(6-14)0.0048BRADYKININB2 (h) (agonist radioligand)-37NPC 5670.038CANNABINOIDCB1 (h) (agonist radioligand)46CP 559400.001CANNABINOIDCB2 (h) (agonist radioligand)71WIN 55212-20.0022CYTOKINESTNF-alpha (h) (agonist radioligand)-23TNF-alpha1.6E-04CHOLECYSTOKININCCK1 (CCKA) (h) (agonist radioligand)81CCK-8s1.5E-04CHOLECYSTOKININCCK2 (CCKB) (h) (agonist radioligand)6CCK-8s1.7E-04CORTICOTROPIN RELEASING FACTORCRFl (h) (agonist radioligand)34sauvagine2.5E-04DOPAMINED1 (h) (antagonist radioligand)67SCH 233903.9E-04DOPAMINED2S (h) (agonist radioligand)597-OH-DPAT0.0033DOPAMINED3 (h) (antagonist radioligand)85(+)butaclamol0.0024ENDOTHELINETA (h) (agonist radioligand)6endothelin-14.9E-05ENDOTHELINETB (h) (agonist radioligand)40endothelin-31.7E-05GABAGABAB(lb) (h) (antagonist radioligand)-17CGP 546260.0022GLUCAGONglucagon (h) (agonist radioligand)-20glucagon0.001CHEMOKINESCCR2 (h) (agonist radioligand)48MCP-18.7E-05HISTAMINEH1 (h) (antagonist radioligand)64pyrilamine0.0023HISTAMINEH2 (h) (antagonist radioligand)37cimetidine0.66HISTAMINEH3 (h) (agonist radioligand)10(R)alpha -Me-histamine0.0016HISTAMINEH4 (h) (agonist radioligand)23imetit0.0047LEUKOTRIENESBLT1 (LTB4) (h) (agonist radioligand)27LTB43.7E-04LEUKOTRIENESCysLTl (LTD4) (h) (agonist radioligand)10LTD46.3E-04MELANIN-CONCENTRATING-HORMONEMCH1 (h) (agonist radioligand)-5human MCH7.8E-05MELANOCORTINMC1 (agonist radioligand)11NDP-alpha -MSH1.2E-04MELANOCORTINMC3 (h) (agonist radioligand)60NDP-alpha -MSH2.7E-04MELANOCORTINMC4 (h) (agonist radioligand)37NDP-alpha -MSH4.0E-04MELATONINMT1 (ML1A) (h) (agonist radioligand)91melatonin2.8E-04MOTOLINmotilin (h) (agonist radioligand)-12[Nleul3]-motilin8.9E-04MUSCARINICM1 (h) (antagonist radioligand)8pirenzepine0.031MUSCARINICM2 (h) (antagonist radioligand)1methoctramine0.032MUSCARINICM3 (h) (antagonist radioligand)-34-DAMP0.001MUSCARINICM4 (h) (antagonist radioligand)194-DAMP9.2E-04NEUROKININNK1 (h) (agonist radioligand)62[Sar9,Met(O2)ll]-SP3.7E-04NEUROKININNK2 (h) (agonist radioligand)52[Nleul0]-NKA (4-10)0.0029NEUROPEPTIDE YY1 (h) (agonist radioligand)29NPY1.6E-04OPIOD & OPIOID-LIKEdelta (DOP) (h) (agonist radioligand)62DPDPE0.002OPIOD & OPIOID-LIKEkappa (KOP) (agonist radioligand)39U 504880.0012OPIOD & OPIOID-LIKEmu (MOP) (h) (agonist radioligand)43DAMGO5.3E-04OPIOD & OPIOID-LIKENOP (ORLl) (h) (agonist radioligand)-4nociceptin8.4E-04PLATELET ACTIVATED FACTORPAF (h) (agonist radioligand)39C16-PAF0.0034PROSTANOIDEP2 (h) (agonist radioligand)53PGE20.0027PROSTANOIDFP (h) (agonist radioligand)54PGF2alpha0.003PROSTANOIDIP (PGI2) (h) (agonist radioligand)16iloprost0.017SEROTONIN5-HT1A (h) (agonist radioligand)-188-OH-DPAT8.3E-04SEROTONIN5-HT1B (antagonist radioligand)42serotonin0.013SEROTONIN5-HT1D (agonist radioligand)18serotonin0.0026SEROTONIN5-HT2A (h) (agonist radioligand)9(±)DOI4.7E-04SEROTONIN5-HT2B (h) (agonist radioligand)70(±)DOI0.0067SEROTONIN5-HT2C (h) (agonist radioligand)32(±)DOI2.4E-04SEROTONIN5-HT4e (h) (antagonist radioligand)2serotonin0.19SEROTONIN5-HT6 (h) (agonist radioligand)42serotonin0.18SEROTONIN5-HT7 (h) (agonist radioligand)14serotonin4.4E-04SOMASTATINsstl (h) (agonist radioligand)18somatostatin-285.5E-04SOMASTATINsst4 (h) (agonist radioligand)40somatostatin-140.0042UROTENSIN-IIUT (h) (agonist radioligand)46urotensin-II9.5E-04VASOACTIVE INTESTINAL PEPTIDEVPAC1 (VIP1) (h) (agonist radioligand)-9VIP2.7E-04VASOPRESSINV1a (h) (agonist radioligand)12[d(CH2)51,Tyr(Me)2]-AVP0.0015VASOPRESSINV2 (h) (agonist radioligand)11AVP0.0013TRANSPORTERS CHOLINEcholine transporter (CHT1) (h) (antagonist radioligand)-41hemicholinium-30.0046DOPAMINEdopamine transporter (h) (antagonist radioligand)63BTCP0.012GABAGABA transporter (antagonist radioligand)-10nipecotic acid2.3NOREPINEPHRINEnorepinephrine transporter (h) (antagonist radioligand)76protriptyline0.0039SEROTONIN5-HT transporter (h) (antagonist radioligand)56imipramine0.0044ION-CHANNELS GABAGABAA1 (h) (alpha 1,beta 2,gamma 2) (agonist radioligand)-36muscimol0.053GABA CHANNELSBZD (central) (agonist radioligand)-31diazepam0.0094GABA CHANNELSCl- channel (GABA-gated) (antagonist radioligand)42picrotoxinin0.33GLUTAMATE CHANNELSPCP (antagonist radioligand)-11MK 8010.0096GLUTAMATE CHANNELSAMPA (agonist radioligand)4L-glutamate0.37GLUTAMATE CHANNELSkainate (agonist radioligand)15kainic acid0.023GLUTAMATE CHANNELSNMDA (antagonist radioligand)9CGS 197550.35GLYCINE CHANNELSglycine (strychnine-insensitive) (antagonist radioligand)4glycine0.28NICOTINIC CHANNELSN neuronal alpha 4beta 2 (h) (agonist radioligand)-3nicotine0.0046NICOTINIC CHANNELSN muscle-type (h) (antagonist radioligand)1alpha -bungarotoxin0.0019SEROTONIN CHANNELS5-HT3 (h) (antagonist radioligand)-2MDL 722220.0086Ca 2+< CHANNELSCa2+ channel (L, dihydropyridine site) (antagonist radioligand)55nitrendipine1.3E-04Ca 2+< CHANNELSCa2+ channel (L, diltiazem site) (benzothiazepines) (antagonist radioligand)-30diltiazem0.057Ca 2+< CHANNELSCa2+ channel (L, verapamil site) (phenylalkylamine) (antagonist radioligand)-4D 6000.027Ca 2+< CHANNELSCa2+ channel (N) (antagonist radioligand)5omega -conotoxin GVIA1.7E-06K +< CHANNELSSKCa channel (antagonist radioligand)14apamin9.7E-06Na +< CHANNELSNa+ channel (site 2) (antagonist radioligand)48veratridine5.9NUCLEAR RECEPTORS NON-STEROID NUCLEAR RECEPTORSPPARgamma (h) (agonist radioligand)91rosiglitazone0.015STEROID NUCLEAR RECEPTORSAR (h) (agonist radioligand)-9mibolerone0.0021STEROID NUCLEAR RECEPTORSEstrogen ER alpha (h) (agonist radioligand)40Diethylstilbestrol4.5E-04STEROID NUCLEAR RECEPTORSGR (h) (agonist radioligand)47dexamethasone0.0035OTHER RECEPTORS SIGMAsigma (non-selective) (h) (agonist radioligand)11haloperidol0.045THYROID HORMONEThyroid Hormone9Triiodothyronine3.9E-05 Table 34. Bioprint results for Compound 1 tested at 10 µM for inhibition of control specific binding inhibition of enzymes in enzyme and cell-based assays. Compound1 ReferenceFamilyEnzyme and Cell-based Assays% Inhibition of Control ValuesCompoundIC 50 (µM)KINASES RTKFLT-1 kinase (h) (VEGFR1)36staurosporine0.0098RTKIRK (h) (InsR)-15staurosporine0.052CTKAbl kinase (h)14staurosporine0.11CTKFyn kinase (h)6PP10.11CTKLvn A kinase (h)9staurosporine0.012CTKZAP70 kinase (h)33staurosporine0.021CMGCCDK2 (h) (cycA)12staurosporine0.011CMGCERK2 (h) (P42mapk)6staurosporine1CMGCp38alpha kinase (h)4SB2021900.033CAMKCaMK2alpha (h)2AlP0.092 OTHER NON-KINASE ENZYMES AA METABOLISMCOX 1(h)81Diclofenac0.0078AA METABOLISMCOX2(h)74NS3980.19ATPASEATPase (Na+ / K+)22ouabain0.25MONOAMINE & NEUROTRANSMITTERacetylcholinesterase (h)32galanthamine0.57MONOAMINE & NEUROTRANSMITTERCOMT (catechol- O-methyl transferase)-6Ro 41-09600.061MONOAMINE & NEUROTRANSMITTERMAO-A (antagonist radioligand)15clorgyline0.0012NO SYNTHASESinducible NOS-11400W0.029PHOSPHODIESTERASESPDE2A1 (h)43EHNA1.2PHOSPHODIESTERASESPDE3B (h)-3milrinone1.2PHOSPHODIESTERASESPDE4D2 (h)55Ro 20-17240.15PHOSPHODIESTERASESPDE5 (h) (non-selective)11dipyridamole0.84PHOSPHODIESTERASESPDE6 (non-selective)4zaprinast0.16SERINE PROTEASEScaspase-3 (h)-3Ac-DEVD-CHO0.0029ASPARTIC PROTEASESBACE-1 (h) (beta - secretase)0OM 99-20.081ASPARTIC PROTEASESHIV-1 protease9pepstatin A2.4METALLOPROTEASESACE (h)14captopril5.8E-04METALLOPROTEASESACE-2 (h)-3Ac-GG-26-NH20.2METALLOPROTEASESMMP-1 (h)-2GM60010.0054METALLOPROTEASESMMP-2 (h)0GM60017.9E-04METALLOPROTEASESMMP-9 (h)1GM60013.6E-04MISCELLANEOUS ENZYMESMT3 (ML2) (agonist radioligand)31melatonin0.16MISCELLANEOUS ENZYMESxanthine oxidase / superoxide 02- scavenging-140allopurinol7.8 In vitro toxicity: Normal Cell Panel Toxicity Assay

[0290] The OncoPanel (Eurofins Panlabs Inc., St Charles, Missouri, USA) normal cell proliferation assay measures the proliferation response of normal cells to drug treatments through high-content fluorescence imaging.Methodology

[0291] Normal cells (see description in Table 35) were grown in special medium for each cell type. Cells were seeded into 384-well plates and incubated in a humidified atmosphere of 5% CO 2 at 37°C. Compounds (information in Table 36) were added the day following cell seeding. At the same time, a time zero untreated cell plate was generated. After a 3-day incubation period, cells were fixed and stained to allow fluorescence imaging of nuclei. Table 35. Description of cells used in normal cell panel toxicity assayNormal cell name Cell type Source Catalog number CCD 841 CoNColon epithelialATCCCRL-1790HMECMammary epithelialATCCPCS-600-010HRECRenal mixed epithelialATCCPCS-400-012Wi38Lung fibroblastATCCCCL-75 Table 36. Information for compounds used in normal cell panel toxicity assay Compound IDF.W.Amount received (mg)Stock conc. (mM)Stock volume (microL)Max final test conc. (microM)Carbonyl cyanide 3-chlorophenylhydrazone204.625.7010.00278610.00Compound 1 318.004.8030.0050030.00Cycloheximide281.355.4010.00191910.00Paclitaxel853.91N / A0.3010000.30Staurosporine466.501.001.0021441.00

[0292] Compounds were serially diluted in half-log steps from the highest test concentration specified in the above table, and assayed over 10 concentrations with a maximum assay concentration of 0.1% DMSO.

[0293] The experimental procedure and calculations are similar to the Oncopanel 10-day incubation cell proliferation assay described previously.Results

[0294] Compound 1 activity (EC 50 IC 50 and GI 50 (µM)) is shown against the reference compound paclitaxel in Table 37. Data on other reference compounds for comparison purposes is shown in Table 38. Table 37. Compound 1 activity (EC 50 IC 50 and GI 50 (µM)) against paclitaxelCompound 1 PaclitaxelCell Linenormal human primary cellsCell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)Cell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)CCD 841 CoNcolon epithelial4.8614.35.270.0119N / A0.0221HMECmammary epithelial30306.39>30>30>30HRECrenal mixed epithelial6.457.984.30.001720.04840.0016Wi38lung fibroblast5.4510.45.920.00390.009410.0036 Table 38. Further reference compound activity CycloheximideCarbonyl cyanide 3-chlorophenylhydrazoneStaurosporineCell LineCell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)Cell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)Cell Count EC 50 (µM)Cell Count IC 50 (µM)Cell Count GI 50 (µM)CCD 841 CoN0.5052.770.58810106.210.000240.000570.00019HMEC3.65100.306>10> 100.1750.00229> 10.00091HREC0.1170.5930.03690.5531.520.3080.000550.00270.0005Wi380.2850.8710.3698.848.846.150.000490.000740.00033

[0295] Table 39 shows representative data for the response when the cell line HREC is treated with compound 1 in an OncoPanel Normal Cell Proliferation Assay. Table 39. Compound 1 against HRECConcentration (microM)Relative cell count (%)MeanStdDev9.55E-0498.58.83.02E-0394.07.49.53E-0393.36.63.01E-0296.08.39.52E-0295.84.53.01E-0196.78.79.51E-0189.34.73.00E+0085.114.49.49E+0040.43.33.00E+0120.95.7

[0296] The data displayed in Table 39 is graphed in Figure 19. Discussion

[0297] Compound 1 and reference compounds, paclitaxel, cycloheximide, carbonyl cyanide m-chlorophenylhydrazone (CCCP) and staurosporine, were tested on 4 normal cell types, CCD 841 CoN, HMEC, HREC and Wi38. In summary, compound 1 showed relatively low toxicity towards all 4 cell lines. Paclitaxel showed low toxicity towards the HMEC cell line and high toxicity towards the other three cell lines. Based on average GI 50 for the 4 normal cell lines, the order of toxicity is staurosporine > paclitaxel > cycloheximide > CCCP > compound 1. In vitro toxicity: ADME-Toxicity Study

[0298] ADME-Toxicity study of compounds 1, 2 and 4 was conducted by Eurofins Panlabs Inc, St Charles, MO, USA using a CYP panel.Methodology

[0299] Cytochrome P450 Inhibition was monitored through HPLC-UV / VIS and HPLC-MS / MS detection. Peak areas corresponding to the metabolite of each substrate were recorded. The percent of control activity was then calculated by comparing the peak area obtained in the presence of the test compound to that obtained in the absence of the test compound. Subsequently, the percent inhibition was calculated by subtracting the percent control activity from 100 for each compound. IC 50 values (concentration causing a half-maximal inhibition of control values) were determined by non-linear regression analysis of the concentration-response curve using Hill equation curve fitting [Dierks, E. A. et al. (2001)].Results

[0300] Table 40. Inhibition of CYPs by compounds 1, 2 and 4 against reference compounds% Inhibition of Control ValuesHuman liver microsomes Compound 1 Compound 2 Compound 4 ReferenceIn Vitro Metabolism1 µM10 µM1 µM10 µM1 µM10 µMCompoundIC 50 µMCYP1A (phenacetin sub.)289238631485Furafylline16CYP2B6 (bupropion sub.)135515381649Clopidogrel0.39CYP2C8 (paclitaxel sub.)147612522461Montelukast0.57CYP2C9 (diclofenac sub.)57720723191Sulfaphenazole0.28CYP2C19 (omeprazole sub.)379034732578Oxybutynin6.7CYP2D6 (dextromethorphan sub.)134518442145Quinidine0.12CYP3A (midazolam sub.)166515371550Ketoconazole0.18CYP3A (testosterone sub.)77717572048Ketoconazole0.18 Summary of ResultsEnzyme - SubstratesCYP1A (phenacetin substrate)

[0301] Compounds 1, 2 and 4 are strong inhibitors at 10 µM (63-92%). With IC 50 values estimated to be < 10, Compounds 1, 2 and 4 are stronger inhibitors the reference standard furafylline (IC 50 16 µM). Compounds 1 and 2 showed moderate inhibition at 1 µM (28% and 38% respectively).CYP2B6 (bupropion substrate)

[0302] Compounds 1, 2 and 4 are relatively weak inhibitors (13-16% at 1 µM) compared with the reference compound clopidogrel (IC 50 0.39 µM).CYP2C8 (paclitaxel substrate)

[0303] Compounds 1, 2 and 4 are relatively weak inhibitors (12-24% at 1 µM) compared with the reference compound montelukast (IC 50 0.57 µM).CYP2C9 (diclofenac substrate)

[0304] Compounds 1 was a very weak at 1 µM (5%) and Compounds 2 and 4 relatively weak inhibitors (20 and 31%) compared with the reference compound sulfaphenazole (IC 50 0.28 µM).CYP2C19 (omeprazole substrate)

[0305] Compounds 1, 2 and 4 are moderately strong inhibitors (25-37% at 1 µM) with activity comparable with oxybutynin (IC 50 6.7 µM).CYP2D6 (dextromethorphan substrate)

[0306] Compounds 1, 2 and 4 are relatively weak inhibitors (12-21% at 1 µM) compared with the reference compound quinidine (IC 50 0.12 µM).CYP3A (midazolam substrate)

[0307] Compounds 1, 2 and 4 are relatively weak inhibitors (15-16% at 1 µM) compared with the reference compound ketoconazole (IC 50 0.18 µM).CYP3A (testosterone substrate)

[0308] Compounds 1, 2 and 4 are relatively weak inhibitors (7-20% at 1 µM) compared with the reference compound ketoconazole (IC 50 0.18 µM).In vivo toxicity: Compound 1 Maximum Tolerated Dose for Mice

[0309] Two studies were conducted by Eurofins Panlabs Taiwan, Ltd. The purpose of Study 1 was to assess the possible adverse effects of compound 1 alone or in combination with carboplatin in Maximum Tolerated Dose (MTD) assay. The purpose of Study 2 is a follow-up study performed at escalating doses.

[0310] The vehicle information and dosing volume used in the studies are shown in Table 41. Table 42 and Table 43 show results for Study 1 in terms of mortality and body weight observations. In regard to Study 2, Table 44 and Table 45 show results for mortality and body weight observations and behavioral, symptomatic i.e. neurological and autonomic signs for compound 1, alone and in combination with carboplatin, are shown in Table 46 and Table 47. Corresponding signs for the vehicles are shown in Table 48 and Table 49. Table 41. Vehicle information and dosing volume for MTD assay studiesStudyTest articleVehicleConcentration (mg / mL)Dosing volume (mL / kg)Dosage (mg / kg)1Compound 1 10% Tween 20 / 90% PBS10101002Compound 1 20% Tween 20 / 80% PBS2010200 Test Substance and Dosing Pattern

[0311] Compound 1 was dissolved in 10% Tween 20 / 90% PBS or 20% Tween 20 / 80% PBS for IP injections. Compound 1 was administrated alone or in combination with carboplatin at a dosing volume of 10 or 20 mL / kg for each substance.Study 1

[0312] For mortality, test substance (Compound 1; 100 mg / kg) alone or in combination with carboplatin (8.75, 17.5, or 35 mg / kg; given on the same day) was administered to mice by IP injection to evaluate the possible adverse effects in MTD assay. The mice were a group of 3 female NOD / SCID mice at 6 - 7 weeks of age. The mortality was observed at 30 min and again at 3, 24, 48 and 72 hours after compound administrations.

[0313] For bodyweight, test substance (Compound 1; 100 mg / kg) alone or in combination with carboplatin (8.75 or 17.5 mg / kg; given on the same day) was administered to a group of 3 female NOD / SCID mice at 6 - 7 weeks of age. The body weight of each animal was measured and recorded daily for 3 days.

[0314] Compound 1 alone did not elicit significant adverse effects and were considered tolerated. All test animals survived over the 72-hour observation period (Table 42). However, Compound 1 in combination with carboplatin was associated with slight to moderate limb tone, and resulted in a 33% mortality after 72 hours of dosing, reflecting the dose level was not well-tolerated (Table 42).

[0315] Compound 1, in combination with the lower doses of carboplatin (8.75 and 17.5 mg / kg), was further investigated in the MTD study. Compound 1, injected with two doses of carboplatin on the same day, was associated with slight to moderate abdominal tone during the first 30 minutes of administrations (Table 44 and Table 45). However, no mortality and body weight losses were observed in test animals over the experimental period, signifying the dose levels were tolerated (Table 44 and Table 45). Table 42. MTD in mice (Study 1, Round 1 & 2)CompoundRouteDose (mg / kg)Response ( death / test)30 min3 hrsDay 1Day 2Day 3Vehicle a< IP10 mL / kg0 / 30 / 30 / 30 / 30 / 3Vehicle a< +Vehicl e b< IP10 mL / kg +10 mL / kg0 / 30 / 30 / 30 / 30 / 3Compound 1 IP100 mg / kg0 / 30 / 30 / 30 / 30 / 3CarboplatinIP35 mg / kg0 / 30 / 30 / 30 / 30 / 3Compound 1 + carboplatinIP100 mg / kg + 35 mg / kg0 / 30 / 30 / 30 / 31 / 3Vehicle a< +Vehicl e b< IP10 mL / kg + 10 mL / kg0 / 30 / 30 / 30 / 30 / 3Compound 1 + carboplatinIP100 mg / kg + 17.5 mg / kg0 / 30 / 30 / 30 / 30 / 3Compound 1 + carboplatinIP100 mg / kg + 8.75 mg / kg0 / 30 / 30 / 30 / 30 / 3Legend: a< 10% Tween 20 / 90% PBS b< 0.9% NaCl Table 43. MTD in mice (Study 1; Round 2) CompoundRouteDose (mg / kg)No.Body Weight ( g )Day 0Day 1Day 2Day 3Vehicle a< +Vehicle b< IP10 mL / kg + 10 mL / kg120201919220202019322212121Compound 1 + carboplatinIP100 mg / kg + 17.5 mg / kg122212120222222221321212121Compound 1 + carboplatinIP100 mg / kg + 8.75 mg / kg122202020221212221321212120 Legend: a< 10% Tween 20 / 90% PBS b< 0.9% NaCl Study 2

[0316] A follow-up MTD study was performed to evaluate for the adverse effects of the test substance (Compound 1) at escalating doses alone or in combination with carboplatin (17.5 mg / kg) via IP in a group of 3 female NOD / SCID mice at 6 - 7 weeks of age. For mortality, treatment with compound 1 at escalating doses (200 mg / kg) alone and in combination with carboplatin (17.5 mg / kg; given on the same day) were administered by IP injection to a group of 3 female NOD / SCID mice at 6 - 7 weeks of age. The mortality was monitored at 30 min and again at 3, 24, 48 and 72 hours after compound administrations.

[0317] For body weight, test substance (Compound 1) at escalating doses (200 mg / kg) alone or in combination with carboplatin (17.5 mg / kg; given on the same day) were administered by IP injection to a group of 3 female NOD / SCID mice at 6 - 7 weeks of age. The body weight of each animal was measured and recorded daily for 3 days.

[0318] On treatment with compound 1 (200 mg / kg) alone and in combination with carboplatin (17.5 mg / kg) exhibited a 33 - 100% mortality, but no marked weight loss during the study period (Table 30 and Table 31). Table 44. MTD in mice (Study 2)CompoundRouteDose (mg / kg)Response ( death / test)30 min3 hrsDay 1Day 2Day 3Vehicle a< IP10 mL / kg0 / 30 / 30 / 30 / 30 / 3Vehicle a< +Vehicle b< IP10 mL / kg + 10 mL / kg0 / 30 / 30 / 30 / 30 / 3PT# 1206425 (UOS-70) (Compound 1) IP200 mg / kg0 / 30 / 31 / 33 / 33 / 3PT# 1206425 (UOS-70) (Compound 1) + carboplatinIP200 mg / kg + 17.5 mg / kg0 / 30 / 30 / 31 / 31 / 3Vehicle a< (20% Tween20 / 80% PBS)IP20 mL / kg0 / 30 / 31 / 32 / 32 / 3Legend: a< 20% Tween 20 / 80% PBS b< 0.9% NaCl Table 45. MTD in mice (Study 2; Round 1 & 2) CompoundRouteDose (mg / kg)No.Body Weight ( g )Day 0Day 1Day 2Day 3Vehicle a< (20% Tween20 / 80% PBS)IP10 mL / kg123222323224232323323222222Vehicle a< +Vehicle b< IP10 mL / kg + 10 mL / kg122212019222222119322202020Compound 1 IP200 mg / kg12221NANA221NANANA32121NANACompound 1 + carboplatinIP200 mg / kg + 17.5 mg / kg12120202122222NANA321201920Vehicle a< IP20 mL / kg123NANANA22222NANA323222221 Legend: a< 20% Tween 20 / 80% PBS b< 0.9% NaCl

[0319] For behavioral, symptomatic i.e. neurological and autonomic signs, test substance (compound 1; 200 mg / kg) alone or in combination with carboplatin (17.5 mg / kg; given on the same day) were administered by IP injection to a group of 3 female NOD / SCID mice at 6 - 7 weeks of age. The animals were then observed for presences of acute toxic symptoms and autonomic effects for 30 min after the first dose.

[0320] Pronounced behavioral effects such as decreased startle, touch response, pinna and placing were observed on compound 1 treatment, alone and in combination with carboplatin (see Table 46). Decreased neurologic signs, such as spontaneous activity, righting, ataxia and low limb post were observed on compound 1 treatment (Table 46). Hypothermia (decreased body temperature) was observed as an autonomic sign (Table 47). Table 46. Behavioral and neurologic signs in mice for compound 1 (Study 2; Round 1)Treatment Compound 1 Compound 1+ carboplatin Route IP IP Dosage 200 mg / kg 200 mg / kg + 17.5 mg / kg BEHAVIORAL No. 1 No. 2 No. 3 No. 1 No. 2 No. 3B.W. (g) 22 21 21 21 22 21 Irritability - - - - - - Hyperactivity - - - - - - Inc. Startle - - - - - - Inc. Touch ------Dec. Startle Response ++++++Dec. Touch Response ++++++Inc. Exploration ------Dec. Exploration ++++++Pinna ++++++Placing ±±±±+±NEUROLOGIC Tremor ---+-+Dec. Spent. Activity ++++++Straub Tail ------Reactivity -+++±+Righting ++±±++Ataxia ++±±++Convulsion C.T.C-T ------Low Limb Post ++++++Abdominal Tone ++++++Limb Tone ++++++Grip Strength -±+-+± Table 47. Autonomic signs in mice for compound 1 (Study 2; Round 1) Treatment Compound 1 Compound 1 + carboplatin Route IP IP Dosage 200 mg / kg 200 mg / kg + 17.5 mg / kg AUTONOMIC No. 1 No. 2 No. 3 No. 1 No. 2 No. 3 Skin Color - - - - - - Respiration D ±D+ D+ D+ D+ D+ Salivation F.V. - - - - - - Lacrimation ------Diarrhea ------Body Temperature ↓+↓+↓+↓+↓+↓+Piloerection ------Inc. Palpebral Size ------Dec. Palpebral Size ----±-Others ------Death ------ Table 48. Behavioral and neurologic signs in mice for vehicles (Study 2; Round 1) Treatment Vehicle a< Vehicle a< +Vehicle b< Route IP IP Dosage 10 mL / kg 10 mL / kg + 10 mL / kg BEHAVIORAL No. 1 No. 2 No. 3 No. 1 No. 2 No. 3 B.W. (g) 23 24 23 22 22 22 Irritability - - - - - - Hyperactivity - - - - - - Inc. Startle ------Inc. Touch ------Dec. Startle Response ------Dec. Touch Response ------Inc. Exploration ------Dec. Exploration ------Pinna ------Placing ------ NEUROLOGIC Tremor ------Dec. Spent. Activity ------Straub Tail ------Reactivity ------Righting ------Ataxia ------Convulsion C.T.C-T ------Low Limb Post ------Abdominal Tone --±±±±Limb Tone ------Grip Strength ------ Table 49. Autonomic signs in mice for vehicles (Study 2; Round 1) Treatment Vehicle a< Vehicle a< +Vehicle b< Route IP IP Dosage 10 mL / kg 10 mL / kg + 10 mL / kg AUTONOMIC No. 1 No. 2 No. 3 No. 1 No. 2 No. 3 Skin Color - - - - - - Respiration - - - - - - Salivation F.V. - - - - - - Lacrimation ------Diarrhea ------Body Temperature ------Piloerection ------Inc. Palpebral Size ------Dec. Palpebral Size ------Others ------Death ------ Legend for Tables 46 to 49 a< 20% Tween 20 / 80% PBS b< 0.9% NaCl - : no effects ±: Slight to moderate effects +: Severe effects Inc.: Increased Dec.: Decreased Spont.: Spontaneous C.: Chronic T.: Tonic C-T: Chronic-Tonic ↓: Low D: Deep In vivo anti-cancer activity: Compound 1 and gemcitabine

[0321] An in vivo study indicates that compound 1 is effective in combination with gemcitabine. The study design is detailed below and in Table 50. There is evidence for synergy from the study results results which are shown in Table 51 and Table 52. Monotherapy and combinations were well tolerated. Table 50. Tumor, Xenograft, Pancreas, MIA PaCa-2 in female nu / nu mice study designTest Conc. Dosage Mice a< Group ArticleRoutemg / mLmL / kgmg / kg(female)1 #< Vehicle b< IPNA10NA qwk x 3 c< 82 GemcitabineIP81080 q4d x 4 d< 84 Compound 1 IP1010100 qwk x 3 c< 86 Compound 1 + GemcitabineIP + IP10 + 810100, qwk x 3 c< + 80, q4d x 4 d< 8 #< Negative control group a< Female nu / nu mice aged 7-8 weeks are implanted with 1 × 10 7< MIA PaCa-2 cells (0.2 mL / mouse), and dosing is initiated when group mean tumor volumes reach ∼80-150 mm 3< . b< Test substance vehicle (10% Tween20 / 90% Saline) c< Doses are administered once weekly for 3 weeks. d< Doses are administered once every four days (four total administrations).Body weight and tumor volumes are recorded twice weekly beginning on Day 1 and continuing until study completion.Tumor growth inhibition (%TGI) is determined twice weekly during the dosing period by the formula: %TGI = (1 -[(T -T0) / (C -C0)]) × 100 where T = mean tumor volume of treated group, T0 = mean tumor volume of treated group at study start, C = mean tumor volume of control group and C0 = mean tumor volume of control group at study start.Study is designed to continue for 28 days, or until the mean tumor volume within negative control group reaches 2000 mm 3< , whichever comes first.After TGI is determined, study may be converted to determine Tumor Growth Delay (TGD).Animals are to be sacrificed if / when:1. Body weight loss > 25%2. Severe tumor ulceration ESTIMATED TIMELINE

[0322] Animal Arrival: Within one month receiving test compounds Tumor cells implantation: Within two weeks after animals are obtained Dosing: Approximately 1-2 weeks after tumor cell implantation SAMPLE REQUIREMENTS Compound 1 150 mg; Gemcitabine 256 mg. PROTOCOL Tumor, Xenograft, Pancreas, MIA PaCa-2

[0323] Procedure: Groups of (8) female nu / nu mice (7-8 weeks old), bred in an animal isolator (IVC racks) under specific pathogens free (SPF) condition at 22 plus or minus 2 °C are used. Viable human pancreatic carcinoma MIA PaCa-2 (ATCC CRL-1420) cells (1.0 × 107 in 0.2 mL) are injected subcutaneously into the right flank of experimental mice. When tumor volumes reach -80-150 mm 3< (about 8-10 days post implant), the animals are randomly assigned into groups of eight, and test compounds and / or vehicle dose administrations are initiated (denoted as Day 1). Test compounds are administered as detailed in the "Study Design" section (Table 50). Tumor volumes and body weights are measured and recorded twice weekly over the course of the study period. Animals are monitored as a group. The endpoint of the experiment is a mean tumor volume in the negative control group of 2000 mm 3< or 28 days, whichever comes first.

[0324] Tumor volume (mm 3< ) is estimated according to the formula for a prolate ellipsoid: length (mm) × [width (mm)]2 × 0.5. Tumor growth inhibition (%TGI) will be determined twice weekly during the dosing period by the formula: %TGI = (1 -[(T -T0) / (C -C0)]) × 100 where T = mean tumor volume of treated group, T0 = mean tumor volume of treated group at study start, C = mean tumor volume of control group and C0 = mean tumor volume of control group at study start [Mohammed et al. 1998].

[0325] All aspects of this work including housing, experimentation, and animal disposal are performed in general accordance with the "Guide for the Care and Use of Laboratory Animals: Eighth Edition" (2011) in an AAALAC-accredited laboratory animal facility. Table 51. Tumor volume change in a pancreas MIA PaCa-2 tumor xenograft model in response to treatment with compound 1 alone or in combination with Gemcitabine.Assay Tumor Xenograft, Pancreas, MIA PaCa-2 WO#1060729 (AB67928) Female nu / nu mice Gr. Treatment Dose (mg / kg) (Route) No. Tumor Volume (mm3) Day1 Day4 Day8 Day11 Day15 1 Vehicle NA (mg / kg) QWK × 3 IP 1 64 125 186 326 574 2 74 65 87 128 151 3 103 97 175 238 476 4 122 111 142 179 422 5 76 63 135 160 258 6 90 79 81 96 171 7 90 84 73 140 326 8 103 125 180 315 629 Mean 90 94 132 198 376 SEM 7 9 17 31 63 2 Gemcitabine 80 mg / kg Q4D × 4 IP 1 65 65 114 165 213 2 74 82 104 97 160 3 104 128 151 215 419 4 115 123 162 228 335 5 76 73 75 103 130 6 88 100 70 85 128 7 91 58 70 94 115 8 101 119 113 127 156 Mean 89 94 107 139 207 SEM 6 10 13 20 39 % T / C 99 100 81 70 55 % TGI 1 0 19 30 45 4 Compound 1 100 mg / kg QWK × 3 IP 1 67 56 126 368 600 2 72 59 95 110 244 3 104 105 125 192 276 4 115 103 107 121 197 5 81 129 187 266 414 6 87 70 111 188 309 7 93 92 177 251 409 8 100 107 138 188 312 Mean 90 90 133 211 345 SEM 6 9 12 30 45 % T / C 100 96 101 107 92 % TGI 0 4 -1 -7 8 6 Compound 1 + Gemcitabine 100 mg / kg QWK × 3 IP + 80 mg / kg Q4D × 4 IP 1 69 46 48 57 80 2 70 111 94 104 116 3 108 86 101 97 103 4 111 132 124 157 265 5 84 68 71 35 95 6 86 67 77 105 123 7 96 55 28 25 23 8 98 94 98 127 210 Mean 90 82 80 88 127 SEM 6 10 11 16 27 % T / C 100 87 61 44 34 % TGI 0 13 39 56 66 Table 52. Body weight change in a pancreas MIA PaCa-2 tumor xenograft model in response to treatment with Compound 1 alone or in combination with Gemcitabine. Assay # 581500 Tumor Xenograft, Pancreas, MIA PaCa-2 WO#1060729 (AB67928) Female nu / nu mice Gr. Treatment Dose (mg / kg) (Route) No. Body Weight (g) Day1 Day4 Day8 Day11 Day15 1 Vehicle NA (mg / kg) QWK × 3 IP 1 28 27 27 27 26 2 27 26 27 27 27 3 25 24 25 26 27 4 24 24 24 24 24 5 26 25 25 25 25 6 25 25 25 26 26 7 25 23 23 24 24 8 25 25 24 25 26 Mean 25.6 24.9 25.0 25.5 25.6 SEM 0.5 0.4 0.5 0.4 0.4 2 Gemcitabine 80 mg / kg Q4D × 4 IP 1 24 23 25 25 26 2 30 28 30 31 31 3 25 22 25 26 27 4 26 25 27 27 27 5 24 24 25 25 25 6 25 24 25 25 25 7 25 24 24 25 25 8 26 25 25 25 25 Mean 25.6 24.4 25.8 26.1 26.4 SEM 0.7 0.6 0.7 0.7 0.7 4 Compound 1 100 mg / kg QWK × 3 IP 1 29 27 29 29 29 2 26 24 26 25 25 3 25 24 26 25 26 4 25 23 25 25 24 5 25 25 25 27 26 6 23 23 23 25 23 7 25 25 25 27 26 8 26 26 26 27 26 Mean 25.5 24.6 25.6 26.3 25.6 SEM 0.6 0.5 0.6 0.5 0.6 6 Compound 1 + Gemcitabine 100 mg / kg QWK × 3 IP + 80 mg / kg Q4D × 4 IP 1 25 24 24 24 24 2 24 23 23 24 24 3 27 27 26 26 26 4 27 25 26 26 26 5 23 22 23 23 23 6 26 25 25 25 24 7 27 26 26 26 26 8 25 24 24 23 23 Mean 25.5 24.5 24.6 24.6 24.5 SEM 0.5 0.6 0.5 0.5 0.5 References

[0326] Ghisalberti EL (1994) The phytochemistry of the myoporaceae. Phytochemistry, 35: 7-33. Davis RA, Caroll AR, Pierens GK (1999). New lamellarin alkaloids from the Australian ascidian, Didemnum chartaceum. J. Nat. Prod., 62(3), 419-24. Ullman EF, Kirakossian H, Singh S, Wu ZP, Irvin BR, Pease JS, Switchenko AC, Irvine JD, Dafforn A, Skold CN (1994) Luminescent oxygen channeling immunoassay: Measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. USA Vol. 91, 5426-5430. Ma H, Deacon S, Horiuchi K (2008). The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov. 3(6): 607-621. Filippakopoulos, P., Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Müller S, Pawson T, Gingras AC, Arrowsmith CH, Knapp S. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell, 149(1): 214-31. Filippakopoulos, P. and S. Knapp (2012) The bromodomain interaction module. FEBS Lett, 586(17): 2692-704. Philpott, M., Yang J, Tumber T, Fedorov O, Uttarkar S, Filippakopoulos P, Picaud S, Keates T, Felletar I, Ciulli A, Knapp S, Heightman TD (2011) Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol Biosyst, 7(10): 2899-908. Kaustov, L., Ouyang H, Amaya M, Lemak A, Nady N, Duan S, Wasney GA, Li Z, Vedadi M, Schapira M, Min J, Arrowsmith CH (2011) Recognition and specificity determinants of the human cbx chromodomains. J Biol Chem 286(1): 521-9. Kim, J., Daniel J, Espejo A, Lake A, Krishna M, Xia L, Zhang Y, Bedford MT (2006) Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep, 7(4): 397-403. Org, T., Chignola F, Hetényi C, Gaetani M, Rebane A, Liiv I, Maran U, Mollica L, Bottomley MJ, Musco G, Peterson P (2008) The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression. EMBO Rep, 9(4): 370-6. Venturini, L., You J, Stadler M, Galien R, Lallemand V, Koken MH, Mattei MG, Ganser A, Chambon P, Losson R, de Thé H. (1999) TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene, 18(5): 1209-17. Xie, S., J. Jakoncic, and C. Qian (2012) UHRF1 double tudor domain and the adjacent PHD finger act together to recognize K9me3-containing histone H3 tail. J Mol Biol, 415(2): 318-28. Adams-Cioaba, M.A., Li Z, Tempel W, Guo Y, Bian C, Li Y, Lam R, Min J. (2012) Crystal structures of the Tudor domains of human PHF20 reveal novel structural variations on the Royal Family of proteins. FEBS Lett, 586(6): 859-65. Hayashi-Takanaka Y, Yamagata K, Wakayama T, Stasevich TJ, Kainuma T, Tsurimoto T, Tachibana M, Shinkai Y, Kurumizaka H, Nozaki N, Kimura H (2011) Nucleic Acids Res. 39(15): 6475-88. Kubicek, S. et al. (2007), Mol. Cell. 25:473-481. Ken-ichi Noma and Shiv I. S. Grewal (2002), Proc Natl Acad Sci U S A. December 10; 99 (Suppl 4): 16438-16445. Rotili, D. and Mai, A. (2011), Genes & Cancer, 2: 663-679. Chowdhury, R. et al. (2011), Eur. Mol. Biol. Org., 12: 463-469. Nottke, A. et al. (2009), Development, 136:879-889. Kristensen, L.H. et al. (2012), FEBS Journal, 279:1905-1914. Heightman T. D. (2011), Current Chemical Genomics, 5: 62-71. King O.N.F. et al. (2010), PLoS ONE, 5:1-12. Hong, S. et al. (2007), PNAS., 104:18439-18444. Pradhan, S. et al. (1999), J. Biol. Chem., 274: 33002-33010. Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. (2004), J Biol Chem. 279(26): 27816-23. Aoki, A. et al. (2001), Nucleic. Acids. Res., 29: 3506-3512. Zhang, H. et al. (2012), J Biol Chem., 287(9):6573-81. Strahl, B.D. and C.D Allis (2000) The language of covalent histone modifications. Nature, 403(6765): 41-5. Michan, S. and Sinclair, D. (2007), Biochem. J., 404: 1-13. Michishita, E. et al. (2008), Nature, 452, 492-496. Kim, W. and Kim, J.E. (2013), J. Physiol.Pharmacol., 64(5):531-534. An S1, Yeo KJ, Jeon YH, Song JJ. (2011), J Biol Chem. 286(10): 8369-74. Yost, J.M. et al. (2011), Curr. Chem. Genomics, 5: 72-84. Shen, X, Liu, Y. et al. (2008), Mol. Cell., 32: 491-502 Nayak, V. et al. (2011), Nucleus, 1:2. Jiang H1, Lu X, Shimada M, Dou Y, Tang Z, Roeder RG.(2013), Nat Struct Mol Biol., 10:1156-63. Ali M1, Hom RA1, Blakeslee W1, Ikenouye L1, Kutateladze TG2. (2014), Biochim Biophys Acta. ;1843(2):366-71. Allali-Hassani A1, Kuznetsova E1, Hajian T1, Wu H1, Dombrovski L1, Li Y1, Gräslund S1, Arrowsmith CH2, Schapira M3, Vedadi M4.(2014), J Biomol Screen.; 19 (6):928-935. Selvi B.R. et al. (2010), Biochim Biophys Acta., 1799(10-12): 810-28. Munoz-Fuentes, V. et al. (2011), PLoS ONE, 6: 1-7. Cheng, D. et al. (2004), J. Biol. Chem., 279: 23892-23899. Li, K.K. et al. (2012), Med Res Rev. 32(4):815-67. Selvi, B. R. et al. (2010), J. Biol. Chem., 285: 7143-7152. Yost, J.M. et al. (2011), Curr. Chem. Genomics, 5: 72-84. Iberg, A.N. et al. (2007), J. Biol. Chem., 283: 3006-3010. Zurita-Lopez CI1, Sandberg T, Kelly R, Clarke SG.(2012), J Biol Chem. 287(11):7859-70. Lee, J. et al. (2005), The journal of biological chemistry, vol. 280, 38: 32890-32896. Du, H.-N. et al. (2008), Gene Dev., 22 : 2786-2798 Schultz, D.C. et al. (2002), Genes Dev., 16: 919-932. Kang, H.B. et al. (2009), FEBS LETT 583: 1880-1886. Sabbattini P, Canzonetta C, Sjoberg M, Nikic S, Georgiou A, Kemball-Cook G, Auner HW, Dillon N. (2007), EMBO J. 26(22):4657-69. Preuss U, Landsberg G, Scheidtmann KH. (2003), Nucleic Acids Res., 31(3):878-85. Han A, Lee KH, Hyun S, Lee NJ, Lee SJ, Hwang H, Yu J. (2011), Bioorg Med Chem., 19(7):2373-7. Baek SH. (2011), Mol Cell., 42(3):274-84 Barnett, S.F. et al. (2005), Biochem. J., 385: 399-408. Misaghi, S. et al. (2009), Mol. Cell. Biol. 29 : 2181-2192. Horton, R.A. et al. (2007), Anal. Biochem., 360 :138-143. Hu, M. et al. (2005), The EMBO Journal 24, 3747-3756. Ye Y. et al. (2011), EMBO reports, 12: 350-357. Tian, X. et al. (2011), Assay and Drug Dev. Technol., 9 :165-173. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nature Reviews Drug Discovery, 11, 384-400. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R and Lichter P. (2013). Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nature Reviews Genetics 14: 765-780. Taverna SD, Li H, Ruthenburg AJ,Allis CD, Patel DJ. (2007) How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers Nature Structural & Molecular Biology 14, 1025-1040. Prinjha RK, Witherington J, Lee K. (2012) Place your BETs: the therapeutic potential of bromodomains Trends in Pharmacological Sciences 33, 3, 146-153. Biggar KL, Li SS-C. (2015) Non-histone protein methylation as a regulator of cellular signalling and function. Nature Rev Mol Cell Biol, 16, 5-17. Tough DF, Lewis HD, Rioja I, Lindon MJ, Prinjha RK (2014). Epigenetic pathways targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. Br J Pharmacol 171: 4981-5010 Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nature Chemical Biology, 10, 305-312. Fu L, Tian M, Li X, Li J-J, Huang J L, Zhang Y, Liu B. (2015). Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 2015 Mar 20; 6(8): 5501-5516. Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K. (2009) ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res., 69: 8491-8498. Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, Salvesen, HB. (2015) ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget, 6: 28440-28452. Weidner-Glunde M, Ottinger M, Schulz TF. (2010) WHAT do viruses BET on? Front Biosci. 15: 537-549. Blus BJ, Wiggins K, S. (2011) Epigenetic virtues of chromodomains. Critical Reviews in Biochemistry and Molecular Biology. 46, 6, 507-526 Cyr AR, Dormann FE. The redox basis of epigenetic modifications: from mechanism to functional consequences. (2011) Antioxidant & Redox Signaling, 15(2), 551-589. Copeland RA, Solomon ME, Richon VM. (2009) Protein methyl transferase as a target class for drug discovery. Nat. Rev. Drug Discovery, 8, 724-732. Shankar RS, Bahirvani AG, Rao VK, Bharathy N, Ow JR, Taneja R. (2013) G9a a multipotent regulator of gene expression. Epigenetics, 8:1, 16-22. Casciello F, Winloch K, Gannon F, Lee JS. (2015) Functional role of G9a histone methyltransferase in cancer. Front. Immunol., 6:487-498. Fuhrmann J, Clancy KW, Thompson PR. (2015) Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev., 115, 5413-5461. Højfelt JW, Agger K, Helin K. (2013) Histone lysine demethylases as targets for anticancer therapy. Nat. Rev. Drug Discov. 917. Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z et al. (2007). JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA 104: 19226-19231. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F et al. (2008). Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res 14: 6634-6639. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594. He J, Nguyen AT, Zhang Y (2011). KDM2b / JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117: 3869-3880. Berry WL, Janknecht R (2013). KDM4 / JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 73: 2936-2942. Kogure M, Takawa M, Cho H-S, Toyokawa G, Hayashi K, Tsunoda T et al. (2013). Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G1 / S transition. Cancer Lett 336: 76-84. Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G et al. (2013). KDM2B promotes pancreatic cancer via polycomb dependent and -independent transcriptional programs. J Clin Invest 123: 727-739. Adcock IM, Lee KY (2006). Abnormal histone acetylase and deacetylase expression and function in lung inflammation. Inflamm Res 55: 311-321. Avvakumov N, Cote J (2007). The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26: 5395-5407. Grabiec A, Tak P, Reedquist K (2008). Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? Arthritis Res Ther 10: 226. Ghizzoni M, Haisma HJ, Maarsingh H, Dekker FJ (2011). Histone acetyltransferases are crucial regulators in NF-kB mediated inflammation. Drug Discov Today 16: 504-511. Iyer A, Fairlie DP, Brown L (2011). Lysine acetylation in obesity, diabetes and metabolic disease. Immunol Cell Biol 90: 39-46. Pirooznia SK and Elefant F (2013). Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities. Front Cell Neurosci 7: 30. Lee, S., et al., (2001) Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction. Cardiovasc Res, 51(1): 131-9. Rubin, B., Laffan RJ, Kotler DG, O'Keefe EH, Demaio DA, Goldberg ME (1978) SQ 14,225 (D-3-mercapto-2-methylpropanoyl-1-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther, 204(2): 271-80. Bunning, P., B. Holmquist, and J.F. Riordan, Substrate specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry, 1983. 22(1): p. 103-10. Hesselgesser, J., et al., Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem, 1998. 273(25): p. 15687-92. Gong, X., Gong W, Kuhns DB, Ben-Baruch A, Howard OM, Wang JM (1997) Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J Biol Chem, 272(18): 11682-5. Combadiere, C., Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM (1998) Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem, 273(37): 23799-804. Grob, P.M., David E, Warren TC, DeLeon RP, Farina PR, Homon CA. (1990) Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor / interleukin-8. J Biol Chem, 265(14): 8311-6. Ahuja, S.K. and P.M. Murphy (1996) The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem, 271(34): 20545-50. Valenzuela-Fernandez, A., Planchenault T, Baleux F, Staropoli I, Le-Barillec K, Leduc D, Delaunay T, Lazarini F, Virelizier JL, Chignard M, Pidard D, Arenzana-Seisdedos F. (2002) Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1) / CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem, 277(18): 15677-89. Dittadi, R., et al., Radioligand binding assay of epidermal growth factor receptor: causes of variability and standardization of the assay. Clin Chem, 1990. 36(6): p. 849-54. Muller-Enoch, D., E. Seidl, and H. Thomas, [6.7-Dihydroxycoumarin (Aesculetin) as a substrate for catechol-o-methyltransferase (author's transl)]. Z Naturforsch C, 1976. 31(5-6): 280-4. Tietge, U.J., Pratico D, Ding T, Funk CD, Hildebrand RB, Van Berkel T, Van Eck M. (2005). Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res, 46(8): 1604-14. Montalibet, J., K.I. Skorey, and B.P. Kennedy (2005) Protein tyrosine phosphatase: enzymatic assays. Methods 35(1): 2-8. Sun, Z.Y. and Z.H. Tu, A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia. Methods Find Exp Clin Pharmacol, 1998. 20(4): p. 283-7. Becker, K., Gromer, S., Schirmer, R.H., Müller, S. (2000) Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem, 267(20): 6118-25. Hatano, T., et al. (1990). Effects of interaction of tannins with co-existing substances. VII. Inhibitory effects of tannins and related polyphenols on xanthine oxidase. Chem Pharm Bull (Tokyo), 38(5): 1224-9. De Backer et al., (1993). Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun 197(3): 1601-1608. Ruat et al., (1990). Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H2 receptor using [125I]iodinated probes. Proc Natl Acad Sci USA. 87(5): 1658-1662. Krueger et al., (2005). G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Exp Ther. 314(1): 271-281. Liu et al., (2001). Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 299(1): 121 - 130. Kubo and Strott, (1987). Differential activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in zones of the adrenal cortex. Endocrinology. 120:214-221. Pufahl et al., (2007). Development of a fluorescence-based enzyme assay of human 5-lipoxygenase. Anal Biochem. 364(2): 204-212. Mansuy et al., (1986). A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisylditholthione. Biochem Biophys Res Comm. 135:1015-1021. Romano et al., (1993). Lipoxin synthase activity of human platelet 12-lipoxygenase. Biochem J. 296: 127-133. Urban et al., (1991). Comparative membrane locations and activities of human monoamine oxidases expressed in yeast. FEBS Lett. 286(1-2): 142 - 146. Svensson et al., (1987). Peroxidase and peroxidase-oxidase activities of isolated human myeloperoxidase. Biochem J. 242:673-680. Yamamoto et al., (2006). A nonradioisotope, enzymatic assay for 2-deoxyglucose uptake in L6 skeletal muscle cells cultured in a 96-well microplate. Anal Biochem. 351(1): 139-45. Cobb, R.R., et al.,(1992) Functional expression of soluble ICAM-1 by baculovirus-infected Sf9 cells. Biochem Biophys Res Commun, 185(3): 1022-33. Stoltenborg, J.K., Tsao PW, George HJ, Bouchard PJ, Wexler EJ, Hausner EA (1994). A fluorescent cellular adhesion assay using insect cell produced human VCAM1. J Immunol Methods, 175(1): 59-68. Lenardo, M.J. and D. Baltimore (1989) NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell, 58(2): 227-9. Sen R., Baltimore D. (1986). Multiple nuclear factors interact with immunoglobulin enhancer sequences. Cell, 46, 705-716. Pantano C., Reynaert N.L., van der Vliet A.V., Janssen-Heininger Y.M.W. (2006). Redox-sensitive kinasesof the nuclear factor κB signalling pathway. Antioxidants & Redox Signaling 8(9-10), 1791-1807. Brigelius-Flohê R., Flohê L. (2011). Basic principle and emerging concepts in redox control of transcription factors. Antioxidants & Redox Signaling, 15(8), 2335-2380. Ghosh G., Wang V.Y-F., Huang D-B., Fusco A. (2015). NF-κB regulation: lessons from structures. Immunol. Rev. 246(1), 36-58. Akdis M., Aab A., Altunbulakli C., Azkur K., Costa R.A., Crameri R., Duan S., Eiwegger T., Eljaszewicz A., Ferstl R., Frei R., Garbani M., Globinska A., Hess L., Huitema C., Kubo T., Komlosi Z., Konieczna P., Kovacs N., Kucuksezer U.C., Meyer N., Morita H., Olzhausen J., O'Mahony L., Perzer M., Prati M., Rabane A., Rhyner C., Rinaldi A., Sokolowska M., Stanic B., Sugita K., Treis A., van der Veen W., Wanke K., Wawrzyniak M., Wawrzyniak P., Wirz O.F., Zakzuk J.S, Akdis C.A. (2016). Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-a: receptors, functions, and role in diseases. Fundamentals of allergy and Immunology, 138, 4, 984-1010. Perkins N.D. (2012). The diverse and complex roles of NF-κB subunits in cancer. Nature Reviews Cancer, 12, 121-133. Sethi G., Shanmugam M.K., Ramachandran L., Kumar A.P., Tergaonkar V. (2012). Multifacet link between cancer and inflammation. Biosci. Rep. 32, 1-15. Parri M., Chiarugi P. (2013). Redox molecular machines involved in tumour progression. Antioxidants & Redox Signaling, 19(15), 1828-1846. D'lgnazio L., Bandarra D., Rocha S. (2016). NF-κB cross talk in immune responses. FEBS Journal 283, 413-424. Ludwig L.M., Nassin M.L., Hadji A., Labelle, J.L. (2016). Killing two cells with one stone: Pharmacologic BCL-2 family targeting for cancer cell death and immune modulation. Frontiers in Peadiatrics, Vol 4, Artcle 135, page 1-13. Xia, M, Huang R, Witt KL, Southall N, Fostel J, Cho MH, Jadhav A, Smith CS, Inglese J, Portier CJ, Tice RR, Austin CP (2008) Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect. 116(3):284-91. Fallahi-Sichani, M., S. Honardejad, L.M. Heiser, J.W. Gray, and P.K. Sorger (2013). Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9: 708-714. Barretina, J., G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE (2001). A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab. Dispos., 29: 23-29. Mohammad R.H., Dugan, M.C., Mohamed, A.N., Almatchy, V.P., Flake, T.M., Dergham, S.T., Shields, A.F., Al-Katib, A.A., Vaitkevicius, V.K. and Sarkar, F.H (1998). Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents. Pancreas 16:19-25. "Guide for the Care and Use of Laboratory Animals: Eighth Edition" (2011), The National Academies Press, Washington, DC.

Claims

1. A compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, or pharmaceutical composition including said compounds for use in treating cancer, wherein: (i) X is CH2, CHOH or C(O); R1 is independently H, OH, OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC4-5alkadienyl, OC(O)C1-5alkyl, OC(O)Ph, OC(O)C2-5alkenyl, OC(O)C4-5alkadienyl or =O; R2 is independently H, OH, OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC4-5alkadienyl, OC(O)C1-5alkyl, OC(O)Ph, OC(O)C2-5alkenyl, OC(O)C4-5alkadienyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; where X is CH2, CHOH or C(O), R4 is OH, OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC4-5alkadienyl, OC(O)C1-5alkyl, OC(O)Ph, OC(O)C2-5alkenyl or OC(O)C4-5alkadienyl; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC4-5alkadienyl, OC(O)C1-5alkyl, OC(O)Ph, OC(O)C2-5alkenyl or OC(O)C4-5alkadienyl; and A---B is CH=C or CH2-CH, or (ii) X is CH2, CHOH or C(O); R1 is independently H, OH, OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC(O)C1-5alkyl, OC(O)Ph, OC(O)C2-5alkenyl or =O; R2 is independently H, OH, OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC(O)C1-5alkyl, OC(O)Ph, OC(O)C2-5alkenyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; where X is CH2, CHOH or C(O), R4 is OH, OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC(O)C1-5alkyl, OC(O)Ph or OC(O)C2-5alkenyl; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl, OCH2Ph, OC2-5alkenyl, OC(O)C1-5alkyl, OC(O)Ph or OC(O)C2-5alkenyl; and A---B is CH=C or CH2-CH, or (iii) X is CH2, CHOH or C(O); R1 is independently H, OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl, OC(O)Ph or =O; R2 is independently H, OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl, OC(O)Ph or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; where X is CH2, CHOH or C(O), R4 is OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; and A---B is CH=C or CH2-CH, or (iv) X is CH2, CHOH or C(O); R1 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R2 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; where X is CH2, CHOH or C(O), R4 is OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl or OC(O)C1-5alkyl; and A---B is CH=C or CH2-CH, or (v) X is CH2; R1 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R2 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; R4 is OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl or OC(O)C1-5alkyl; and A---B is CH=C or CH2-CH, or (vi) X is CHOH; R1 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R2 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; R4 is OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl or OC(O)C1-5alkyl; and A---B is CH=C or CH2-CH, or (vii) X is C(O); R1 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R2 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; R4 is OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl or OC(O)C1-5alkyl; and A---B is CH=C or CH2-CH.

2. The compound for use according to claim 1, wherein: (i) the compound is a compound of Formula (Ia): or (ii) the compound is a compound of Formula (Ic): or (iii) the compound is a compound of Formula (Ii):

3. The compound for use according to claim 1 or claim 2, wherein A---B is CH=C.

4. The compound for use according to any one of claims 1 to 3, wherein the compound is selected from the group consisting of: and 5. The compound for use according to claim 4, wherein the compound is:

6. The compound for use according to any one of claims 1-5, wherein the cancer is selected from the group consisting of: bladder cancer; bone cancer; brain cancer; breast cancer; a cancer of the central nervous system, optionally wherein the cancer of the central nerous system is selected from a glioma, a medulloblastoma and a neuroblastoma; cancer of the adrenal glands; cancer of the placenta; cancer of the testis; cervical cancer; colon cancer; kidney cancer; head and neck cancer; myeloma; leukemia; liver cancer; lung cancer, optionally wherein the lung cancer is selected from a non-small cell lung cancer and a small cell lung cancer; melanoma; ovarian cancer; pancreatic cancer; prostate cancer; skin cancer; stomach cancer; thyroid cancer; uterine cancer; a carcinoma, optionally wherein the carcinoma is selected from an adenosquamous cell carcinoma and a squamous cell carcinoma; a lymphoma, optionally wherein the lymphoma is selected from Burkitt's lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma; a sarcoma, optionally wherein the sarcoma is selected from a soft tissue sarcoma, a soft tissue osteosarcoma, a liposarcoma, rhabdomyosarcoma and a fibrosarcoma; an eye cancer; esophageal cancer; a bile duct cancer and vulva cancer.

7. A compound of Formula (I), a stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein: X is CH2; R1 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R2 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; R3 is independently H, OH, OC1-5alkyl, OC(O)C1-5alkyl or =O; and no more than one of R1, R2 and R3 can be H; R4 is OH, OC1-5alkyl, OCH2Ph, OC(O)C1-5alkyl or OC(O)Ph; or X and R3 form a six-membered ether ring or lactone ring, or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom wherein R4 is respectively OH or OC1-5alkyl or OC(O)C1-5alkyl; and A---B is CH=C or CH2-CH, provided that: (A) where R2 is H, X is not CH2; and (B) where R2 is H, and X and R3 form a six-membered ether ring or a six membered ring containing a hemiacetal carbon atom or an acetal carbon atom, A---B is CH=C.

8. The compound according to claim 7, wherein: (i) the compound is a compound of Formula (Ia): or (ii) the compound is a compound of Formula (Ic): or (iii) the compound is a compound of Formula (Ii):

9. The compound according to claim 7 or claim 8, wherein A---B is CH=C.

10. The compound according to any one of claims 7 to 9, wherein the compound is selected from the group consisting of:

11. The compound according to claim 10, wherein the compound is:

12. A pharmaceutical composition comprising a compound, stereoisomer, pharmaceutically acceptable salt or solvate thereof, according to any one of claims 7 to 11, or a mixture thereof, and a pharmaceutically acceptable excipient.

13. The compound according to any one of claims 7 to 11, or the pharmaceutical composition according to claim 12, for use as a medicament optionally for use in treating cancer.

14. The compound according to any one of claims 7 to 11, or the pharmaceutical composition according to claim 12, for use in the treatment of a disease or disorder, wherein the disease or disorder is selected from the group consisting of: acute coronary syndrome; an aging disease or disorder; an allergic disease; Alzheimer's disease; atherosclerosis; an autoimmune disease; a bacterial infection; cancer; dementia; depression; diabetes; dyslipidemia; hyperlipidemia; hypertension; itchytosis; an immune disease; a metabolic disease or disorder; a neurological disease or disorder; obesity; Parkinson's disease; pain; rheumatoid arthritis and skin disease or disorder, optionally wherein the skin disease or disorder is selected from eczema, psoriasis, acne, scar, inflammation, a burn, sunburn, skin damage and skin irritation.

15. A pharmaceutical composition comprising a compound of claim 11 in combination with Gemcitabine for use in treating cancer.